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ABSTRACT OF DISSERTATION 
PROTEOMICS AND PHOSPHOPROTEOMICS OF BRAIN: (1) ANALYSES OF 
THE PINK1 KNOCKOUT MODEL OF PARKINSON DISEASE; (2) INSIGHTS 
INTO THE PROGRESSION OF ALZHEIMER DISEASE; AND (3) THE NAKED 
MOLE RAT MODEL OF SALUBRIOUS AGING 
 
Proteomics is the field of science in which proteins produced by an 
organism (the proteome) are identified. The level of a particular protein can vary 
with time and the influence of cellular stressors. The study of phosphoproteomics 
is vital because tyrosine, serine and threonine phosphorylation modulate protein 
structure and function and is a crucial regulator of cellular signaling pathways. 
Dysregulation of protein and phosphorylation levels has been reported in multiple 
neurodegenerative disorders including Parkinson disease (PD) and Alzheimer 
disease (AD). 
 
PINK1 is a mitochondrial serine/threonine kinase that polices 
mitochondrial integrity. Mutations in this protein are associated with familial early-
onset PD. PD is characterized by accumulated Lewy bodies, largely composed of 
aggregated alpha-synuclein, and progressive dopaminergic neuronal 
degeneration in the substantia nigra. In this dissertation study, proteomics 
identified differences in protein expression and protein phosphorylation levels in 
the brains of PINK1 knockout mice. The observed changes suggest that 
perturbed metabolism, diminished proteostasis, decreased neuronal plasticity, 
and aberrant cellular signaling are implicated in familial PD pathogenesis. 
 
AD is characterized by senile plaques, neurofibrillary tangles and synapse 
loss. Previously, multiple AD brain proteins were reported from our laboratory as 
abnormally phosphorylated, indicating that deregulated phosphorylation may play 
a key role in AD pathogenesis. In this dissertation study, quantitative 
phosphoproteomic analyses were conducted on the inferior parietal lobule from 
three different clinical stages of AD, i.e., late-stage AD, amnestic mild cognitive 
impairment (MCI) and preclinical AD (PCAD). The differential phosphoproteins 
identified provide insights into underlying mechanisms promoting the 
 
preservation of memory in PCAD with expansive AD pathology, while uncovering 
early aberrant phosphorylation events in MCI that conceivably may be involved in 
the progressive cognitive decline leading to dementia. 
 
Aging is a primary risk factor for development of neurodegenerative 
disorders, including AD and PD. The naked mole-rat (NMR), which can live for 32 
years, is currently under investigation to gain insights into extending human 
lifespan and healthspan. In this dissertation research, age-related alterations of 
the brain proteome and phosphoproteome of the NMR were identified, revealing 
key proteins involved in neuronal plasticity, energy metabolism, autophagy, and 
the ubiquitin-proteasome system that may contribute to salubrious longevity. 
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CHAPTER 1 
Introduction 
 The studies described in this work utilize proteomics and 
phosphoproteomics techniques to gain a greater understanding of underlying 
biochemical mechanisms that contribute to pathology and clinical presentation of 
Alzheimer and Parkinson diseases. Additionally, changes in the brain proteome 
and phosphoproteome that occur with age in the naked mole-rat (NMR) are 
probed to examine mechanisms that may be central in maintaining an 
exceptionally long, healthy lifespan. Further, proteomic insights into key proteins 
involved in promoting/hindering neurodegenerative disease mechanisms may 
provide biomarkers to aid in early detection and development of effective, 
targeted therapeutics. 
Many neurodegenerative diseases share common characteristics 
including: changes in energy metabolism, diminished proteostasis networks, 
increased oxidative stress, altered cellular signaling, and reductions in 
neuroplasticity, neurotransmission and cellular structure (Beal 1992, Butterfield 
and Kanski 2001, Palop, Chin et al. 2006, Rubinsztein 2006). Parkinson disease 
(PD) and Alzheimer disease (AD) are the two most common age-related 
neurodegenerative diseases. Although these disorders usually appear later in 
life, mutations in key genes can induce early onset, inheritable forms of the 
disease. In this dissertation research, we examined the proteome and 
phosphoproteome of the PINK1 (phosphatase and tensin homologue induced 
kinase1) knockout mouse model of PD at the earliest inception of disease 
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presentation (6 months-old). Further, we analyzed changes in the 
phosphoproteome in the inferior parietal lobule from three different pathological 
stages of AD: preclinical AD (PCAD), amnestic mild cognitive impairment (MCI), 
and AD to evaluate mechanisms involved in disease progression from MCI to AD 
as well as understanding underlying mechanisms that preserve memory and 
cognitive function despite the presence of expansive senile plaque (SP) and 
neurofibrillary tangle (NFT) pathology typical to AD brains. 
Even though the greatest single risk factor for neurodegeneration is aging 
(Lin and Beal 2006), most neurodegenerative research is conducted on short-
lived species. However, by examining the age-related changes in the proteome 
and phosphoproteome of the longest-lived rodent, the NMR, may provide 
superior insights into proteins that may play critical roles in mechanisms that 
resist neurodegeneration and facilitate cellular proteostasis for healthy cognitive 
aging and improved quality of life.  
 The overall hypothesis of this dissertation research is that the underlying 
biochemical changes, as evident by evaluation the proteome and 
phosphoproteome of neurodegenerative brain, contribute to disease progression, 
pathogenesis, and clinical presentation and how proteomic investigations of the 
NMR could possibly identify key proteins that contribute to mechanisms 
promoting salubrious longevity. To support the overall hypothesis, this 
dissertation addresses the following: 
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1. What changes occur in the proteome and phosphoproteome of brain from 
PINK1-KO mice at the earliest stage of PD-like pathology? 
2. Which proteins exhibit altered phosphorylation states in the inferior 
parietal lobule (IPL) of amnestic MCI and are they harbingers of AD? 
3. What are the differences in the phosphoproteome of IPL of PCAD and AD 
subjects and how does a brain heavy with SPs and NFTs negate cognitive 
impairment? 
4. What are the underlying mechanisms promoting a long healthspan and 
lifespan in the NMR? 
a. What are the biochemical changes in brain metabolism as these 
animals age? 
b. Which proteins are implicated in maintaining robust proteostasis 
networks throughout their long lives? 
c.  Are there alterations in levels or activity of proteins associated with 
neuroplasticity, neurotransmission, or structure which may 
contribute to the extraordinary traits of the NMR? 
 
 
 
 
 
 
Copyright © Judy Carol Triplet 2015
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CHAPTER 2 
BACKGROUND 
2.1 Neurodegeneration overview 
 Neurodegenerative diseases are a collection of disorders characterized by 
selective, progressive loss of neuronal structure and function. Oftentimes, these 
diseases share certain common characteristics, including: alterations in energy 
metabolism, mitochondrial dysfunction, increased oxidative stress, failing 
proteostasis networks, aggregation of misfolded proteins, and neuronal cell death 
(Beal 1992, Butterfield and Kanski 2001, Lin and Beal 2006, Palop, Chin et al. 
2006). Since aging is the greatest risk factor for developing a neurodegenerative 
disease, a potential global therapy may conceivably lie in targeting key proteins 
in one or more of these common neurodegenerative pathways to ameliorate 
disease severity and promote a healthy lifespan. 
2.1.1 Parkinson disease (PD)  
2.1.1.1 PD overview 
 PD is the most common neurodegenerative movement disorder that 
affects approximately 1-2% of the population over the age of 65 and 3-5% of the 
population over 85 years-old (Fahn 2003). Additionally, 5-10% of PD patients 
may have an early-onset form of the disease with symptom onset occurring 
before the age of 50 (Alves, Forsaa et al. 2008). Except for incidences of PD 
caused by inheritable DNA mutations, the etiology of PD remains unclear, though 
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a number of contributing factors (in addition to age) have been implicated: 
exposure to environmental toxic metals or pesticides (Priyadarshi, Khuder et al. 
2001), having a family member with PD (Kurz, Alves et al. 2003), mitochondrial 
dysfunction and oxidative stress (Henchcliffe and Beal 2008, Bueler 2009), and 
failure of proteostasis networks (McNaught, Olanow et al. 2001, Lynch-Day, Mao 
et al. 2012). 
2.1.1.2 PD Pathology and physiology 
 PD is characterized by the aggregation of phosphorylated α-synuclein 
(Ser-129) within Lewy bodies and by the catastrophic death of the majority of 
dopaminergic (DA) neurons in the pars compacta region of the substantia nigra, 
although other neuronal types have been reportedly depleted as well (Braak, Del 
Tredici et al. 2003, Anderson, Walker et al. 2006). Significant DA neuron loss can 
result in one or more of the four cardinal motor symptoms of PD: resting tremor, 
bradykinesia, muscular rigidity, and postural instability (Jankovic 2008).  The 
vulnerability of DA neurons has been linked to their reportedly reduced 
mitochondrial reserve as compared to that of other neuronal types (Matsuda, 
Kitagishi et al. 2013). Without an ample reserve of mitochondria, DA neurons are 
more susceptible to apoptosis during periods of acute energy crisis, 
mitochondrial dysfunction and oxidative stress (Hauser and Hastings 2013, Van 
Laar and Berman 2013). Other typical non-motor PD symptoms, which include 
anosmia, constipation, depression, hallucinations, REM sleep disorder, and 
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cognitive decline (Chaudhuri, Healy et al. 2006) may appear many years before 
the onset of motor-related symptoms. 
2.1.1.3 PINK1  
2.1.1.3.1 PINK1 function 
 Mutations in PTEN induced kinase 1 (PINK1), a mitochondrial 
serine/threonine kinase, are associated with autosomal recessive-inherited early 
onset PD (Kawajiri, Saiki et al. 2011). PINK1 is short-lived neuroprotective 
protein that polices mitochondrial integrity (Narendra, Jin et al. 2010). When 
mitochondria are functioning in a healthy steady-state, PINK1 is imported to the 
inner mitochondrial membrane where it is immediately cleaved by proteases, 
including PARL (presenillins-associated rhomboid-like protein), and retro-
translocated to the cytosol for proteasomal degradation (Figure 2.1) (Deas, Plun-
Favreau et al. 2011).  
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Figure 2.1 PINK1 in healthy mitochondria. Cleavage of PINK1 at the inner 
mitochondrial membrane in healthy mitochondria. 
However, when mitochondria become dysfunctional and depolarize (Figure 2.2), 
PINK1 import into the mitochondria is blocked and PINK1 accumulates on the 
outer mitochondrial membrane where it recruits and phosphorylates Parkin, an 
E3 ligase, to initiate mitophagy for disposal of the damaged organelle (Matsuda, 
Sato et al. 2010). 
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Figure 2.2 Pink1 in damaged mitochondria. PINK1 accumulating on the outer 
membrane of damaged mitochondria, recruiting Parkin for mitophagy. 
With malfunctioned PINK1, damaged mitochondria accumulate and disrupt 
energy and calcium homeostasis (Heeman, Van den Haute et al. 2011). 
2.1.1.3.2 PINK1 knockout (KO) PD mouse model 
 PINK1 KO mice do not develop α-synuclein-containing Lewy bodies, 
nigrostraital neurodegeneration or manifestation of the four cardinal motor 
symptoms; however, pre-motor symptoms are present, including anosmia and 
gait disturbances (Glasl, Kloos et al. 2012). Consequently, PINK1 KO mice are a 
good model to study early PD development and early biomarkers (Glasl, Kloos et 
al. 2012). Further, PINK1 KO mice reportedly have decreased dopamine release, 
reduced synaptic plasticity (Kitada, Pisani et al. 2007), progressive weight loss 
and motor disturbances that correlate to reduced dopamine (Gispert, Ricciardi et 
al. 2009). Further, in the brain of PINK1 KO mice, mitochondria exhibit functional 
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defects as they have decreased ATP production (Gispert, Ricciardi et al. 2009), 
reduced capacity for Ca2+ storage (Akundi, Huang et al. 2011) and increased 
sensitivity to oxidative stress (Gautier, Kitada et al. 2008). 
2.1.1.4 Mitochondria and superoxide 
2.1.1.4.1 Mitochondria 
The mitochondrial respiratory chain, located on the inner mitochondrial 
membrane, is composed of five multisubunit protein complexes, which generate 
ATP by electron (e-) mediated coupling of H+ and O2 to form H2O. The majority of 
energy generated by oxidative phosphorylation is spent maintaining ion 
gradients, propagating action potentials, releasing and recycling 
neurotransmitters; therefore, mitochondrial dysregulation can be detrimental to 
neuronal survival (Attwell and Laughlin 2001).  
2.1.1.4.2 Superoxide 
 Up to 2% of oxygen consumed in this process is converted to superoxide 
(.O2-) due to e- leakage from the ETC (primarily from complex I and II) and 
transference to O2 (Chouchani, Pell et al. 2014). Superoxide can lead to 
oxidative damage in a number of ways: (i) by direct damage by free radical chain 
reactions; (ii) by reaction with nitric oxide to form peroxynitrite leading to protein 
nitration; and (iii) indirectly by conversion to H2O2 by superoxide dismutase 
(SOD), which though Fenton reactions can oxidize H2O2 producing a hydroxide 
anion and a hydroxyl radical leading to lipid peroxidation and protein oxidation 
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(Figure 2.3). The hydroxyl radical is considered to be one of the most toxic free 
radical reactive oxygen species due to high reactivity and irreversible lipid, 
protein and DNA modifications (Halliwell 2007).  
Figure 2.3 Consequences of superoxide production. Pathways to protein 
nitration, lipid peroxidation and protein oxidation. 
2.1.2 Alzheimer disease (AD) 
2.1.2.1 AD overview 
AD, the most common neurodegenerative disease, afflicts 11% of the 
population over the age of 65 and 32% of people over 75 (Hebert, Weuve et al. 
2013). Interestingly, about two-thirds of the 5.2 million Americans with AD are 
women (Hebert, Weuve et al. 2013). Since the greatest risk factor for developing 
AD is age; and to date, no significant difference has been found between men 
and women who develop AD (Hebert, Scherr et al. 2001), except for the longer 
average lifespan of women. Other proposed AD contributing factors include: Aβ 
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toxicity, oxidative stress, dysfunctional energy metabolism, and inflammation 
(Butterfield and Kanski 2002, Hynd, Scott et al. 2004, Tuppo and Arias 2005). 
2.1.2.2 AD pathology and physiology 
 Neuropathological hallmarks of AD include the extensive distribution of 
extracellular senile plaques (SPs), intracellular neurofibrillary tangles (NFTs), 
amyloid β-peptide (Aβ) oligomers, and loss of synapses, which results in 
increased neuronal death. SPs are insoluble, fibrous Aβ-containing aggregations 
that are often surrounded by dystrophic neurites. NFTs are insoluble aggregates 
containing hyperphosphorylated tau proteins that have uncoupled from 
microtubules, leading to disassembly of the microtubules and decimation of 
neuronal infrastructure and axonal transport. Severity of AD clinical symptoms 
tends to correlate with the quantity and distribution of SPs, NFTs and lost 
synapses (Braak and Braak 1995, Thal, Rub et al. 2002). The pathology and 
underlying biochemical mechanisms lead to escalating memory loss and 
cognitive dysfunction that culminates in severe dementia.  
2.1.2.3 AD progression 
2.1.2.3.1 Amnestic mild cognitive impairment (MCI) 
 MCI is considered to be a transition between normal cognition and AD as 
the MCI brain generally displays levels of SPs, NFTs, neuronal loss, and 
oxidative stress that are intermediate to levels in AD (Morris, Storandt et al. 
2001); however, SP density and abundance can vary widely (Villain, Chetelat et 
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al. 2012). A more reliable indicator that correlates with increased cognitive 
impairment and synapse loss is the measurement of Aβ oligomers, of which 
Aβ(1-42) is most toxic (Butterfield and Kanski 2002, Pham, Crews et al. 2010). 
Additionally, MCI subjects have non-age-related cognitive deficits but exhibit no 
signs of dementia or hindrance in performing every-day tasks (Petersen 2004). 
MCI is divided into two specific categories: amnestic MCI, which involves 
memory loss, and non-amnestic MCI, which does not affect memory (Portet, 
Ousset et al. 2006). Moreover, amnestic MCI is considered to be a preferential 
harbinger of AD (Portet, Ousset et al. 2006) and the conversion rate to AD is 
approximately 10-15% per annum (Maioli, Coveri et al. 2007). Proteomic 
research into this disease stage may conceivably uncover biomarkers to facilitate 
early AD detection and increase understanding of early mechanisms involved in 
disease progression. 
2.1.2.3.2 Preclinical AD (PCAD) 
 Individuals with PCAD display no cognitive deficits, however, at 
postmortem, they exhibit extensive distribution of SP and NFT pathology (Erten-
Lyons, Woltjer et al. 2009). PCAD brains are not only uncommon but also 
possess some remarkable traits including: minimal or no loss of neurons (Price, 
Ko et al. 2001), increased synaptic plasticity (O'Brien, Resnick et al. 2009), levels 
of oxidative stress similar to control brain (Aluise, Robinson et al. 2010, Aluise, 
Robinson et al. 2011), increased neuronal hypertrophy (Iacono, O'Brien et al. 
2008), and alterations to proteins involved in anion transport (Lyubartseva, Smith 
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et al. 2010). Identifying neurochemical mechanisms that inhibit cognitive decline 
despite heavy SP and NFT burden may provide critical clues towards therapeutic 
interventions stopping progressive memory loss. 
2.1.3. Oxidative stress 
 Oxidative stress is implicated in multiple neurodegenerative disorders 
(Uttara, Singh et al. 2009). Oxidative stress occurs in a system when levels 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) overwhelm 
antioxidant defenses (Dasuri, Zhang et al. 2013). An oxidatively-stressed 
environment leads to damaged biomolecules, such as lipid membranes and 
proteins, and can induce post translational modifications that may result in 
altered protein structure and function, protein unfolding and aggregation, among 
others (Butterfield and Lauderback 2002).  
2.1.3.1 Reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
 ROS and RNS are toxic species and free radicals that include: 
superoxide, hydroxyl radical, hydrogen peroxide, nitric oxide, and peroxynitrite, 
among others. ROS and RNS are tightly controlled by antioxidant enzymes, e.g., 
superoxide dismutase (SOD), biliverdin reductase, glutathione peroxidase, 
peroxiredoxins, catalase, and many heat shock proteins, and molecules, such as 
glutathione, vitamins C, D and E, and lipoic acid, to maintain the cellular redox 
state (Gilgun-Sherki, Melamed et al. 2001). An imbalance in this system can lead 
to oxidative damage to lipids, proteins and DNA (Halliwell 2007).  
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2.1.3.3 Lipid peroxidation and 4-hydroxy-2-nonenal (HNE) 
 Lipid peroxidation occurs in three stages: initiation, propagation and 
termination. Initiation occurs when an allylic hydrogen is removed from the lipid 
leaving a carbon-centered radical that can react with O2 to form a peroxyl radical. 
Propagation occurs as a radical-radical chain reaction leads to further allylic 
hydrogen abstraction, which can cause production of reactive alkenals, loss of 
lipid asymmetry and apoptosis (Castegna, Lauderback et al. 2004, Butterfield, 
Bader Lange et al. 2010). Lipid peroxidation of arachidonic acid leads to the 
formation of 4-hydroxy-2-nonenal (HNE). HNE can render proteins dysfunctional 
by binding to His, Lys and Cys residues via a Michael’s addition reaction, thereby 
altering the protein’s structure and function (Butterfield, Bader Lange et al. 2010).  
2.1.3.4 Tyrosine nitration 
 Tyrosine nitration occurs when a nitro group is added to tyrosine at the 3-
position. The presence of this nitrite group sterically blocks tyrosine kinase-
mediated phosphorylation, causing altered protein activity (Tangpong, Cole et al. 
2007). Further, increased levels of tyrosine nitration elevate the likelihood of 
proteasomal degradation of the protein and can lead to neuronal death (Gow, 
Duran et al. 1996, Mattson, Goodman et al. 1997).  
2.1.3.5 Protein carbonyl (PC) 
 PCs are the most wildly measured marker of oxidative stress (Dalle-
Donne, Scaloni et al. 2005). PCs can be formed on proteins through a variety of 
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mechanisms, including: Michael addition reactions with lipid peroxidation 
products, direct oxidation of amino acid side chains, peptide backbone scission, 
and glycooxidation (Aksenov, Aksenova et al. 2001). 
2.2 The naked mole-rat (NMR)  
 The NMR is arguably best known due to their unusually long healthspans 
and hold the world record as the longest lived rodent (Buffenstein 2005, Grimes, 
Reddy et al. 2014). Though being the size of a mouse, NMRs can live up to 32 
years while maintaining normal body function and activity for 75-80% of their 
lifespan (Buffenstein 2008, Edrey, Park et al. 2011). These remarkable NMRs 
are not only resistant to cellular senescence, but they do not develop cancers, as 
there are no indications of spontaneous neoplasia and only one route to tumor 
development with experimentally-induced tumorigenesis (Buffenstein 2008, 
Liang, Mele et al. 2010, Tian, Azpurua et al. 2013), while other typical lab rodents 
develop cancers. It was recently discovered that malignant transformation of cells 
could occur in NMR cell culture if high-molecular-mass hyaluronan (HMM-HA) 
was removed (Tian, Azpurua et al. 2013). The mass of NMR HMM-HA is over 5 
times that of a mouse or human analog and is implicated in mechanisms of early 
contact inhibition (Tian, Azpurua et al. 2013). The role that HMM-HA plays in 
mediating NMR cancer resistance is currently under investigation. Because of 
these extraordinary traits, the NMR genome was sequenced and released in 
2011 to help decipher underlying mechanisms that promote a long and healthy 
lifespan. 
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2.2.1 NMR: Habitat and behavior 
 The naked mole-rat (NMR; Heterocephalus glaber; sand puppy) is a 
subterranean burrowing rodent indigenous to the hot and arid sub-Saharan 
region of North East Africa. NMRs live in large colonies that average 75-80 
individuals, but can be as large as 300 NMRs (Brett 1991).  
NMRs are the only known eusocial mammals, a social structure akin to 
that of bees or termites. Each colony has one dominate, breeding female (the 
queen) that consorts with up to 3 breeding males (Lacey and Sherman 1991). All 
other members of the community are somewhat smaller in size and 
reproductively repressed; however, these subordinates can become reproductive 
if removed from the colony (Holmes, Goldman et al. 2008). Interestingly, 
subordinate males and females exhibit a remarkable lack of differences in 
anatomy and behavior (Edrey, Park et al. 2011). Furthermore, a NMR colony has 
a strict division of labor of communal tasks, including: gathering of food, defense 
against predation, juvenile caretaking, and excavating of tunnel systems (Jarvis 
1981). 
Living in a deep and thermally stable ecological niche, NMRs have 
evolved several remarkable traits. This sealed underground environment is highly 
hypoxic, yet NMRs manage to cope with low oxygen levels, where in many 
vertebrates, only a few minutes of oxygen deprivation leads to irreparable 
neurological injury (Larson, Drew et al. 2014). Notably, as with most 
subterranean endothermic species, NMRs have low basal metabolism rates and 
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NMRs can greatly reduce their metabolism during periods of starvation 
(O'Connor, Lee et al. 2002). Additionally, NMRs are thermoconformers and 
therefore expend no energy in regulating their body temperature. Instead, NMRs 
huddle together or retreat deeper into burrows for warmth.  
2.2.2 NMR and oxidative stress 
 Surprisingly, NMRs have been shown to produce high levels of ROS 
compared to mice (Lambert, Boysen et al. 2007). Even at an early age, NMRs 
reportedly have high levels of oxidative damage; however, these global levels do 
not increase and oxidized proteins do not accrue with age (Andziak and 
Buffenstein 2006, Lewis, Andziak et al. 2013). High levels of oxidative damage 
typically affect multiple cellular processes and contribute to age-related decline 
(Morimoto and Cuervo 2009). But clearly, NMRs have seemingly evolved 
mechanisms to repair or eradicate oxidative damage accumulation, since even 
young NMRs are more resistant to resultant oxidative stress damage than mice 
(Labinskyy, Csiszar et al. 2006). Antioxidants are a key ROS combatant; 
however, when levels of selected antioxidants (SOD 1 & 2, catalase and 
glutathione peroxidase) were measured in the NMR, they were not elevated 
compared to shorter-lived species (Andziak, O’Connor et al. 2005), suggesting 
that a superior antioxidant defense system is not the primary contributing factor 
for NMR resistance to oxidative stress. 
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2.2.3 Proteostasis in the NMR 
 NMRs are extremely resilient to cellular stress as their proteins are 
resistant to unfolding (Perez, Buffenstein et al. 2009). In most species, damaged 
proteins accumulate with age and is one of the hallmarks of aging (Zwickl, 
Seemuller et al. 2001). These proteins can aggregate and cause damage, such 
as the clogging proteasomes, disrupting cellular homeostasis. NMRs are an 
exception to this age-related accumulation of damaged proteins (Perez, 
Buffenstein et al. 2009). This resistance to oxidative stress in the NMR is 
hypothesized to be a result of their ability to maintain proteostasis through 
mechanisms assisting in protein repair or elimination (Rodriguez, Wywial et al. 
2011). 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Judy Carol Triplet 2015 
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CHAPTER 3 
METHODS 
3.1 Tissue homogenization 
 For all studies in this dissertation, selected brain tissues were prepared 
using a Wheaton glass homogenizer (~40 passes) with ice-cold isolation buffer 
[0.32 M sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/ml PMSF, 4 
µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml aprotinin and 10 µg/ml phosphatase 
inhibitor cocktail 2]. Homogenates were vortexed and then sonicated on ice for 
10 s at 20% power, two times resting the sample for 20 s in-between, using a 
Fisher 550 Sonic Dismembrator (Pittsburgh, PA, USA). Protein concentrations of 
the homogenates were determined by the Pierce BCA method (Rockford, IL, 
USA) (Smith, Krohn et al. 1985). 
3.2 Bicinchoninic acid (BCA) protein assay 
Global protein concentrations of all samples in this dissertation research 
were determined using the bicinchoninic acid (BCA) protein assay. The first step 
of this assay utilizes the Biuret reaction for the reduction Cu2+ to Cu+ by the 
chelation of nearby peptide bonds. The second step is the formation of a 
chelating complex containing 2 BCA molecules in a 4-coordination complex with 
one Cu+ (Figure 3.1). A greater amount of protein will result in a darker purple 
solution (absorbing at 562nm) as there would be a greater number of 
chomophoric BCA complexes in solution. Bovine serum albumin (BSA) was used 
as the protein standard and Beer’s law was used for calculations of protein 
concentration. 
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Figure 3.1 Formation of the BCA/Cu+ Complex. Reduction of Cu2+ for 
chelation to bicinchoninic acid (BCA). 
3.3 Measurement of global oxidative stress markers 
 The slot blot method was used to determine levels of global makers of 
oxidative stress: protein carbonyls, 3-nitrotyrosine (3NT) and protein-bound 4-
hydroxy-2-nonenal (HNE). The slot blot process involves preparation of samples 
(described below), loading samples in duplicate onto a nitrocellulose membrane 
utilizing the slot blot apparatus, blocking the membrane, detecting the desired 
modification with a primary antibody, labeling the primary antibody with a 
secondary antibody for detection and the quantification of the data using BioRad 
Image Lab software. 
3.4 Detection of oxidative stress markers 
3.4.1 Quantification of protein carbonyls 
 Global levels of protein carbonyls (PC) were determined in naked mole-rat 
brain. First, 5 µL of homogenized sample, combined with 5 µL of a 12% sodium 
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dodecyl sulfate (SDS) solution  was derivatized with 10 µL of a 2,4-
dinitrophenylhydrazine (DNPH) solution [1:10 dilution with a 1x PBS, a 
phosphate buffer solution with sodium chloride and mono and dibasic sodium 
phosphates] to form dinitrophenylhydrazone Schiff bases. The solution was 
incubated for 20 min at 22˚C. Next, 7.5 µL of a neutralization buffer [2 M Tris, pH 
6.8, in 30% (v/v) glycerol] was added to react with the remainder of the DNPH 
solution. Utilizing the BCA data, the solution is further diluted with phosphate 
saline buffer (PBS) solution (10 mM, pH 8 with 0.88% NaCl) for a final protein 
concentration of 1 ng/µL. The protein-bound hydrazone-adducts were transferred 
to a nitrocellulose membrane using the slot blot apparatus and then detected 
immunochemically. 
3.4.2 Determination of 3-nitrotyrosine and protein-bound HNE  
 To measure global levels of 3-NT and protein-bound HNE, 5 µL of the 
sample is added to 5 µL of the 12% SDS solution and 10 µL of a Laemmle buffer 
[0.125 M Tris base, pH 6.8, 4% (v/v) SDS, and 20% glycerol] for 20 min, then 
diluted to 1 ng/µL with PBS, transferred to a nitrocellulose membrane and 
detected immunochemically. 
3.4.3 Immunochemical development of nitrocellulose membrane 
 Nitrocellulose membranes were blocked in 3% BSA in Wash Blot solution 
[150 mM sodium chloride, 3 mM monobasic sodium phosphate, 17 mM dibasic 
sodium phosphate and 0.04% (v/v) Tween 20], with gentle rocking  for 1.5 h at 
22˚C. To this solution, the appropriate antibody was added (derivatized-PC 
22 
 
(1:300 dilution), 3-NT (1:5000) and HNE (1:5000)) for 2 h. The membrane was 
then rinsed and rocked in Wash Blot three times for 5, 5 and 10 min. Next, 2.5 µL 
of an anti-rabbit IgG alkaline phosphatase conjugated secondary antibody in 20 
mL of wash blot was added for exactly one hour. The membrane was rinsed and 
rocked in Wash Blot again three times for 5, 10 and 10 min. The secondary 
antibody was detected by adding 30 mL of an alkaline phosphatase (ALP) buffer 
[0.5 M Tris, 0.1 M sodium chloride, 5 mM magnesium chloride hexahydrate, pH 
9.5] with 99 µL of 5-bromo-4-chloro-3-indolyl phosphate dipotassium (BCIP) and 
198 µL of nitrotetrazolium blue chloride (NBT). BCIP is hydrolyzed by ALP to 
form 5-bromo-4-chloro-3-indole and inorganic phosphate and NBT is added as 
an oxidizer to form an insoluble dark blue precipitate after being reduced for 
colorimetric detection. Membranes were rocked in this developing solution until 
colored slots appear. Relative color intensities are compared between the 
samples, relating relative oxidation levels.  
3.5 Proteomics 
 For all studies in this dissertation, significantly altered protein levels and 
phosphorylation states were detected using a 2D-PAGE approach in conjunction 
with protein-gel staining and protein identification by MS/MS. 
3.5.1 Isoelectric focusing 
 Isoelectric focusing (IEF) is a technique for separation of proteins based 
on their isoelectric point (pI). First, 200 µg of brain homogenate proteins were 
shaken for 2 h at 22˚C in 200 µl of  rehydration buffer [8 M urea, 2.0% (w/v) 
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CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01% Bromophenol Blue]. 
Samples were sonicated for 10 s and applied to 11 cm ReadyStrip IPG strips, pH 
3-10 (Bio-Rad, Hercules, CA, USA). The IPG strips were actively rehydrated at 
20 °C for 18 h at 50 V and then isoelectrically focused at a constant temperature 
of 20 °C beginning at 300 V for 2 h linearly, 500 V for 2 h linearly, 1000 V for 2 h 
linearly, 8000 V for 8 h linearly, and finishing at 8000 V for 10 h rapidly, using a 
Protean IEF cell (Bio-Rad). IPG strips were stored at -80 °C until second 
dimension separation. 
3.5.2 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
 2-D-Page separates proteins based on their molecular weight and shape. 
First, IPG strips were thawed for 10 min and equilibrated in buffer A [50 mM Tris–
HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v glycerol, 0.5% dithiothreitol (DTT)] 
for 10 min and then in buffer B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) 
SDS, 30% v/v glycerol, 4.5% iodoacetamide (IA)] for 10 min. IPG strips were next 
placed into Linear Gradient (8-16%) Precast Criterion Tris–HCl polyacrylamide 
gels, 11 cm (Bio-Rad). Precision Plus Protein All Blue (Bio-Rad) or 
PeppermintStick (Invitrogen, Grand Island, NY, USA) molecular weight standards 
were run with samples at a constant voltage of 200 V for approximately 65 min in 
Tris-Glycine SDS running buffer. 
3.5.3 Pro-Q Diamond phosphoprotein staining 
 Pro-Q Diamond phosphoprotein gel stain allows for the detection of 
phosphoserine, phosphothreonine and phosphotyrosine protein residues; and the 
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intensity of the resultant protein spot is correlated with the number of phosphate 
groups attached. After completion of 2D-PAGE, gels were removed from their 
casings and fixed in 50mLsolution [10% (v/v) acetic acid, 50% (v/v) methanol] for 
30 min, two times, at 22˚C on a gently rocking platform. Gels were washed in 
100mL of deionized (DI) water (3 times; 30 min each). Next, 60 mL of Pro-Q 
Diamond stain was added to the gel in the dark and covered with aluminum foil 
and rocked for 90 min. Gels were destained in 100 mL of destaining solution 
[20% acetonitrile (ACN), 50 mM sodium acetate, pH 4] in the dark (4 times; 30 
min each). The gels were then washed 3 times for 30 min each in 100 mL of DI 
water in the dark. The gels, transported wrapped in aluminum foil, were scanned 
at 580 nm using either a GE Healthcare Life Sciences Typhoon FLA 9500 
scanner (PINK1 knockout project) or a BioRad ChemiDoc MP System Imager 
(Alzheimer disease and naked mole-rat projects). 
3.5.4 Sypro Ruby protein staining 
 Sypro Ruby gel protein stain allows for the detection and quantification of 
total protein content. This staining method is also used in conjunction with Pro-Q 
Diamond phosphoprotein stain to allow for normalization of the phosphorylated 
proteins so that a highly abundant but lightly phosphorylated protein can be 
distinguished from a lowly expressed but highly phosphorylated protein.  
 After scanning Pro-Q Diamond-stained gels, the gels were fixed in 50 mL 
solution [7% (v/v) acetic acid, 10% (v/v) methanol] for 45 min. After removing the 
fixing solution, 50 mL of Sypro Ruby stain was added for overnight staining (15 
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hr) at 22˚C with gentle rocking. Gels were rinsed and transferred to 50 mL DI 
water and scanned at 450 nm using the afore-mentioned scanners. Gels were 
stored in DI water at 4 °C until protein spot excision. 
3.5.5 Image analyses 
 For all proteomic and phosphoproteomic studies in this dissertation, spot 
intensities from the Pro-Q Diamond and Sypro Ruby-stained 2D-gel images were 
quantified densitometrically according to the total spot density using PDQuest 2-
D analysis software (Bio-Rad). 
3.5.5.1 Differential protein expression 
 Spot intensities from Sypro Ruby-stained 2D-gel images of were 
quantified by densitometry. Intensities of gel spot were normalized to the total gel 
density. Protein spots of gels from a particular study were first manually matched 
together and then matched by the PDQuest program using powerful 
automatching algorithms for accurate spot-matching. Resultant data of 
normalized intensity of each protein spot were compared between groups using 
the appropriate statistical analysis. Figure 3.2 shows the method used to 
determine differential protein levels in samples and provides an illustration of a 
PDQuest gel map comparison. 
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Figure 3.2 Proteomic methods. Flow chart depicting analysis sequence in 2-D 
gel-based detection of differential protein levels. 
3.5.5.2 Differential phosphorylation levels 
 Protein spots from Pro-Q Diamond-stained 2D-gel images were quantified 
and matched together in the same manner as the Sypro Ruby-stained gels. Next, 
two master gels, one from the Pro-Q Diamond images and one from the Sypro 
Ruby stained images, were matched together in the same manner as described 
above. Figure 3.3 shows the phosphoproteomics method for determining the 
identity of proteins with differential protein phosphorylation levels. The PDQuest 
software provided numerical data corresponding to the intensity of the protein 
spot and the intensity of the phosphoprotein spot. The phosphoprotein spot 
densities were then normalized to the Sypro Ruby spot densities and the 
resultant normalized phosphoprotein spot densities were compared. Spots with a 
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statistically significant difference based on appropriate statistical testing were 
considered for in-gel trypsin digestion and subsequent identification. 
 
Figure 3.3 Phosphoproteomic methods. Flow chart depicting analysis 
sequence in 2-D gel-based detection of differential protein phosphorylation. 
3.5.6 In-gel trypsin digestion 
 Significant protein spots were excised from 2D-gels with a clean, sterilized 
razor blade or pipette tip and individually transferred to Eppendorf 
microcentrifuge tubes. Gel plugs were incubated with 20 µL of 0.1 M ammonium 
bicarbonate (NH4HCO3) for 15 min, and with 30 µL of ACN for 15 min. Gel plugs 
were dried under a flow hood at RT for 30 min. Next, 30 µL of 20 mM DTT in 0.1 
M NH4HCO3 was added at 56°C for 45 min. The DTT/NH4HCO3 solution was 
then removed and replaced with 30 µL of 0.05 M IA in 0.1 M NH4HCO3 and 
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incubated at 22˚C for 15 min. Next, the IA solution was removed and plugs 
incubated for 15 min with 150 µL of 0.05 M NH4HCO3. Then, 200 µL ACN was 
added to this solution and incubated for 15 min. Solvent was removed and gel 
plugs were allowed to dry for 30 min under a flow hood. Plugs were rehydrated 
with 10 µL modified trypsin solution (Promega, Madison, WI, USA) in 0.05 M 
NH4HCO3 (enough to completely cover the gel plugs) and incubated with shaking 
overnight at 37 °C. 
3.5.7 Gel-peptide extraction and purification 
 The next day, the digest solution was transferred into a new Eppindorf 
microcentrifuge tube. Next, approximately 20 µL of a 5% ACN, 0.1% formic acid 
(FA) solution was added to the old tube containing the gel plug (twice the volume 
necessary to submerge the gel), and sonicated in a bath for 15 min. To this, 30 
µL of a solution containing 95% ACN, 0.1% FA and 0.001 M NH4CO3 was added 
and sonicated for 15 min. This resulting solution was combined with the 
supernatant digest solution in the new Eppendorf tube. Using a Speed Vac, the 
samples were concentrated to a volume of 10 µl. Using C18 ZipTips (Sigma-
Aldrich, St. Louis, MO, USA), salts and contaminants were removed from the 
tryptic peptide solutions. To prepare the column in the ZipTip, 10 µL of 100% 
ACN was aspirated into the tip and then expelled 5 times. Next, 10 µL of a 50% 
ACN solution containing 0.1% FA was aspirated and expelled 5 times for column 
equilibration. The trypsin digested solution was then slowly drawn up and pushed 
gently out of the column 10 times for peptide adherence. Unwanted contaminants 
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were removed from the peptides in the ZipTip by washing with 10 µL of a 5% 
ACN and 0.1% FA solution 3 times. To elute the peptides from the column, 10 µL 
of a 50% ACN and 0.1% FA solution was drawn up and then expelled into a new 
Eppendorf tube. The eluant was drawn up and expelled 5 times to ensure 
complete peptide removal from the column. Samples were stored at -80˚C until 
MS/MS analysis. 
3.5.8 NanoLC-MS 
 Samples desalted with C18 Zip Tips and reconstituted in 10 µL 5% 
ACN/0.1% FA were analyzed by a nanoAcquity (Waters, Milford, MA)-LTQ 
Orbitrap XL (Thermo Scientific, San Jose, CA) system in data dependent scan 
mode. An in-house packed capillary column (0.1 x 130 mm column packed with 
3.6 µm, 200Å XB-C18) and a gradient with 0.1% FA and ACN/0.1% FA at 200 
nL/min were used for separation. The MS spectra were acquired by the orbitrap 
at 30,000 resolution and MS/MS spectra of the six most intense ions in MS scan 
were obtained by the orbitrap at 7,500 resolution.  
3.5.9 Database interrogation and protein identification 
 Data files from all samples in this dissertation research were searched 
against the most current version of the Swiss-Prot database by SEQUEST 
(Proteome Discoverer v1.4, Thermo Scientific). At least two high-confidence 
peptide matches were required for protein identification (false discovery rate 
<1%). Proteins matched with the same peptides are reported as one protein 
group. Exact peptide masses of digested proteins from the MS experiments were 
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compared with theoretical peptide masses in the database to produce a list of 
potential peptide matches. Proteins receive a confidence score based on the 
number of peptides identified and the percentage of the protein’s amino acid 
sequence covered. The data accompanying the identified protein includes the 
expected molecular weight and isoelectric point. Preliminary verification of the 
identified protein is made by comparing the position of the excised gel plug with 
the expected position of the identified protein. 
3.5.10 Immunoprecipitation 
 Brain proteins (250 µg) were suspended in 500 µL IP buffer [0.05% NP-
40, leupeptin 4 µg/mL, pepstatin 4 µg/mL, aproprotin 5 µg/mL, phosphatase 
inhibitor cocktail 10 µg/mL in a phosphate buffer solution, pH 8 (8 M NaCl, 0.2 M 
KCl, 1.44 M Na2HPO4, 0.24 M KH2PO4, pH adjusted with NaOH)] and allowed to 
shake for 30 min at 4˚C. Next, 50 µL of Protein A/G beads (per sample) were 
washed and centrifuged at 2500 RPM (5 min; 4˚C). The washed beads were 
added to pre-clear the samples of non-specific protein A/G artifacts (90 min; 
4˚C). Samples were centrifuged at 2500 RPM (5 min; 4˚C) and the supernatant 
was transferred to new Eppendorf tubes with an antibody (1:50 dilution) and 
shaken overnight at 4˚C. The next morning, 50 µL of protein A/G beads were 
washed as and incubated with the protein samples (90 min; 4˚C). The 
supernatant was removed and the beads were washed in IP buffer with shaking 
(5 times; 10 min each). Beads were preserved for 1D-PAGE experiments. 
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3.5.11 One-dimensional polyacrylamide gel electrophoresis (1-D PAGE) 
 Whole brain homogenates (50 µg) were suspended in 4X sample loading 
buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% β-mercaptoethanol, 
0.01% Bromophenol Blue] diluted to 1X with distilled water, heated at 95 °C for 5 
min and cooled on ice. Samples and Precision Plus Protein All Blue Standards 
were loaded into a Criterion precast (4-12%) Bis-Tris polyacrylamide 12 well gels 
and run at RT in a Criterion Cell vertical electrophoresis buffer tank (Bio-Rad) 
filled with a 1X dilution of XT MOPS running buffer at 80 V for 15 min to ensure 
proper protein stacking. The voltage was then increased to 120 V for 
approximately 100 min at RT for the duration of the electrophoretic run. 
3.5.12 Western blotting 
 1D-gels were directly transferred to nitrocellulose membranes (0.2 nm) 
using a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V for 30 min. After the 
transfer, membranes were blocked with 3% bovine serum albumin (BSA) in 
Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM NaHPO4 and 0.04% (v/v) 
Tween 20] or TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20] for 1.5 h. 
Primary antibodies were added to blocking solution for 2 h. Blots were rinsed two 
times for 5 min each and one time for 10 min in either Wash Blot or TBS-T, 
followed by a 1 h incubation with a secondary antibody. Blots were rinsed three 
times for 5, 10 and 10 min each in Wash Blot or TBS-T and developed 
chemiluminescently using Clarity Western ECL Substrate (Bio-Rad). After 
developing for 5 min at RT in the dark, blots were scanned using a Bio-Rad 
32 
 
ChemiDoc XRS+ imaging system and quantified using Image Lab software (Bio-
Rad). Blots were then typically rinsed with Wash Blot or TBS-T (5 min, two times) 
and then stripped with Re-Blot Plus Strong solution (GE Healthcare, Pittsburgh, 
PA, USA) for 10 min at RT, followed by two 5 min rinses with Wash Blot or TBS-
T for re-probing with additional antibodies.  
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CHAPTER 4 
QUANTITATIVE EXPRESSION PROTEOMICS AND PHOSPHOPROTEOMICS 
PROFILE OF BRAIN FROM PINK1 KNOCKOUT MICE: INSIGHTS INTO 
MECHANISMS OF FAMILIAL PARKINSON DISEASE 
4.1 Overview 
Parkinson disease (PD) is an age-related, neurodegenerative motor 
disorder characterized by progressive degeneration of dopaminergic neurons in 
the substantia nigra pars compacta and presence of α-synuclein-containing 
protein aggregates. Mutations in the mitochondrial Ser/Thr kinase PTEN-induced 
kinase 1 (PINK1) are associated with an autosomal recessive familial form of 
early-onset PD. Recent studies have suggested that PINK1 plays important 
neuroprotective roles against mitochondrial dysfunction by phosphorylating and 
recruiting Parkin, a cytosolic E3 ubiquitin ligase, to facilitate elimination of 
damaged mitochondria via autophagy-lysosomal pathways. Loss of PINK1 in 
cells and animals leads to various mitochondrial impairments and oxidative 
stress, culminating in dopaminergic neuronal death in humans. Using a 2-D 
PAGE proteomics approach, the differences in expressed brain proteome and 
phosphoproteome between six month-old PINK1-deficient mice and wild-type 
mice were identified. The observed changes in the brain proteome and 
phosphoproteome of mice lacking PINK1 suggest that defects in signaling 
networks, energy metabolism, cellular proteostasis and neuronal structure and 
plasticity are involved in the pathogenesis of familial PD. 
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4.2 Introduction 
Parkinson disease (PD) is the most common neurodegenerative 
movement disorder. The relative risk of developing PD increases with age and 
approximately 1-2% of the population above 65 years is affected (Twelves, 
Perkins et al. 2003, Pilsl and Winklhofer 2012). PD is characterized by the 
accumulation of Serine-129 phosphorylated α-synuclein aggregates (Anderson, 
Walker et al. 2006) within Lewy bodies and the loss of the majority of 
dopaminergic (DA) neurons in the substantia nigra pars compacta, causing 
drastically diminished dopamine release in the striatum (Braak, Tredici et al. 
2003). In addition to the cardinal motor symptoms (resting tremor, bradykinesia, 
rigidity, postural instability), PD patients frequently suffer from a variety of non-
motor symptoms that may occur decades earlier and include cognitive decline, 
depression, hallucinations, REM sleep disorder and anosmia (Chaudhuri, Healy 
et al. 2006, Jankovic 2008). Although the precise cause of PD remains elusive, 
significant contributing factors are believed to include exposure to environmental 
toxins, oxidative stress, inflammation, mitochondrial dysfunction, and failure of 
proteostasis networks associated with protein aggregation (Henchcliffe and Beal 
2008, Bueler 2009, Tansey and Goldberg 2010). 
While the majority of PD cases are sporadic, an estimated 5-10% of 
patients develop PD as a result of inheritable mutations in one of several genes 
(Gasser, Hardy et al. 2011). Mutations in Pink1 are the second most common 
cause of autosomal recessive familial early onset PD (Valente, Abou-Sleiman et 
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al. 2004, Bonifati, Rohe et al. 2005, Bonifati 2012). PINK1 is a mitochondrial 
kinase consisting of 581 amino acids that encode for a mitochondrial targeting 
sequence, a transmembrane domain and a Ser/Thr kinase domain. PINK1 is 
believed to confer neuroprotection by policing mitochondrial integrity (Narendra, 
Jin et al. 2010, Jin and Youle 2012), and a growing amount of research links 
dysfunction of mitochondrial dynamics with PD (Heeman, Van den Haute et al. 
2011, Hauser and Hastings 2013, Van Laar and Berman 2013). DA neurons may 
be particularly vulnerable to mitochondrial dysfunction and oxidative stress due to 
reduced mitochondrial reserve compared to other types of neurons and the 
reliance on calcium influx for pace-making (Liang, Wang et al. 2007, Surmeier, 
Guzman et al. 2011). In normal cells with healthy mitochondria, PINK1 is 
imported to the inner mitochondrial membrane where the N-terminal 
mitochondrial targeting sequence is cleaved by the mitochondrial protease, 
PARL (Deas, Plun-Favreau et al. 2011, Meissner, Lorenz et al. 2011). 
Subsequently, PINK1 is retro-translocated to the cytosol where it is degraded by 
the proteasome (Yamano and Youle 2013). However, a proportion of PINK1 
remains in the cytoplasm (Haque, Thomas et al. 2008, Lin and Kang 2008) and 
cytosolic PINK1 has been implicated in the regulation of various pathways, 
including AKT signal transduction and cell survival, synaptic plasticity, DA 
synthesis and mitophagy (Haque, Thomas et al. 2008, Murata, Sakaguchi et al. 
2011, Akundi, Zhi et al. 2012, Fedorowicz, de Vries-Schneider et al. 2014, Zhou, 
Refai et al. 2014). Import of PINK1 to the inner mitochondrial membrane is 
blocked when the mitochondrial electron transport chain becomes dysfunctional 
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and membrane potential (ΔΨm) is decreased (Matsuda, Sato et al. 2010, Amo, 
Sato et al. 2011). PINK1 then accumulates on the outer mitochondrial membrane 
where it phosphorylates Ser65 in the ubiquitin-like domain of the E3 ligase, 
Parkin, to initiate mitophagy (Kazlauskaite, Kondapalli et al. 2014). When PINK1 
kinase activity is inactivated in mice and flies via gene ablation, mitochondrial 
dysfunction ensues and structurally abnormal mitochondria accumulate in cells 
(Park, Lee et al. 2006, Exner, Treske et al. 2007, Gautier, Kitada et al. 2008, 
Akundi, Huang et al. 2011, Heeman, Van den Haute et al. 2011, Gautier, Giaime 
et al. 2012, Akundi, Zhi et al. 2013). Further, mutations in PINK1 cause a 
decrease in mitochondrial complex I activity and ATP production, as well as 
elevated production of reactive oxygen species (Yuan, Guo et al. 2010, Deas, 
Plun-Favreau et al. 2011, Koh and Chung 2012, Morais, Haddad et al. 2014). 
In this study, we utilized a 2-D PAGE proteomics approach to identify 
proteins with differential expression levels and phosphorylation states in the 
brains of PINK1 knockout (KO) mice versus wild-type controls to further study the 
molecular mechanisms of PINK1-related PD.  
4.3 Materials and Methods 
4.3.1 Materials 
All chemicals used in these studies were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) with noted exceptions: Criterion precast polyacrylamide 
gels, ReadyStrip IPG strips, TGS and XT MOPS electrophoresis running buffers, 
0.2 nm nitrocellulose membrane, Precision Plus Protein All Blue Standards, 
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Sypro Ruby Protein Stain, mineral oil, dithiothreitol, iodoacetamide, biolytes, and 
urea were purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond 
phosphoprotein stain, PeppermintStick phosphoprotein molecular weight marker, 
and anti-phosphoserine, anti-phosphothreonine and anti-phosphotyrosine 
antibodies raised in rabbits were purchased from Invitrogen (Grand Island, NY, 
USA). Anti-HSP70 and anti-aldolase A antibodies raised in rabbits were 
purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-MAPK1/2 
polycolonal antibody raised in rabbits, C18 ZipTips, and Re-Blot Plus Strong 
stripping solution were purchased from Millipore (Billerica, MA, USA). Calmodulin 
polyclonal antibody raised in rabbits was purchased from Santa Cruz 
Biotechnology (Dallas, TX, USA).  Amersham ECL rabbit IgG horseradish 
peroxidase (HRP)-linked secondary antibody, protein A/G beads and ECL-Plus 
Western blotting detection reagents were purchased from GE Healthcare 
(Pittsburgh, PA, USA). Modified trypsin solution was obtained from Promega 
(Madison, WI, USA). 
4.3.2 Animals and brain tissue 
The generation and characterization of the PINK1-deficient mice used in 
this study has been described previously (Akundi, Huang et al. 2011). The animal 
housing facility regularly underwent serological testing to certify a healthy, virus 
and pathogen free facility. Subjects were fed Richland Laboratory Rodent Diet 
5001 and water ad libitum. The animal rooms were maintained with a 12 hour 
light:12 hour dark cycle (lights on at 0600) at 20-22˚C. For the experimental 
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groups of animals, n=6 per group, whole brains were isolated from mice rendered 
unconscious by CO2 inhalation and euthanized by cervical dislocation using 
procedures approved by the UK Institutional Animal Care and Use Committee.  
Dissected brains were flash-frozen in liquid nitrogen and stored at -80˚C until 
use. 
4.3.3 Sample preparation 
Mouse brains were thawed and individual homogenates were prepared 
using a Wheaton glass homogenizer (~40 passes) with ice-cold isolation buffer 
[0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES, 0.2µg/ml PMSF, 
4µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml aprotinin and 5 µg/ml phosphatase 
inhibitor cocktail 2]. Homogenates were vortexed on ice and then sonicated on 
ice for 10 s at 20% power, two times, with a Fisher 550 Sonic Dismembrator 
(Pittsburgh, PA, USA). Protein concentrations of the homogenates were 
determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al. 
1985). 
4.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
Isoelectric focusing (IEF). IEF was performed as described previously 
(Sultana, Boyd-Kimball et al. 2007). Briefly, brain homogenate proteins (200 µg) 
were shaken for 2 h at RT in 200 µl of  rehydration buffer [8 M urea, 2.0% (w/v) 
CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01% Bromophenol Blue]. 
Samples (200 µl) were applied to 11 cm pH 3-10 ReadyStrip IPG strips (linear 
gradient). Strips were actively rehydrated at 20 °C for 18 h at 50 V. Next, the 
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samples were isoelectrically focused at a constant temperature of 20 °C 
beginning at 300 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 8000 V for 8 h, and 
finishing at 8000 V for 10 h. IPG strips were stored at -80 °C until second 
dimension separation (SDS PAGE). 
SDS PAGE. IEF strips were thawed and equilibrated with buffer A and 
buffer B (buffer A [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 30% v/v 
glycerol, 0.5% DTT], buffer B [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% (w/v) SDS, 
30% v/v glycerol, 4.5% iodoacetemide]). IPG strips were next placed into 
Criterion precast linear gradient (8–16%) Tris–HCl polyacrylamide gels, 1 IPG + 
1 Well Comb, 11cm. Invitrogen PeppermintStick molecular weight marker and 
samples were run at a constant voltage of 200 V for approximately 65 min in Tris-
Glycine SDS running buffer. 
4.3.5 Gel staining 
Proteins and phosphoproteins were detected using SYPRO Ruby and 
Pro-Q Diamond phosphoprotein gel stain according to manufacturer’s directions 
and as previously described (Di Domenico, Sultana et al. 2011). Briefly, gels 
were fixed in solution [10% (v/v) acetic acid, 50% (v/v) methanol] (50 mL) and 
washed in deionized water. Next, 60 mL of Pro-Q Diamond stain was added with 
gentle rocking for 90 min. Gels were then destained 4 times for 30 min each in 
100 mL of destaining solution [20% acetonitrile, 50mM sodium acetate, pH 4]. 
The gels were washed in deionized water and scanned at 580 nm using a GE 
Healthcare Life Sciences Typhoon FLA 9500 scanner. The gels were then 
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stained overnight with 50 mL of Sypro Ruby gel stain. Gels were rinsed and 
placed in deionized water. Gels were scanned at 450 nm and then stored at 4 °C 
until protein spot excision. 
4.3.6 Image analysis 
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2D-
gel images of wild-type (WT) and PINK1 KO samples were quantified by 
densitometry using PDQuest 2-D Analysis Software (Hercules, CA, USA). 
Intensities of each gel were normalized to the total density of each gel. Protein 
spots were manually and automatically matched with the PDQuest program. Spot 
densities in KO and WT samples were compared and spots with a statistically 
significant difference based on a Student’s two-tailed t-test (p<0.05) were 
considered for in-gel trypsin digestion and subsequent identification. 
Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel 
images of PINK1-/- and WT samples were quantified and matched together in the 
same manner as the SYPRO Ruby-stained gels. Next, two master gels were 
chosen, one from the Pro-Q Diamond images and one from the Sypro Ruby 
stained images. The phosphoprotein master image was then matched to the 
master Sypro Ruby stained image in the same manner as described above. The 
PDQuest software provided numerical data corresponding to the intensity of the 
protein spot. The phosphoprotein spot densities were then normalized to the 
Sypro Ruby spot densities and the resultant normalized phosphoprotein spot 
densities in KO and WT samples were compared and spots with a statistically 
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significant difference based on a Student’s two-tailed t-test (p<0.05) were 
considered for in-gel trypsin digestion and subsequent identification. 
4.3.7 In-gel trypsin digestion/peptide extraction 
Protein spots were excised from 2D-gels with a clean, sterilized razor 
blade and individually transferred to Eppendorf microcentrifuge tubes for trypsin 
digestion as previously described (Thongboonkerd, McLeish et al. 2002). Gel 
plugs were incubated with 20 µL of 0.1 M ammonium bicarbonate (NH4HCO3) for 
15 min, and with 30 µL of acetonitrile for 15 min. Gel plugs were dried under a 
flow hood at RT for 30 min. Next, 30 µl of 20 mM DTT in 0.1 M NH4HCO3 was 
added at 56°C for 45 min. The DTT/NH4HCO3 solution was then removed and 
replaced with 30 µl of 0.05 M iodoacetamide (IA) in 0.1 M NH4HCO3 and 
incubated at RT for 15 min. Next, the IA solution was removed and plugs 
incubated for 15 min with 150 µl of 0.05 M NH4HCO3 at RT. Then, 200 µl 
acetonitrile was added to this solution and incubated for 15 min at RT. Solvent 
was removed and gel plugs were allowed to dry for 30 min at RT under a flow 
hood. Plugs were rehydrated with modified trypsin solution in 0.05 M NH4HCO3 
(enough to completely cover the gel plugs) and incubated with shaking overnight 
at 37 °C. The next day, the salts and contaminants were removed from the tryptic 
peptide solutions using C18 ZipTips in accordance with manufacturer’s directions. 
Samples were stored at -80˚C until MS/MS analysis. 
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4.3.8 NanoLC-MS with Data Dependent Scan 
Samples desalted with C18 Zip Tips were reconstituted in 10 µL 5% 
ACN/0.1% FA and analyzed by a nanoAcquity (Waters, Milford, MA)-LTQ 
Orbitrap XL (Thermo Scientific, San Jose, CA) system in data dependent scan 
mode. An in-house packed capillary column (0.1 x 130 mm column packed with 
3.6 µm, 200Å XB-C18) and a gradient with 0.1% FA and ACN/0.1% FA at 200 
nL/min were used for separation. The MS spectra were acquired by the orbitrap 
at 30,000 resolution and MS/MS spectra of the six most intense ions in MS scan 
were obtained by the orbitrap at 7,500 resolution. Data files from each sample 
were searched against the most current version of the Swiss-Prot database by 
SEQUEST (Proteome Discoverer v1.4, Thermo Scientific). At least two high-
confidence peptide matches were required for protein identification (false 
discovery rate <1%). Proteins matched with the same peptides are reported as 
one protein group. 
4.3.9 Immunoprecipitation and Western blotting validations 
Immunoprecipitation (IP). Whole brain homogenized protein extracts (250 
µg) were suspended in 500 µL IP buffer [0.05% NP-40, leupeptin 4 µg/mL, 
pepstatin 4 µg/mL, aproprotin 5 µg/mL, phosphatase inhibitor cocktail 10 µg/mL 
in a phosphate buffer solution, pH 8 (8 M NaCl, 0.2 M KCl, 1.44 M Na2HPO4, 
0.24 M KH2PO4, pH adjusted with NaOH)] and allowed to shake for 30 min at 
4˚C. Next, 50 µL of Protein A/G beads (per sample) were washed and 
centrifuged at 2500 RPM for 5 min at 4˚C. The washed beads were added to the 
43 
 
individual protein samples to pre-clear of non-specific protein A/G artifacts for 90 
min at 4˚C. Samples were then centrifuged at 2500 RPM for 5 min at 4˚C and the 
supernatant was transferred to new Eppendorf tubes with either anti-MAPK1 
antibody (1:50 dilution) or anti-calmodulin antibody (1:50) and shaken overnight 
at 4˚C. The next morning, 50 µL of protein A/G beads were washed as and 
incubated with the protein samples for 90 min at 4˚C. After removing the 
supernatant, the beads were again washed 5 times with IP buffer with 10 min of 
shaking in IP buffer between centrifugations. The beads were preserved for a 
1D-PAGE experiment. 
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Whole 
brain homogenates (50 µg) or beads from immunoprecipitation experiments were 
suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% 
SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue] diluted to 1X with 
distilled water, heated at 95 °C for 5 min and cooled on ice. Samples and 
Precision Plus Protein All Blue Standards were loaded into a Criterion precast (4-
12%) Bis-Tris polyacrylamide 12 or 18 well gels and run at RT in XT MOPS 
running buffer at 80 V for 15 min. The voltage was then increased to 120 V for 
approximately 100 min at RT for the duration of the electrophoretic run. 
1D-Western blotting. 1D-gels were directly transferred to nitrocellulose 
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad, 
Hercules, CA, USA). After the transfer, membranes were incubated in a blocking 
solution of 3% bovine serum albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM 
44 
 
NaH2PO4, 17 mM NaHPO4 and 0.04% (v/v) Tween 20] at RT for 1.5 h.  Each 
protein of interest was detected by incubation with a primary antibody (1:8000 
dilution), in blocking solution at RT with gentle rocking for 2 h. Blots were rinsed 
two times for 5 min each and one time for 10 min in Wash Blot, followed by a 1 h 
incubation with a horseradish peroxidase (1:3000) secondary antibody at RT with 
gentle rocking. Blots were rinsed three times for 5, 10 and 10 min each in Wash 
Blot and developed chemiluminescently using Clarity Western ECL substrate. 
After developing for 5 min at RT in the dark, blots were scanned using a Bio-Rad 
ChemiDoc XRS+ imaging system and quantified using Image Lab software 
(Hercules, CA, USA). Blots rinsed and then stripped with Re-Blot Plus Strong 
solution for exactly 10 min at RT, followed by three 5 min rinses with Wash Blot. 
The membranes were then blocked once again in 3% BSA for 1.5 h. Next, an 
anti-tubulin antibody (1:20000) or anti-phosphoserine, anti-phosphothreonine and 
anti-phosphotyrosine antibodies (1:10000) were added to the Wash Blot solution 
with 2 h more of gentle rocking at RT. Membranes were then washed, incubated 
with a secondary HRP-conjugated antibody, washed, developed 
chemiluminescently and scanned.  
4.3.10 Statistical analysis 
All statistical analyses were performed using a two-tailed Student’s t-test, 
in which p<0.05 was considered statistically significant for Western blot and 
PDQuest analysis. Fold-change values of easily discernible protein spots were 
determined by dividing the average, normalized spot intensities in the knockout 
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gels by the average, normalized spot intensities of the wild-type gels. Only spots 
with a 1.25 fold change or greater in normalized spot density were considered for 
MS/MS analysis. Protein and peptide identifications obtained with the SEQUEST 
search algorithm with p<0.01 were considered to be statistically significant. 
4.4 Results 
4.4.1 PDQuest and MS/MS analysis 
Proteomic analyses of the isolated brain proteins were conducted using a 
2D-PAGE approach with Sypro Ruby and Pro-Q Diamond staining in conjunction 
with MS/MS analysis. Protein spot intensities were compared between PINK1(-/-) 
and PINK1(+/+) control mice to determine differentially expressed and 
phosphorylated proteins. Figure 4.1 shows representative examples obtained 
from SYPRO Ruby-stained 2-D gel images of the isolated proteins from 6 month 
old PINK1(-/-) and PINK1(+/+) mice with significant differentially expressed proteins 
labeled. Figure 4.2 shows typical images of Pro-Q Diamond-stained gels with 
protein spots showing altered phosphorylation states labeled in the images. 
Graphs displaying normalized phosphorylation intensity of each sample are also 
provided. 
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Figure 4.1 Sypro Ruby-stained gels of PINK1 KO and WT mice. 
Representative 2-D gel images of isolated proteins from the brains of 6 
month-old WT mice and PINK1 KO mice (n=6). Proteins whose 
expression was significantly altered are labeled in the images and NFL 
spot is enlarged to demonstrate differential levels (p<0.05). Used by 
permission of John Wiley and Sons. 
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Figure 4.2 Pro-Q Diamod-stained PINK1 KO and WT gels. Representative 
images of Pro-Q Diamond-stained 2-D gels with protein spots showing altered 
phosphorylation states labeled in the images. Bar graphs displaying normalized 
phosphorylation intensity (Pro-Q Diamond spot density divided by SYPRO Ruby 
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spot density) of each of n=6 WT (blue) and n=6 KO (red) samples [total of 12 
individual gels] are also provided (p-value<0.05). Used by permission of John 
Wiley and Sons. 
PDQuest analysis of all of the 2-D images found 29 protein spots suitable 
for extraction and whose expression or phosphorylation state was significantly 
altered in the brains of PINK1(-/-) mice as compared to the WT controls. After in-
gel trypsin digestion and peptide extraction, MS/MS analysis coupled to 
interrogation of protein databases was utilized to determine the identity of the 
proteins. Tables 4.1 and 4.2 list the proteins in the brains of PINK1(-/-) mice that 
showed significantly altered expression or phosphorylation states. Other 
information listed in the tables include: the spot number as labeled by the 
PDQuest program, the SwissProt accession number, percentage of the protein 
sequence covered by matching peptides, the number of peptide sequences 
identified by the MS/MS analysis, the protein confidence score, the expected 
molecular weight and isoelectric point of the identified protein, as well as the fold-
change levels and p-values obtained from the PDQuest analysis. Regarding fold-
change values, a ↑1.33-fold means the protein expression in the KO brain is 33% 
more than in WT brain. A ↓0.0885-fold means protein expression in the KO brain 
is 91.15% less than in WT brain. All proteins were identified by more than one 
peptide sequence. Further, identified protein spots were visually compared 
against the theoretical molecular weights and isoelectric points from the mass 
spectrometry analysis.  
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Table 4.1 Proteins with altered expression in brain of PINK1 KO mice. 
PDQuest and MS/MS results of brain proteins with significantly altered 
expression in the PINK1 KO mice versus WT mice. Fold calculated by dividing 
average KO protein spot intensity by WT protein spot intensity. 
 
The 23 brain proteins with significantly altered expression were identified as: 
neurofilament light peptide (↓0.580-fold), V-type proton ATPase subunit F 
(↓0.725-fold), prohibitin (↓0.464-fold), dihydropyrimidinase-related protein 2 
(DRP2, also called collapsing response mediated protein 2, CRMP2) (↓0.0186-
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fold), heat shock-related 70 kDa protein 2 (↓0.213-fold), acyl-protein thioesterase 
1 (↓0.0130-fold), carbonyl reductase [NADPH] 3 (↓0.0244-fold), proteasome 
subunit alpha type-2 (↓0.0898-fold), hypoxanthine-guanine 
phosphoribosyltransferase (↓0.0885-fold), malate dehydrogenase, cytoplasmic 
(↓0.0121-fold), actin-related protein 2/3 complex subunit 2 (↓0.0110-fold), 
voltage-dependent anion-selective channel protein 2 (↓0.607-fold), isocitrate 
dehydrogenase [NADPH] cytoplasmic (↓0.226-fold), vesicle-fusing ATPase 
(↓0.0396-fold), elongation factor 2 (↓0.411-fold) and peptidyl-prolyl cis-trans 
isomerase A, also known as cyclophilin A (↓0.181-fold), gamma-enolase (↑1.24-
fold), T-complex protein 1 subunit epsilon (↑1.33-fold), D-3-phosphoglycerate 
dehydrogenase (↑3.69-fold), isoform 3 of dynamin-1 (↑1.41-fold), transgelin-3 
(↑1.47-fold), fructose-bisphosphate aldolase A (↑2.99-fold) and transketolase 
(↑1.52-fold).  
The six proteins found to have differential phosphorylation states were: 
calmodulin (↓0.418-fold), 14-3-3 protein epsilon (↓0.480-fold), neurofilament 
medium polypeptide (↓0.275-fold), V-type proton ATPase catalytic subunit A 
(↓0.313-fold), dual specificity mitogen-activated protein kinase kinase 1 (↑2.34-
fold), and mitogen-activated protein kinase 1 (↑3.39-fold). 
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Table 4.2 Proteins with altered phosphorylation levels in brain of PINK1 KO 
brain. PDQuest and MS/MS results of proteins with significantly altered 
phosphorylation states in the brain of PINK1 KO mice versus WT mice.  
 
4.4.2 Immunoprecipitation and Western blot validation experiments 
To validate the changes in protein expression and phosphorylation as 
determined by the PDQuest analysis of the 2-D gels, immunochemistry and 1-D 
Western blotting analysis of PINK1(-/-) and WT samples was performed. Figures 
4.3 A and B show the Western blot images from the immunoprecipitation 
experiments after probing with anti-phosphoserine, anti-phosphothreonine and 
anti-phosphotyrosine antibodies where the immunoprecipitated protein, MAPK1 
and calmodulin, respectively, was used as the loading control. Figures 4.3 C & D 
display the corresponding histogram plot representations of the data.  
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Figure 4.3 MAPK1 and CaM differential phosphorylation levels in brain of 
PINK1 KO mice. Western blot validations and corresponding bar graph 
representations from immunochemistry experiments of (A & C) the significant 
increase in the phosphorylation of MAPK1 and (B & D) the significant decrease in 
the phosphorylation of Calmodulin (CaM) in the brains of PINK1 KO mice as 
compared to WT mice using the corresponding IP antibody as the loading control 
(n=5, p-value<0.05). Antibodies detected by chemiluminescence. Used by 
permission of John Wiley and Sons. 
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Figure 4.4 HSP70 and aldolase A expression in PINK1 KO brain. Western 
blot validations and corresponding bar graph representations of (A & C) the 
down-regulation of HSP70.2 and (B & D) the up-regulation of aldolase A in the 
brains of PINK1 KO mice as compared to WT mice using tubulin as a loading 
control (n=6, p-value<0.05). Antibodies detected by chemiluminescence. Used by 
permission of John Wiley and Sons. 
The findings from these analyses confirmed a significant increase in the 
phosphorylation of MAPK1 (p=0.045) and a decrease in the phosphorylation of 
calmodulin (p=0.032) in the brain of PINK1(-/-) mice. Figures 4.4 A & B present 
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the Western blot images of PINK1(-/-) and control samples after probing with 
antibodies for HSP70 protein 2 and aldolase A, respectively, where tubulin was 
used as the loading control. Figures 4.4 C& D are the corresponding bar graphs 
of the results. The results of the Western blot analyses confirmed a significant 
decrease in the expression of HSP70 protein 2 (p=0.047) and a significant 
increase in the expression of aldolase A (p=0.049) in the PINK1(-/-) model. The p-
values of most of these results are slightly higher than the values obtained from 
the 2-D proteomic studies. These differences may be attributed to the sensitivity 
of the Sypro Ruby staining of the 2-D images as compared to the range 
limitations of the chemiluminescent development of the 1-D Western blots.  
4.5 Discussion  
This current study focuses on protein expression and phosphorylation 
changes in the brains of 6 month-old PINK1(-/-) mice compared to PINK1(+/+) mice. 
Six month-old mice were selected based on the observation that at this age 
PINK1(-/-) mice begin to exhibit a PD phenotype, including reduced dopamine 
levels, providing a model to study early changes occurring in brains with PINK1-
related disease progression (Akundi, Huang et al. 2011). Proteomics studies 
revealed twenty-nine proteins with significantly altered expression or 
phosphorylation levels in the brains of PINK1 knockout mice (versus control 
mice). These proteins can be subdivided into the following categories that are 
discussed separately below: cellular signaling, energy metabolism, proteostasis 
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networks, oxidative stress, and neuronal plasticity, neurotransmission and 
structure.  
4.5.1 Cellular signaling 
Regulation of protein phosphorylation status by protein kinases and 
protein phosphatases is essential in the control of cellular signaling pathways. 
Ablation of the kinase PINK1 in mice revealed deregulated downstream 
phosphorylation events in the brain that may contribute to familial PINK1-related 
PD pathogenesis. Interestingly, lack of PINK1 is associated with increased 
phosphorylation of both MAP kinase kinase 1 (MEK1) and its downstream target 
MAPK1 that modulate vital functions including cell cycle, immunity, autophagy, 
apoptosis, and cell survival (Dzamko, Zhou et al. 2014). Interestingly, it has been 
reported that PINK1 deficiency resulted in increased p38 phosphorylation leading 
to dysfunction of astrocytes (Choi, Kim et al. 2013). In many neurodegenerative 
disorders, MAPKs display increased activity and can produce substantial 
physiological effects with only modest changes in their phosphorylation state 
(Zhu, Guo et al. 2003, Di Domenico, Sultana et al. 2011). Phosphorylated 
MAPKs have been shown to aggregate in the halo region of Lewy bodies and 
may have an early pathogenic role in PD (Zhu, Kulich et al. 2002).  
Two additional ubiquitous signaling proteins were found to have 
decreased phosphorylation states in the brains of PINK1(-/-) mice: calmodulin 
(CaM) and 14-3-3 protein epsilon. CaM has been identified as a regulator of 
more than 100 proteins involved in numerous pathways regulating apoptosis, 
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neuronal plasticity, cytoskeletal organization, neurotransmitter release, cellular 
growth and proliferation and is a vital regulator of calcium homeostasis 
(DeLorenzo 1980, Benaim and Villalobo 2002, Xia and Storm 2005). 14-3-3 
proteins are known to interact with more than 200 ligands including: kinases, 
phosphatases and transmembrane receptors and have been implicated in 
numerous neurological disorders (Fu, Subramanian et al. 2000, Foote and Zhou 
2012). Aberrant phosphorylation of either of these identified proteins has the 
potential to cause a myriad of deleterious downstream effects.  
Prohibitin (PHB), another ubiquitously expressed pleiotropic modulator of 
signaling pathways, was found to have significant down-regulated expression in 
the brains of PINK1 KO mice. One of PHB’s more interesting functions is as a 
chaperone in the assembly of the electron transport chain, and reduced 
production of ATP has been noted with the loss of PINK1 (Theiss and Sitaraman 
2011). Additionally, PHB also has been reported to play a defensive role against 
oxidative stress, and decreased expression of PHB has been correlated to the 
aging process (Robinson, Joshi et al. 2011), both risk factors or mediators of PD. 
Further supporting the results of this study, PHB has been shown to be 
significantly decreased in brains of subjects with PD (Ferrer, Perez et al. 2007, 
Zhou and Qin 2013). 
Decreases in expression were also found in acyl-protein thioesterase 1 
(APT1) and peptidyl-prolyl cis-trans isomerase A (PPIaseA). APT1 catalyzes the 
removal of palmitate at CYS residues from the cytosolic surface of membrane 
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proteins (Dekker, Rocks et al. 2010). APT1 regulates protein-protein interactions, 
cell signaling, membrane localization, subcellular trafficking, vesicle transport and 
lysosomal degradation (Tian, McClafferty et al. 2012, Kong, Peng et al. 2013). 
PPIaseA, also known as cyclophilin A, is a multifunctional proteins that catalyzes 
the cis-trans isomerization at proline residues, playing a role in cellular signaling, 
inflammation response and protein trafficking (Lang, Schmid et al. 1987, 
Takahashi, Hayano et al. 1989).  
4.5.2 Energy metabolism 
A significant number of proteins identified as having altered expression 
are involved in energy metabolism pathways. We and other groups have shown 
that PINK1 deficiency impairs mitochondrial respiration, triggering metabolic 
adaptations including increased glycolysis (Diedrich, Kitada et al. 2011, Yao, 
Gandhi et al. 2012, Akundi, Zhi et al. 2013, Requejo-Aguilar, Lopez-Fabuel et al. 
2014). The results of previous discoveries combined with the results of this 
current investigation provide a more detailed molecular mechanism for the 
increase of glycolysis noted in PINK1-related PD. Specifically, from this current 
study, we observed an up-regulation of several proteins related to glycolysis in 
PINK1-deficient mice. These include fructose-bisphosphate aldolase A (ALDOA), 
gamma-enolase (ENO2), D-3-phosphoglycerate dehydrogenase (3-PGDH), and 
transketolase (TK). Not only are ALDOA and ENO2 substrates directly involved 
in the glycolytic pathway, but ENO2 has been shown to be neuroprotective when 
up-regulated in microglial cells (Butterfield and Lange 2009, Hafner, Glavan et al. 
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2013). Further, 3-PGDH is an oxidoreductase that catalyzes the transition of 3-
phosphoglycerate to 3-phosphohydroxypyruvate, the first step in the serine 
biosynthesis pathway. L-serine is a crucial neurotrophic factor in the CNS as it is 
a precursor for nucleotides, neurotransmitters, sphingolipids, phosphatidylserine 
and L-cysteine (Ren, Qiang et al. 2013). Moreover, the increased levels of 
neuronal-specific ENO2 and 3-PGDH are likely a cellular stress response to 
prevent cell death in the absence of PINK1 (presence of mitochondrial 
dysfunction), consistent with the finding that blocking glycolysis in PINK1-
deficient mouse embryonic fibroblasts led to rapid death of these cells (Akundi, 
Zhi et al. 2013).  Additionally, TK is an enzyme that catalyzes two key reactions 
in the pentose phosphate pathway (PPP), resulting in the production of 
glyceraldehyde-3-phosphate and fructose-6-phosphate. Up-regulation of TK 
provides for more of these essential substrates to be fed into the glycolytic 
pathway. Moreover, the PPP provides NADPH, which is needed to reduce 
oxidized glutathione (GSSG) to reduced glutathione (GSH). Loss of GSH is 
arguably the earliest neurochemical alteration in PD brain. 
Dopaminergic (DA) neurons are reportedly more reliant upon 
mitochondrial energy metabolism than other types of neurons due, in part, to 
their reduced mitochondrial reserve (Kingsbury, Cooper et al. 2001, Van Laar 
and Berman 2013). In PD, depletion of ATP is major factor in the cascade 
leading to the neurodegeneration of these DA neurons (Mallajosyula, Chinta et 
al. 2009). Significant decreased levels of cytoplasmic malate dehydrogenase 
(MDHc), and hypoxanthine-guanine phosphoribosyltransferase (HPRT) were 
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observed in the brain homogenates of PINK1 KO mice. MDHc is a metabolic 
protein of the malate-aspartate shuttle that aids in the transfer of reducing 
equivalents of NADH into the mitochondria for consumption by complex I of the 
electron transport chain. A reduction of this key enzyme would result in impaired 
mitochondrial ATP synthesis. Moreover, reduced MDHc expression is a plausible 
contributor to the reduction of complex I activity that is reported in PD and PINK1 
model organisms (Gautier, Kitada et al. 2008, Liu, Acin-Perez et al. 2011), as 
cytosolic NADH cannot cross the outer mitochondrial membrane without the 
enzymatic action of MDHc.  
HPRT is another metabolic enzyme that is an essential player in the 
purine salvage pathway for the generation of purine nucleotides (Sculley, 
Dawson et al. 1992). Increasing nucleotide metabolism is essential for 
mitochondrial biogenesis fission events to maintain a pool of healthy 
mitochondria and has been shown to be neuroprotective in PINK1 models of PD 
(Tufi, Gandhi et al. 2014). Interestingly, HPRT deficiency is reported to 
dysregulate neurogenesis (Guibinga, Hsu et al. 2010), which in adults is 
responsible for generating new neurons for the olfactory bulb (Altman 1969) and 
the subgranular zone of the hippocampus (Eriksson, Perfilieva et al. 1998). 
Consistent with this observation, PINK1 deficient mice have anosmia (Glasl, 
Kloos et al. 2012). And, in PD, impaired olfaction occurs 2-7 years before onset 
of motor symptoms in over 75% of patients (Lang 2011). Furthermore, HPRT 
knockout mice were shown to have decreased levels of dopamine that correlated 
with age (Micheli, Camici et al. 2011). Thus, we suggest that decreased 
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expression of HPRT could quite possibly be a candidate as an early PD 
biomarker. 
4.5.3 Proteostasis networks 
Disruption of two intracellular degradation systems, the ubiquitin-
proteasome system and autophagy-lysosome pathway, has been shown to play 
central roles in PD pathology (Lim 2007, Pan, Kondo et al. 2008). Dysregulation 
of these pathways causes accumulation and aggregation of abnormal proteins 
and damaged organelles, leading to cellular toxicity, dysfunction and 
neurodegeneration (Pan, Kondo et al. 2008). Without functional PINK1, 
mitophagy fails, resulting in accumulated dysfunctional mitochondria and 
elevated apoptotic rates (Lenzi, Marongiu et al. 2012). In this current study of 
PINK1 KO mouse brain, two subunits of V-type proton ATPase were found to be 
altered in either phosphorylation or expression: V-ATPaseA and V-ATPaseF. V-
ATPase is a membrane transport protein whose function is to establish a proton 
gradient, creating an acidic environment in many intracellular compartments, 
including lysosomes (Beyenbach and Wieczorek 2006). Previously, we have 
shown that C. elegans expressing mutant α-synuclein and tau have altered V-
ATPase and decreased autophagy (Di Domenico, Sultana et al. 2012). Further, 
when the function of V-ATPase is inhibited, autophagy may become 
dysfunctional because the acidic environment in lysosomes required for 
enzymatic hydrolysis cannot be generated (Pan, Kondo et al. 2008). Additionally, 
with diminished lysosomal function, more α-synuclein can accumulate and impair 
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cellular trafficking which may lead to neurodegeneration in PD (Dehay, Martinez-
Vicente et al. 2013). The catalytic subunit A (V-ATPaseA) was found to have 
decreased phosphorylation. V-ATPaseA is known to be phosphorylated by 
protein kinase A at Ser-175; and, in liver cells, phosphorylation of subunit A leads 
to a decreased activity (Alzamora, Thali et al. 2010), possibly due to decreased 
binding affinity of ATP to V-ATPaseA. The F subunit of V-type proton ATPase (V-
ATPaseF) was identified as having decreased expression, suggesting an overall 
decrease in vacuolar acidification and autophagy. 
Additional proteins involved in the proteostasis network that were found to 
have significantly decreased expression were: proteasome subunit alpha type-2 
(PSA2), heat shock-related 70 kDa protein 2 (HSP70.2), and voltage-dependent 
anion-selective channel protein 2 (VDAC-2). PSA2 proteins compose the end 
rings of the 20S proteasome, an ATP dependent multi-protein assembly that is 
known to degrade oxidized proteins (Davies 2001).  Hence, elevated oxidatively 
modified proteins in PD conceivably could be due in part to diminished function of 
the 20S proteasome. Moreover, since the 20S proteasome comprises the core of 
the 26S proteasome, the overall protein degradation abilities of ubiquitin-
proteasome system could conceivably be diminished. Consistent with these 
results, decreased proteasomal function and expression has been noted in PD 
patients and PD animal models (Bukhatwa, Zeng et al. 2010, Ebrahimi-Fakhari, 
Wahlster et al. 2012, Martins-Branco, Esteves et al. 2012).  
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  HSP70 is an ubiquitously expressed molecular chaperone that mediates 
the folding of newly translated proteins, stabilizes proteins against aggregation, 
aids in clathrin mediated endocytosis, exocytosis (including synaptic vesicles) 
and is an important mediator for relaying targeted proteins to the ubiquitin-
proteasome system and autophagy-lysosomal pathways (Meimaridou, Gooljar et 
al. 2009, Alvarez-Erviti L and et al. 2010, Redeker, Pemberton et al. 2012). We 
have previously demonstrated that viral gene transfer of HSP70 protects against 
toxin-induced dopaminergic neuron loss in a sporadic model of PD in mice 
(Dong, Wolfer et al. 2005). In addition, HSP70 suppressed α-synuclein toxicity in 
a transgenic Drosophila model of familial PD (Auluck, Chan et al. 2002). 
Therefore, the finding of reduced HSP70 expression is intriguing and is 
consistent with the notion of an increased vulnerability of dopaminergic neurons 
to mitochondrial and proteotoxic stressors in the absence of PINK1.  
VDAC2 is a mitochondrial membrane porin that opens at low or zero 
membrane potential, and allows diffusion of small hydrophilic molecules and ions 
and thus plays a role in mitochondrial metabolic processes (Blachly-Dyson and 
Forte 2001, Shoshan-Barmatz and Gincel 2003). VDACs are also involved in 
mitochondrial autophagy, possibly by recruiting Parkin to docking sites in 
defective mitochondrial membranes, tagging the organelles for degradation by 
lysosomes (Sun, Vashisht et al. 2012). A decrease in the expression of this 
protein in PD would inhibit the removal of malfunctioning mitochondria, 
contributing to an increase of cellular detritus and subsequent neuronal 
dysregulation.  
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4.5.4 Oxidative Stress  
Increased levels of reactive oxygen species have been noted in PD and 
PD model organisms (Jenner 2003, Heeman, Van den Haute et al. 2011, Di 
Domenico, Sultana et al. 2012, Varcin, Bentea et al. 2012). Not only does 
aberrant mitochondrial function and dysfunction of proteostasis networks impact 
oxidative stress, but loss of neurotropic factors contributes as well. Consistent 
with this observation, two additional neuroprotective enzymes were found in the 
present study to have decreased expression in in the brain of the PINK1 KO 
mouse: carbonyl reductase [NADPH] 3 (CBR3) and cytoplasmic isocitrate 
dehydrogenase [NADP+] (IDHc). CBR3 is an oxidoreductase that reduces 
oxidative stress by catalyzing the reduction of carbonyls to their corresponding 
alcohols (Miura, Nishinaka et al. 2008). This reduction of oxidative stress-
mediated carbonyls leads to the creation of a less toxic species (Oppermann 
2007). IDH also plays a defensive role combating oxidative damage as it 
contains a tagging sequence that can direct damaged proteins to peroxisomes 
for degradation (Xu, Zhao et al. 2004). Additionally, IDHc, utilizing NADP+ as a 
cofactor, generates NADPH, which noted above is an important cofactor for 
maintaining reduced glutathione, a key antioxidant. Supporting our data, 
knockdown studies of IDHc in PC12 cell lines demonstrated changes in cellular 
redox status, increased oxidative damage and apoptotic cell death (Yang and 
Park 2011). Further, cell lines that expressed lower levels of IDHc were shown to 
have increased lipid peroxidation, peroxide generation and oxidative damage to 
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DNA (Lee, Koh et al. 2002). Consequently, we opine that these proteins may 
contribute to the oxidative stress observed in PD brain. 
4.5.5 Neuronal plasticity, trafficking and structure 
Mitochondrial dysfunction is implicated in various neuronal degenerative 
diseases, leading to decreased neuroplasticity and neurite outgrowth (Cheng, 
Hou et al. 2010). Furthermore, PINK1 has previously been reported to be a 
possible contributor in the regulation of neurite outgrowth, and its deficiency 
causes dysregulation of this process (Samann, Hegermann et al. 2009). In the 
present study, we uncovered a significant decrease in two proteins involved in 
neurite outgrowth: elongation factor 2 (EF2) and dihydropyrimidase-related 
protein 2 (DRP2; CRMP2). EF2 mediates ribosomal translocation of peptidyl- 
tRNA from the A to the P site during protein translation, which has been shown to 
regulate neurite outgrowth in advancing growth cones (Nairn and Palfrey 1987, 
Iketani, Iizuka et al. 2013). When EF2 is down-regulated or inhibited by EF2 
kinase, protein synthesis driving the growth cone is blocked; therefore, formation 
of new neuronal connections are inhibited (Sutton, Taylor et al. 2007). 
Furthermore, down-regulation of global protein synthesis has been linked to 
impaired chaperone and proteasome activity as cells lower protein synthesis 
when protein folding and/or degradation pathways are impaired to reduce the 
burden of aggregated and misfolded proteins (van Oosten-Hawle and Morimoto 
2014), consistent with the observed decreases of HSP70 and proteasomal 
subunit expression in this study. Moreover, reducing protein synthesis has shown 
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to be beneficial in a Drosophila PINK1 model (Liu and Lu 2010). Thus, while 
reduced expression of EF2 may affect neurite formation it may also be an 
adaptive, overall neuroprotective response.  
DRP2, also called CRMP2, is a signaling protein that interacts with binding 
partners and carries out multiple functions, some of which include: neurite 
outgrowth and retraction, growth cone guidance, kinesin-dependent axonal 
transport, neurotransmitter release, endocytosis, vesicular cycling, synaptic 
assembly, Ca2+  homeostasis, organization of the dendritic field and neuronal 
differentiation (Hensley, Venkova et al. 2011, Khanna, Wilson et al. 2012, Tan, 
Ma et al. 2013). Even though DRP2 expression decreases with age, higher levels 
remain in areas of neurogenesis and neuroplasticity (Charrier, Reibel et al. 
2003). Consequently, PINK1(-/-) mice deficient in CRMP2 would have severely 
diminished capacity in their brains to change and adapt. 
In PD, multiple neuronal networks experience altered neurotransmission, 
a condition that is exacerbated by α-synuclein overexpression (Barone 2010, 
Nemani, Lu et al. 2010). In the PINK1(-/-) model in particular, there is a significant 
reduction in the neurotransmitter dopamine. Decreased expression of V-ATPase 
in the PINK1 KO mouse is a probable contributor in the breakdown in 
neurotransmission. Working in conjunction with the H+/neurotransmitter 
antiporter, V-ATPase assists in the concentration of neurotransmitters into 
synaptic vesicles (Beyenbach and Wieczorek 2006). Disruption of this process 
leads to decreased levels of neurotransmitters in the synaptic cleft. Further, 
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synaptic vesicle trafficking at the presynaptic cleft is maintained by a cycle of 
protein complex assembly and disassembly of the SNARE complexes; failure of 
this cycle can lead to loss of neuronal structure and function (Esposito, Ana Clara 
et al. 2012). A central protein involved in this process, vesicle-fusing ATPase, 
also known as N-ethylmaleimide-sensitive fusion protein (NSF), was found in the 
present study to be significantly decreased in the PINK1(-/-) brain. NSF is a 
membrane trafficking chaperone required for intracellular membrane fusion and 
vesicle-mediated transport (Whiteheart, Rossnagel et al. 1994, Bomberger, 
Parameswaran et al. 2005). Specifically for neurotransmission, NSF facilitates 
membrane fusion of SNARE complexes (in conjunction with SNAP) for synaptic 
exocytosis, subsequent disassembly of the complex and mobilization of the 
reserve neurotransmitter pool (Neuwald 1999, Lin and Scheller 2000, Whiteheart, 
Schraw et al. 2001), while also promoting re-sensitization of surface receptors on 
the plasma membrane (Bomberger, Parameswaran et al. 2005). Knockout of 
NSF leads to an accumulation of synaptic vesicles at the axon terminals and at 
the docking site (Whiteheart, Schraw et al. 2001). Consistent with our results and 
the above notion, PINK1 deficient Drosophila neurons show that rapid stimulation 
of synaptic vesicles is defective (Morais, Verstreken et al. 2009). 
Loss of neuronal scaffolding is accompanied by decreased expression of 
structural proteins. In this study we found two structural proteins to be 
significantly decreased in the PINK1 KO brain: neurofilament light peptide (NFL) 
and actin-related protein 2/3 complex subunit 2 (ARPC2). NFL is a component in 
Lewy bodies and a major structural element in neurons, forming the backbone for 
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other neurofilaments (Fuchs and Cleveland 1998). In the substantia nigra of PD 
subjects, reduced levels of NFL and NFL mRNA were found and correlated with 
the severity of the disease (Hill, Arai et al. 1993, Liu, Xie et al. 2011).  ARPC2 is 
part of a structural protein complex that plays a role regulating the polymerization 
and branching of actin filament networks (Gournier, Goley et al. 2001, Spillane, 
Ketschek et al. 2012). Furthermore, in the current study, the phosphorylation 
state of neurofilament medium polypeptide (NFM) also was found to be 
significantly decreased. NFM is a structural protein that supports axonal caliber, 
and altered levels of NFM phosphorylation affect the function of larger 
neurofilaments. Additionally, phosphorylation of NFM produces inter-filament 
cross bridges that increase axonal structure; therefore, a decrease in NFM 
phosphorylation would be predicted to lead to a decrease in axonal caliber 
(Mukai, Toshimori et al. 1996). Thus, defects in neuronal structural proteins may 
contribute to the pathogenesis of recessive familial PD. 
In conclusion, ablation of PINK1 in mice results in differential expression 
and altered phosphorylation states of multiple brain proteins with critical functions 
involved in early changes in cellular signaling pathways, energy metabolism, 
proteostasis networks, oxidative stress, neurotransmission and neuronal 
structural plasticity (Figure 4.5).  
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Figure 4.5 Summary of PINK1 KO proteomics and phosphoproteomics. 
Schematic diagram summary of expression proteomics and phosphoproteomics 
profiles of the PINK1 KO mouse brain. We hypothesize that such changes 
contribute to the reputed and known changes in PD. Used by permission of John 
Wiley and Sons. 
Our findings provide a starting point for future investigations of the impact that 
these differentially expressed and phosphorylated proteins and their regulated 
pathways may have on the pathogenesis of PD; particularly the role of potential 
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environmental triggers that interact with mutated PD susceptibility gene. In 
addition, further studies are required to determine if the proteins identified here 
may serve as therapeutic targets to interfere with the progression of PD or as 
part of a panel of potential biomarkers for PD. 
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CHAPTER 5 
QUANTITATIVE PHOSPHOPROTEOMIC ANALYSES OF THE INFERIOR 
PARIETAL LOBULE FROM THREE DIFFERENT PATHOLOGICAL STAGES 
OF ALZHEIMER DISEASE 
5.1 Overview 
Alzheimer disease (AD), the most common age-related neurodegenerative 
disorder, is clinically characterized by progressive neuronal loss resulting in loss 
of memory and dementia. AD is histopathologically characterized by the 
extensive distribution of senile plaques and neurofibrillary tangles, and synapse 
loss. Amnestic mild cognitive impairment (MCI) is generally accepted to be an 
early stage of AD. MCI subjects have pathology and symptoms that fall on the 
scale intermediately between ‘normal’ cognition with little or no pathology and 
AD. A rare number of individuals, who exhibit normal cognition on psychometric 
tests but whose brains show widespread postmortem AD pathology, are 
classified as ‘asymptomatic’ or ‘preclinical’ AD (PCAD). In this study, we 
evaluated changes in protein phosphorylation states in the inferior parietal lobule 
of AD, MCI, PCAD, and control brain using a 2-D PAGE proteomics approach in 
conjunction with Pro-Q Diamond phosphoprotein staining. Statistically significant 
changes in phosphorylation levels were found in 19 proteins involved in energy 
metabolism, neuronal plasticity, signal transduction, and oxidative stress 
response. Changes in the disease state phosphoproteome may provide insights 
into underlying mechanisms for the preservation of memory with expansive AD 
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pathology in PCAD and the progressive cognitive decline in MCI that escalates to 
the dementia and the characteristic pathology of AD brain. 
5.2 Introduction 
Alzheimer disease (AD) is neuropathologically characterized by the 
increasing accumulation of extracellular senile plaques (SPs), intracellular 
neurofibrillary tangles (NFTs), synapse loss, and increased neuronal cell death. 
SPs are insoluble fibrous material containing deposits of amyloid-β-peptide (Aβ) 
along with other proteins and dystrophic neurites. NFTs are formed following tau 
hyperphosphorylation, which leads to tau uncoupling from microtubules and 
aggregating with other proteins, thereby significantly hindering axonal transport. 
Distribution and quantity of SPs and NFTs and loss of synapses tend to correlate 
with disease severity (Thal, Holzer et al. 2000, Thal, Rub et al. 2002). Clinically, 
the pathology and underlying biochemical mechanisms bring about escalating 
memory loss and worsening cognitive function that culminates with severe 
dementia. 
Mild cognitive impairment (MCI) is considered to be an intermediate 
disease state between persons with no cognitive impairment and individuals with 
AD (Petersen 2004). Clinically, MCI-diagnosed patients have non-age-related, 
failing cognition, yet do not exhibit signs of dementia, as primary day-to-day 
functional abilities are not overtly affected  (Morris, Storandt et al. 2001). The 
amnestic MCI subtype, in particular, is considered to be a potential, preferential 
harbinger of AD (Portet, Ousset et al. 2006). Histopathologically, the MCI brain 
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tends to have intermediary quantities of NFTs, neuronal loss and atrophy than is 
associated with a control or AD brain (Gomez-Isla, Price et al. 1996, Kordower, 
Chu et al. 2001). Differences in SP deposition and density are generally 
intermediate to AD pathology, but this can widely vary (Morris, Storandt et al. 
1996, Markesbery 2010, Villain, Chetelat et al. 2012). However, levels of Aβ 
oligomers, in particular Aβ(1-42), which is the most toxic Aβ (Butterfield and 
Kanski 2002, Klein, Stine et al. 2004), are reported to correlate more reliably to 
severity of cognitive impairment and loss of synaptic biomarkers (Pham, Crews 
et al. 2010). Diagnosis of disease stage must not only consider NFT and SP 
pathology and global cognition evaluations, but also biochemical changes which 
may relate to either cognitive decline or a compensatory disease response. 
Insights into underlying mechanisms of disease progression at earliest detectable 
stages may be critical in slowing disease progression. 
While advanced SP distribution can be present at any stage of cognition, 
extensive distributions of NFTs are a rarity in people who are considered 
cognitively intact (Arriagada, Growdon et al. 1992, Erten-Lyons, Woltjer et al. 
2009).  These subjects, whose brains exhibit considerable SP and NFT 
pathology postmortem, yet were asymptomatic with no signs of failing cognition 
antemortem, are referred to as having preclinical AD (PCAD) (Abner, Kryscio et 
al. 2011). Interesting characteristics of PCAD brains include: larger brain 
volumes than in MCI or AD (Erten-Lyons, Woltjer et al. 2009), little or no neuronal 
loss (Price, Ko et al. 2001), increased neuronal hypertrophy (Iacono, O'Brien et 
al. 2008), overall increase in synaptic plasticity (O'Brien, Resnick et al. 2009), 
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and changes in proteins involved in Zn transport (Lyubartseva, Smith et al. 
2010). Insights into neuroprotective mechanisms that prevent cognitive deficits 
despite heavy SP and NFT load may provide key insights into halting mental 
decline that leads to dementia.  
Proposed contributing factors of AD include: oxidative stress, Aβ-induced 
toxicity, inflammation, and dysfunction of energy metabolism (Markesbery 1997, 
Butterfield and Kanski 2002, Hynd, Scott et al. 2004, Ho, Drego et al. 2005, 
Tuppo and Arias 2005). Accumulating evidence suggests that free radicals 
produced during oxidative stress play a key role in AD and other 
neurodegenerative diseases (Browne, Ferrante et al. 1999, Butterfield 2002, 
Zwerschke, Mazurek et al. 2003, Lin and Beal 2006, Triplett, Zhang et al. 2015). 
Oxidative stress may lead to post translational modifications of proteins such as 
carbonylation, nitration and 4-hydroxyl-2-nonenal (HNE) adducts that change 
protein structure and can result in loss of function, protein unfolding and  
aggregation (Butterfield and Lauderback 2002, Butterfield, Reed et al. 2007). In 
AD, oxidative stress appears to be an early event as global levels of carbonyls, 
3-nitrotyrosine and HNE are significantly increased in MCI brain; however, these 
global markers of oxidative stress in PCAD were generally similar to levels in 
control brains (Butterfield, Reed et al. 2006, Butterfield, Reed et al. 2007, Aluise, 
Robinson et al. 2010, Bradley, Markesbery et al. 2010, Aluise, Robinson et al. 
2011). 
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Protein phosphorylation is a fundamental mechanism mediating diverse 
cellular functions that is strictly regulated by kinases and phosphatases; aberrant 
phosphorylation of neuronal proteins is a characteristic of several 
neurodegenerative diseases (Humbert and Saudou 2003, Hasegawa, Arai et al. 
2008, Di Domenico, Sultana et al. 2011, Triplett, Zhang et al. 2015). Evaluating 
phosphorylation states in proteins in the three different pathological stages of AD 
may provide valuable insights into the biological pathways that contribute to or 
impede neurodegeneration in AD. In the current study, global protein 
phosphorylation levels in the inferior parietal lobule (IPL) were determined using 
2-D PAGE in conjunction with a multiplexed proteomics technology (Steinberg, 
Agnew et al. 2003). By comparing the phosphoproteome of control, PCAD, MCI, 
and AD brain, 19 proteins were found with significant differential phosphorylation 
levels in the disease states. These proteins are involved in are involved in 
underlying biochemical processes that contribute to disease pathology and 
clinical presentation. 
5.3 Materials and Methods 
5.3.1 Materials 
All chemicals used in this study were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) unless otherwise noted. ReadyStrip IPG strips (pH 3-10), 
Criterion precast polyacrylamide gels (8-16% Tris/HCl or 4-12% Bis/Tris), TGS 
and MOPS electrophoresis running buffers, Precision Plus Protein All Blue 
Standards, mineral oil, Sypro Ruby protein stain, dithiothreitol (DTT), 
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iodoacetamide (IA), biolytes, urea, and nitrocellulose membranes were 
purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond phosphoprotein 
stain and anti-phosphoserine, anti-phosphotyrosine, and anti-phosphothreonine 
antibodies were obtained from Invitrogen (Grand Island, NY, USA). Re-Blot Plus 
Strong stripping solution and C18 ZipTips were purchased from Millipore 
(Billerica, MA, USA). Amersham ECL IgG peroxidase-linked secondary 
antibodies, ECL Plus Western blotting reagents, and Protein A/G beads were 
purchased from GE Healthcare (Pittsburgh, PA, USA). Pierce BCA protein assay 
reagents were purchased from Thermo Scientific (Waltham, MA, USA). Modified 
trypsin digestion solution was obtained from Promega (Madison, WI, USA). Anti-
CRMP2 and anti-SMP30 (senescence marker protein-30; regucalcin) antibodies 
were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  
5.3.2 PCAD, MCI, AD, and control subjects 
Frozen IPL tissue specimens from well-characterized PCAD, MCI, AD, 
and respective age-matched control subjects (n=7 for each group) were obtained 
from the University of Kentucky Rapid Autopsy Program of the Alzheimer 
Disease Clinical Center, with an average post-mortem interval (PMI) of 2.62 h. All 
the subjects underwent annual physical and neurological exams. Control and 
PCAD subjects exhibited no history of dementia or other neurological disorders 
and had MMSE test scores in the normal range. Criterial categorizing the stage 
of disease progression has been previously described (Aluise, Robinson et al. 
2011). Table 5.1 lists the relevant demographical data. 
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Table 5.1 Demographic data of PCAD, MCI, AD and control subjects. Raw 
and average data of subjects in this current dissertation study. 
 
5.3.3 Sample preparation 
IPL sample homogenates were prepared using a Wheaton glass 
homogenizer (~40 passes) and diluted with  ice-cold isolation buffer, pH 7.4 [0.32 
M sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5 
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µg/mL aprotinin, 4 µg/mL pepstatin, 4 µg/mL leupeptin,  and 10 µL/mL 
phosphatase inhibitor cocktail 2]. Protein concentrations of the homogenates 
were determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et 
al. 1985). 
5.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
 2-D PAGE experiments were performed as described previously (Sultana, 
Boyd-Kimball et al. 2007). In short, 200 µg of each sample was suspended in 
rehydration buffer [8 M urea, 2 M thiourea, 50 mM DTT, 2.0% (w/v) CHAPS, 
0.2% Biolytes, 0.01% bromophenol Blue] (200 µL total volume), applied to IPG 
strips and actively rehydrated for 18 h at 50 V and 20°C for 18 h. Next, proteins 
were isoelectricly focused at 20°C starting at 300 V for 2 h, 500 V for 2 h, 1000 V 
for 2 h, 8000 V for 8 h, and finishing at 8000 V for 10 h. IPG strips were 
immediately stored at -80 °C. 
For the second dimension, IEF strips were thawed, equilibrated for 10 min 
in the dark with 4 mL of an equilibration buffer [50 mM Tris–HCl, pH 6.8, 6 M 
urea, 1% (w/v) SDS, 30% v/v glycerol] containing 0.5% DTT, and then re-
equilibrated for 10 min in the dark with 4 mL of the same equilibration buffer 
containing 4.5% IA. Next, the strips were rinsed and placed into 11 cm Criterion 
precast polyacrylamide gels (8–16% Tris–HCl). Samples and Precision Plus 
Protein All Blue molecular standards were run at 200 V for 65 min in TGS 
running buffer. 
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5.3.5 Pro-Q Diamond and Sypro Ruby gel staining 
Phosphorylated proteins were detected and normalized using Pro-Q 
Diamond and Sypro Ruby gel stains according to manufacturer’s directions. In 
brief, gels were fixed in 50 mL of solution [10% (v/v) acetic acid, 50% (v/v) 
methanol] (30 min, two times) and washed with 100 µL of deionized (DI) water 
(30 min, three times). Next, gels were stained with 80 mL of Pro-Q Diamond for 
90 min and then destained in 100 mL of solution [20% acetonitrile (ACN), 50 mM 
sodium acetate, pH 4] (30 min, four times). The gels were washed in 100 µL of DI 
water (30 min, three times) and scanned at 580 nm with ChemiDoc XRS+ 
imaging system (Bio-Rad, Hercules, CA, USA). Gels were then incubated in 50 
mL of Sypro Ruby gel stain overnight (15 h). The Sypro Ruby stain was removed 
and the gels were rinsed in DI water. The gels were scanned at 450 nm with the 
ChemiDoc imager and then stored at 4 °C in DI water until protein spot 
extraction. 
5.3.6 Image Analysis 
2D-gel images of the stained gels were quantified using PDQuest 2-D 
analysis software (Bio-Rad), according to the manufacturer’s instructions. Briefly, 
protein spots intensities were matched, measured, and normalized to the total 
spot density in the gel for the Pro-Q Diamond-stained images and then for the 
Sypro Ruby-stained images. Next, a high match analysis was conducted to 
match each Pro-Q Diamond stained sample to the corresponding Sypro-Ruby 
stained sample. The phosphoprotein spot densities were then normalized to the 
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Sypro Ruby spot densities so that a highly abundant but lightly phosphorylated 
protein could be differentiated from a lowly abundant but highly phosphorylated 
protein. Only protein spots identified in the PCAD, MCI and AD gels as having 
statistically significant, differential phosphorylation states from the control were 
considered for in-gel trypsin digestion and protein identification by MS/MS. 
5.3.7 In-gel trypsin digestion/peptide extraction 
Protein spots in PCAD, MCI, and AD gels identified as being statistically 
different from control group were excised, transferred to individual Eppendorf 
microcentrifuge tubes, and trypsin digested as described previously 
(Thongboonkerd, McLeish et al. 2002). Briefly, gels were incubated in 20 µL of 
0.1 M ammonium bicarbonate (NH4HCO3) for 15 min. Next, 30 µL of ACN was 
added and incubated for another 15 min. After removal of the solvents, the gel 
plugs were dried under a flow hood and then incubated with 20 µL of 20 mM DTT 
in 0.1 M NH4HCO3 for 45 min at 56°C. The DTT/NH4HCO3 solution was removed 
and 20 µL of a 50 mM IA in 0.1 M NH4HCO3 solution was added for 15 min. The 
IA/NH4HCO3 solution was removed and replaced with 150 µL of a 50 mM 
NH4HCO3 solution for 15 min. Next, 200 µL of ACN was added for 15 min of 
incubation. The gel plugs were dried under a flow hood after removal of the 
solvents. The gel plugs were incubated with shaking at 37°C in 10 µL of modified 
trypsin solution in 50 mM of NH4HCO3 overnight (16 h). C18 ZipTips were used to 
remove salts and contaminants from the tryptic peptide solutions. Tryptic peptide 
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solutions were reconstituted in 10 µL of 5% ACN/0.1% formic acid (FA) and 
stored at -80˚C until MS/MS analysis. 
5.3.8 NanoLC-MS with Data Dependent Scan 
A nanoAcquity (Waters, Milford, MA)-LTQ Orbitrap XL (Thermo Scientific, 
San Jose, CA) platform using a data dependent scan mode was implemented in 
the analyses of the tryptic peptide solutions. An in-house packed capillary column 
(0.1 x 130 mm column packed with 3.6 µm, 200Å XB-C18) with a gradient using 
0.1% FA and ACN/0.1% FA at 200 nL/min was used for separation. The orbitrap, 
operating at 30,000 resolution, was used to obtain MS spectra. For the MS/MS 
spectra of the six most intense parent ions, the orbitrap was operated at 7,500 
resolution. To identify the protein in each peptide sample, the latest version of the 
Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, Thermo 
Scientific) was used in the interrogation of data files. At least two high-confidence 
peptide matches were used for protein identification, and the false discovery rate 
was less than 1%. Proteins were reported as one protein group if they were 
matched with the same peptides. Initial verification of the MS/MS data was 
accomplished by the comparison of the expected molecular weight (MW) and 
isoelectric point (PI) of the identified protein to MW and PI of the extracted gel 
plug. 
5.3.9 Immunoprecipitation and Western blotting validations 
Individual brain homogenates (250 µg) were suspended in an IP buffer 
solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na2HPO4, 0.24 M KH2PO4, 0.05% 
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NP-40, aproprotin 5 µg/mL, leupeptin 4 µg/mL, pepstatin 4 µg/mL, and 
phosphatase inhibitor cocktail 10 µL/mL] (500 µL total volume). Samples were 
shaken with Protein A/G agarose beads for 1.5 h at 4˚C for preclearance of 
endogenous antibodies. Each sample was agitated overnight in IP buffer at 4˚C 
with either anti-SMP30 or anti-CRMP2 antibodies (1:50 dilution). Protein A/G 
agarose beads were mixed with the sample for 1.5 h and washed with 500 µL of 
IP buffer (10 min, 5 times). The beads were suspended in 4X sample loading 
buffer [0.5 M Tris (pH 6.8), 40% glycerol, 8% SDS, 20% β-mercaptoethanol, 
0.01% Bromophenol Blue] (diluted to 1X with DI water). Samples were heated at 
95°C for 5 min and cooled before loading into Criterion precast 18 well 
polyacrylamide gels (4-12% Bis-Tris). Using XT MOPS running buffer, samples 
and Precision All Blue MW marker were run at 80 V for 15 min and then at 120 V 
for 100 min. The in-gel proteins were transferred onto a nitrocellulose membrane 
with a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V for 30 min. After the 
transfer, membranes were blocked in solution (3% bovine serum albumin (BSA) 
in TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h. Anti-
phosphoserine, anti-phosphothreonine, and anti-phosphotyrosine antibodies 
were added to the blocking solution (1:8000 dilution) and incubated for 2 h. Next, 
the blots were washed with TBS-T (5 min, three times) and incubated for 1 h with 
a peroxidase secondary antibody in TBS-T (1:3000). The membranes were 
washed in TBS-T (10 min, three times), developed with Clarity Western ECL 
substrate, scanned using Bio-Rad ChemiDoc XRS+ imaging system, and 
quantified using Image Lab software (Bio-Rad). The blots were then stripped with 
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Re-Blot Plus Strong solution, rinsed with TBS-T (5 min, three times each), 
probed with either anti-SMP30 or anti-CRMP2 antibodies (1:2000), developed 
and scanned. 
5.3.10 Statistical analysis  
All data are presented as mean+SEM. A one-way ANOVA statistical test 
with post hoc Tukey t-test was used in determining significance (p<0.05) in 
PDQuest analyses. A Student’s t-test was used in Western blot analysis. Protein 
spot fold-change values were calculated by dividing the average, normalized spot 
intensities of the PCAD, MCI, or AD group by the average, normalized spot 
intensities of the gels of the control group. Spot were extracted for MS/MS 
analysis if the fold change of the normalized spot density was 50% or more, 
whether elevated or decreased from controls. Proteins identified with the 
SEQUEST search algorithm were considered to be statistically significant if 
p<0.01. 
5.4 Results 
For the evaluation of phosphorylation levels of proteins in the IPL, the 
average, normalized protein spot densities from the PDQuest analysis of control, 
PCAD, amnestic MCI and AD samples were compared. Figure 5.1 shows 
representative Sypro Ruby-stained 2-D gels, while Figure 5.2 shows the same 
gels developed with Pro-Q Diamond phosphoprotein stain. Protein spots with 
statistically significant altered phosphorylation levels are labeled in the 
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appropriate gels. PDQuest analyses of all 2-D gels found 19 proteins whose 
phosphorylation levels differed in at least one of the comparisons. 
 
Figure 5.1 Sypro Ruby-stained gels of control, PCAD, amnestic MCI and AD 
brain. Representative Sypro Ruby-stained 2-D gel images of isolated proteins 
from the IPL of (A) control, (B) PCAD, (C) amnestic MCI, and (D) AD subjects. 
Extracted protein spots of proteins whose phosphorylation levels were 
significantly altered (p<0.05) in each group are labeled in the images. 
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Figure 5.2 Pro-Q Diamond-stained gels of control, PCAD, amnestic MCI and 
AD brain. Representative Pro-Q Diamond-stained 2-D gel images of isolated 
proteins from the IPL of (A) control, (B) PCAD, (C), amnestic MCI, and (D) AD 
subjects. Proteins with significantly altered (p<0.05) phosphorylation levels in 
each group are labeled in the images. 
Tables 5.2-5.4 summarize the PDQuest and MS/MS data and includes: 
the protein spot number as labeled by PDQuest, the SwissProt accession 
number, the percentage of the protein sequence identified by MS/MS analyses, 
the number peptide sequences identified, the confidence score of the protein, the 
expected molecular weight and predicted isoelectric point of the identified 
protein, and the p-values and fold-change levels of phosphorylation. 
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Table 5.2 Significantly altered phosphoproteins of the IPL of PCAD and control 
subjects. PDQuest and MS/MS results of IPL proteins of control versus PCAD subjects 
with significantly altered phosphorylation states as compared to control subjects. 
 
 
 
Table 5.3 Significantly altered phosphoproteins of the IPL of MCI and control 
subjects. PDQuest and MS/MS results of IPL proteins of control versus MCI subjects 
with significantly altered phosphorylation states as compared to control subjects.  
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Table 5.4 Significantly altered phosphoproteins of the IPL of AD and control 
subjects. PDQuest and MS/MS results of IPL proteins of control versus AD subjects 
with significantly altered phosphorylation states as compared to control subjects. 
 
Proteins were identified with two or more peptide sequences. To ensure 
correct identification of the proteins, the expected molecular weight and 
isoelectric point of the identified protein were visually compared to the spot of the 
extracted gel plug.  
In comparing the IPL of PCAD and control brains (Table 5.2), 8 proteins 
found to have significantly altered phosphorylation levels: Heat shock 70kDa 
protein 12A (↑8.92-fold); isoform 2 of gelsolin (↓0.280-fold); regucalcin 
(↓0.0170-fold); L-lactate dehydrogenase b-chain (↑28.7-fold); septin 2 (↑2.89-
fold); flavin reductase [NADPH] (↑8.86-fold); and isoform CNPI of 2’,3’-cyclic 
nucleotide-3’-phosphodiesterase (↓0.0083-fold). Analysis of the IPL of MCI and 
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control specimens (Table 5.3) revealed 5 proteins that had significantly different 
phosphorylation levels: citrate synthase (↑3.88-fold); transitional endoplasmic 
reticulum ATPase (↓0.0571-fold); isoform 2 of gelsolin (↓0.383-fold); regucalcin 
(↓0.0262-fold); EF-hand domain-containing protein D1 (↓0.0710-fold). The 
largest differences were observed in the comparison of the IPL of AD and control 
brains (Table 5.4), in which 14 proteins exhibited significant differential levels of 
phosphorylation. These 14 proteins were: voltage-dependent anion-selective 
channel protein 1 (↓0.149-fold); isoform 2 of voltage dependent anion-selective 
channel protein 2 (↓0.0829-fold); isoform 2 of gelsolin (↓0.179-fold); L-lactate 
dehydrogenase b-chain (↑34.8-fold); dihydropyrimidinase-related protein 2 [also 
called collapsing response mediator protein 2, CRMP-2] (↑3.51-fold); guanine 
nucleotide-binding protein G(o) subunit alpha (↑6.11-fold); EF-hand domain-
containing protein D1 (↓0.0802-fold); transitional endoplasmic reticulum ATPase 
(↓0.258-fold); Cu/Zn superoxide dismutase (↓0.0097-fold); peroxiredoxin 1 
(↓0.0489-fold); regucalcin (↓0.108-fold); stathmin (↓0.0454-fold); syntaxin-
binding protein 1 (↓0.177-fold); and carbonyl reductase 1 (↓0.392-fold). Some 
of these proteins were found to have significantly different phosphorylation levels 
in multiple group comparisons and their relationships are illustrated in the Venn 
diagram of Figure 5.3. 
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Figure 5.3 Significant differentially phosphorylated proteins of the IPL in 
AD progression. Venn diagram of significant differentially phosphorylated IPL 
proteins illustrating the overlapping proteins involved in the progression of AD. 
 
To validate MS/MS results, immunoprecipitation experiments were carried 
out. Figure 5.4 shows the images from the immunoprecipitation experiments after 
probing with anti-phosphoserine, anti-phosphothreonine and anti-
phosphotyrosine antibodies in which the immunoprecipitated protein of each 
experiment, SMP30 or CRMP2, was used as the loading control.  
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Figure 5.4 SMP30 and CRMP2 phosphorylation in IPL from control, PCAD, 
MCI and AD brain. Western blots and corresponding bar graph representations 
from immunochemistry experiments evaluating changes in global 
phosphorylation levels of SMP30 and CRMP2 in the IPL of control, PCAD, 
amnestic MCI, and AD subjects (n=4 for each age group, *p<0.05). 
Immunoreactivity with specific antibodies was detected by chemiluminescence. 
 
The findings from the SMP30 analysis confirmed a significant decrease in 
the global phosphorylation levels of SMP30 in the IPL in the following 
comparisons: PCAD versus control (p=0.0371), MCI versus control (p=0.0489), 
and AD versus control (p=0.00872). Analysis of the CRMP2 immunoprecipitation 
experiment verified the increased phosphorylation of CRMP2 in the AD brain 
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versus control, (p=0.00733). Additionally, global levels of phosphorylated CRMP2 
were also significantly increased in the IPL of MCI, (p=0.0118).  
5.5 Discussion 
 Neuropathologically, AD progression is quantified by increasing SPs, 
NFTs, and synaptosomal loss. Clinically, the underlying biochemical mechanisms 
contributing to these pathologies result in progressive cognitive deficits, 
culminating in dementia. The PCAD brain is intriguing, as it possesses 
accumulation of SPs and NFTs, but does not have loss of synapses, cognition, or 
global changes in oxidative stress (Aluise, Robinson et al. 2011).  In this current 
study, the phosphoproteome of the IPL of control, PCAD, MCI, and AD brains 
were compared to not only assess phosphorylation changes in brain proteins 
involved in disease progression from control to MCI and AD, but also to evaluate 
underlying biochemical pathways that may contribute to prevention of memory 
loss in the presence of abundant AD pathology. Significant changes in 
phosphorylation were found that may provide insights into clinical manifestations 
of underlying pathology. These insights are discussed in areas concerning: 
energy metabolism and mitochondrial dysfunction, oxidative stress and stress 
response, and neuronal plasticity, neurotransmission and cellular signaling. 
Energy metabolism and mitochondrial dysfunction 
Cognitive decline in AD is associated with cortical atrophy, reduced 
cerebral glucose metabolism and mitochondrial dysfunction and is reviewed in 
(Ferreira, Resende et al. 2010, Kapogiannis and Mattson 2011). The majority of 
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the energy generated by glucose oxidation is spent maintaining ion gradients, 
propagating action potentials, and the release and recycling of neurotransmitters 
(Attwell and Laughlin 2001). Therefore, regulating and maintaining high energy 
production is essential for neuronal survival. 
Lactate dehydrogenase (LDH) is a metabolic enzyme that catalyzes the 
reversible production of lactate from pyruvate. Of the five different isoforms of 
LDH, LDHB activity preferentially promotes the conversion of lactate to pyruvate 
to provide a source of fuel (Newington, Harris et al. 2013). Lactate production 
has been shown to be increased in both sporadic and familial AD (Sims, Finegan 
et al. 1985, Hoyer, Oesterreich et al. 1988), especially in areas of AD pathology 
(Kapogiannis and Reiter). In the current study, phosphorylation levels LDHB 
were significantly increased in AD compared to control and MCI and also 
increased in PCAD as compared to control. Though the effect of phosphorylation 
of LDHB has yet to be determined, it is reasonable to speculate that 
phosphorylation may conceivably decrease LDHB activity, as increased lactate 
levels in AD brain have been confirmed by multiple groups (Sims, Finegan et al. 
1985, Hoyer, Oesterreich et al. 1988). It is interesting that LDHB phosphorylation 
is significantly increased in the IPL of brains with extensive SP and NFT 
pathology, and it is reasonable to speculate that phosphorylation of LDHB could 
be a potential neuroprotective mechanism to induce the Warburg effect in an 
attempt to decrease mitochondrial throughput, thereby decreasing resultant ROS 
production and oxidative stress. 
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In the IPL of the MCI brain, on the other hand, citrate synthase (CS) had 
significantly increased levels of phosphorylation compared to control. 
Phosphorylation of CS has been reported to increase the enzymatic activity of 
this enzyme (Kojima and Numata 2002). Since CS is considered to be the TCA 
enzyme that drives the cycle (Wiegand and Remington 1986), the significant 
increase of phosphorylated CS may be an  attempt to increase availability of ATP 
to meet cellular energy demands required to sustain functions in a deteriorating 
environment.  Additionally, in AD brain, it has been previously shown that there is 
no change in the activity of CS (Canevari, Clark et al. 1999, Bubber, Haroutunian 
et al. 2005). Consistent with these results, the phosphorylation levels of CS in the 
AD brain in this current study were similar to control brain. Further, in contrast to 
the PCAD and AD brain, the MCI brain does not contain as many SP and as 
much NFT pathology. So perhaps, increasing energy production takes 
precedence over minimizing ETC-related oxidative stress in the MCI brain, 
though this is speculation at present. 
Voltage dependent anion channels (VDACs) are the primary porins of the 
outer mitochondrial membrane that are involved the regulation of metabolic flux 
by modulating membrane permeability (Blachly-Dyson and Forte 2001, Shoshan-
Barmatz and Gincel 2003). VDACs are key participants in numerous processes 
including: Ca2+ signaling, synaptic plasticity, apoptosis, and mitophagy (Murgia, 
Giorgi et al. 2009, Sun, Vashisht et al. 2012). Therefore, dysregulation of VDACs 
may result in a considerable shift in cellular metabolism and homeostasis that 
promote neuronal dysregulation. Consistent with this notion, dysregulation of 
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VDACs has been reported in multiple neurodegenerative diseases, including AD 
(Ghosh, Pandey et al. 2007, Israelson, Arbel et al. 2010, Cuadrado-Tejedor, 
Vilarino et al. 2011, Triplett, Zhang et al. 2015). In the current study, 
phosphorylation levels of VDAC1 were decreased in PCAD and AD compared to 
control and isoform 2 of VDAC2 was decreased in AD brain compared to control. 
VDAC1, in particular, has been reported to be directly blocked by phosphorylated 
tau and Aβ (Manczak and Reddy 2012), impeding mitochondrial influx. The most 
abundant VDAC, VDAC1, has 11 known phosphorylation sites and VDAC2 has 4 
known sites, but effects of phosphorylation at these sites remain largely 
undetermined for VDAC1 and completely unknown for VDAC2 (reviewed in 
(Kerner, Lee et al. 2012)). However, as both PCAD and AD brains contain high 
amounts of Aβ and phosphorylated tau, it is reasonable to speculate that global 
dephosphorylation of VDAC1 may serve to either enhance the interaction with Aβ 
and phosphorylated tau to inhibit influx through the pore to limit oxidative 
phosphorylation or to promote closure of the pore by phosphorylation itself to 
constrain ETC-related oxidative stress.  It is hypothesized that the different 
isoforms of VDACs play distinct, although sometimes over-lapping roles 
(Messina, Reina et al. 2012). VDAC2 has been reported to complex with BAK, a 
pro-apoptotic protein, to inhibit the initiation of apoptosis (Cheng, Sheiko et al. 
2003). And since phosphorylation of isoform 2 of VDAC2 was only significantly 
decreased in the IPL of AD brain, it is interesting to speculate that decreased 
phosphorylation of VDAC2 may diminish its affinity towards BAK, thereby 
promoting cell death.  
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Oxidative stress and stress response 
Dysregulated energy metabolism and mitochondrial dysfunction can lead 
to increased levels of reactive oxygen species, in particular, superoxide radical. 
Cu/Zn superoxide dismutase (SOD1) catalyzes the conversion of superoxide to 
H2O2 and O2. Analysis of APP transgenic mice showed decreased activity of 
SOD1 which correlated to increased Aβ and contributed to increased oxidative 
damage (Schuessel, Schäfer et al. 2005). Similarly, SOD1 activity was reported 
to be significantly reduced in AD brain and is associated with increased oxidative 
stress (Marcus, Thomas et al. 1998). In the current study, phosphorylation levels 
of SOD1 in the IPL of AD brain were significantly decreased compared to control. 
Although little is known about how phosphorylation affects any one of the 11 
known phosphorylation sites, considering the reported decrease in SOD1 activity 
in AD and the decrease in global SOD1 phosphorylation, it may be conceivable 
that decreased SOD1 phosphorylation promotes decreased activity of this 
important antioxidant, contributing to the increased oxidative stress reported in 
AD (Butterfield and Lauderback 2002). 
Peroxiredoxin 1 (PRDX1) is another antioxidant enzyme that had 
decreased phosphorylation levels in the IPL of the AD brain compared to both 
control and PCAD brains. PRDX1 regulates the cellular redox state by reducing 
peroxides to water and the corresponding alcohol. By regulating H2O2 levels, 
PRDX1 may also play a role in cellular signaling by regulating TNFα-mediated 
inflammation (Kang, Chae et al. 1998) and modulating the peroxide-dependent 
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signaling of the ASK/p38 MAPK pathway (Jarvis, Hughes et al. 2012). Levels of 
PRDX1 are reportedly increased in AD and DS brain (Kim, Fountoulakis et al. 
2001). Further, phosphorylation on Thr90 has been shown to decrease 
peroxidase activity by 80% and results in H2O2 accumulation (Chang, Jeong et 
al. 2002). Additionally, phosphorylation on Tyr-194 has also been shown to 
inactivate the protein (Woo, Yim et al. 2010). Therefore, the increased levels of 
PRDX1 as well as the decrease in phosphorylation levels likely increases protein 
activity as a compensatory response to the overwhelming levels of oxidative 
stress in AD brain. 
Levels of protein carbonyls are the most widely-used indicator of oxidative 
stress as carbonyl levels are increased with age and age-related diseases 
(Aksenov, Aksenova et al. 2001, Dalle-Donne, Scaloni et al. 2005). Carbonyl 
reductase (CBR1) plays a protective role in an oxidative stress-induced 
environment by catalyzing the reduction of carbonyl-containing compounds as 
well as a variety of other substances, including HNE (Wermuth 1981, Forrest and 
Gonzalez 2000, Doorn, Maser et al. 2004). Interestingly, CBR1 has been shown 
to be oxidatively modified by HNE in the hippocampus of MCI brain (Reed, 
Perluigi et al. 2008). Additionally, CBR1 is biologically important because it can 
reduce the nitrosyl bond of S-nitrosoglutathione (GSNO) (Bateman, Rauh et al. 
2008). GSNO plays an important function in NO signaling by acting as an 
intracellular NO reservoir. Therefore, CBR1 is a mechanism that terminates NO 
signaling that regulates many processes including: memory and learning, 
inflammatory response, neuronal plasticity, and apoptotic mechanisms, among 
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others (De La Monte, Sohn et al. 2000, Staab, Hartmanova et al. 2011). 
Pathways involving NO have been implicated in AD and (Togo, Katsuse et al. 
2004). Expression and activity of CBR1 is reported to be increased in AD and 
DS, likely as a cellular stress response to increased carbonyls (Lemieux, Malfoy 
et al. 1993, Balcz, Kirchner et al. 2001).  In the current study, phosphorylation 
levels of CBR1 were significantly decreased in AD as compared to both control 
and MCI brains. Implications of CBR1 phosphorylation are presently unknown; 
but, considering (i) PCAD brains  exhibit SP and NFT pathology; (ii) 
phosphorylation levels were decreased in AD but not PCAD; and (iii) global 
measures of protein carbonyls have been shown to be similar in the IPL of 
control and PCAD brains (Aluise, Robinson et al. 2011), while carbonyls are 
increased in AD brain (Hensley, Hall et al. 1995, Aksenov, Aksenova et al. 2001), 
it is reasonable to speculate that decreased phosphorylation of CBR1 likely 
increases enzymatic activity as a stress response to carbonyl-related oxidative 
stress. 
Interestingly, flavin reductase (FR), also known as biliverdin reductase B 
(BVR-B) (Shalloe, Elliott et al. 1996), was significantly increased in PCAD brain. 
BVR-B is a NADPH-dependent enzyme that  that catalyzes the reduction of 
flavins including the conversion of biliverdin to bilirubin, an antioxidant-scavenger 
of free radicals that promotes a reduced cellular state (Stocker, Yamamoto et al. 
1987, Barone, Di Domenico et al. 2014). Moreover, both biliverdin and bilirubin 
have been reported to prevent oxidative stress and apoptosis (Jansen, Hortmann 
et al. 2010, Barone, Di Domenico et al. 2014). Further, BVR is a pleiotropic 
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(Ser/Thr and Tyr) kinase with roles in modulating phosphatidylinositol-3-kinase 
(PI3K) and MAPK signaling pathways which are involved in cell survival, synaptic 
plasticity and memory consolidation, among others (Maines 2007, Kapitulnik and 
Maines 2009). Phosphorylation is reportedly required for BVR activity (Salim, 
Brown-Kipphut et al. 2001). Therefore, the increase in phosphorylation levels of 
BVR-B in PCAD brain demonstrates a potential mechanism by which a brain, 
heavy with SP and NFT pathology, may conceivably still be able to maintain 
synaptic plasticity and normal cognitive function. In addition, another highly 
conserved BVR isoform, BVR-A, is reported to be extensively modified by 
oxidative stress, particularly by nitration, in AD brain (Barone, Di Domenico et al. 
2011). Since phosphorylation and nitrosative modifications are in competition for 
the same Tyrosine hydroxyl groups on proteins, a highly oxidative environment 
such as exists in AD brain, could result in reduced activity of BVR, resulting in 
decreased synaptic plasticity and memory consolidation. 
Protein aggregation can result in increased cellular oxidative stress 
leading to elevated expression of heat shock proteins and amplified intracellular 
Ca2+ levels that can lead to cell death (Stefani and Dobson 2003). Hsp70 
chaperone proteins can respond to cellular stress by refolding misfolded proteins 
or leading them towards degradation, as well as obstructing apoptosis by 
blocking recruitment of procaspase-9 to the apoptosome (Beere, Wolf et al. 
2000). In the current study, Hsp70 protein 12A (hsp70A12A) showed significantly 
increased phosphorylation in PCAD brain. The specific functionality of the 
hsp70A12A isoform within the Hsp70 family is currently unknown. However, 
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phosphorylation of Hsp70 by CK1, CK2 and GSK3β at the highly conserved C-
terminal domain of Hsp70 reportedly inhibits binding to CHIP, a Ub-ligase that 
mediates protein degradation or aggregation, and promotes binding affinity to co-
chaperone HOP, which promotes protein re-folding (Muller, Ruckova et al. 2013). 
Binding effects due to phosphorylation by other co-chaperones are currently 
being studied, but phosphorylation-dependent interactions with co-chaperones 
are critical regulators of Hsp70 activities. Therefore, as SPs and NFTs cause 
elevated Hsp70 production, the increased phosphorylation of the C-terminal 
domain likely promotes protein refolding to prevent further protein aggregation. 
Phosphorylation effects of other Hsp70 domains have yet to be elucidated; 
however, since PCAD brains contain high SP and NFT pathology and have no or 
low neuronal loss, global phosphorylation likely contributes to increased Hsp70 
activity to promote proteostasis and cell survival. 
The endoplasmic reticulum (ER) is sensitive to disturbances in cellular 
homeostasis and can either initiate signaling cascades or unfolded protein 
response  to manage stress situations or induce apoptosis to save tissue from 
necrotic injury (Salminen, Kauppinen et al. 2009). In AD, ER stress can also lead 
to inflammation and AD pathology (Salminen, Kauppinen et al. 2009). The 
transitional endoplasmic reticulum ATPase (aka valosin-containing protein; VCP) 
is a pleiotropic protein involved in a wide array of cellular functions, including: 
ER-associated degradation (ERAD), ubiquitin-proteasome mediated proteolysis, 
autophagy, mediation of ER stress-induced apoptosis, vesicle transport and 
fusion, activation of transcription factors, and peroxisomal assembly (Dai, Chen 
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et al. 1998, Ogura and Wilkinson 2001, Wang, Song et al. 2004, Song, Wang et 
al. 2007). VCP has been connected to protein misfolding and aggregation-linked 
neurodegeneration (Weihl 2011). Previously, we showed VCP phosphorylation 
levels to be significantly decreased in the hippocampus in AD (Di Domenico, 
Sultana et al. 2011). In the current study, phosphorylation levels of VCP were 
significantly decreased in MCI brain as compared to control and PCAD brain and 
also decreased in AD brain relative to control. Phosphorylation of VCP has been 
reported to promote UPS-related degradation and prevent apoptosis (Yu, Yang 
et al. 2013). We opine that decreased VCP phosphorylation in MCI and AD IPL 
may be indicative of a mechanism to eradicate cells that are too damaged to 
rescue as a means to prevent necrosis. However, VCP has over 60 known 
phosphorylation sites and putative consequences of phosphorylation of various 
residues includes: ER assembly (Lavoie, Chevet et al. 2000), inhibition of ER-
Golgi transport (Kano, Tanaka et al. 2004), degradation of misfolded 
glycoproteins (Li, Zhao et al. 2008), ERAD regulation (Klein, Barati et al. 2005), 
and regulation binding with some of over 40 known adaptor proteins (Kano, 
Kondo et al. 2005, Klein, Barati et al. 2005, Yeung, Kloppsteck et al. 2008, 
Madsen, Seeger et al. 2009), and others reviewed in (Ewens, Kloppsteck et al. 
2010). 
Neuronal plasticity, neurotransmission and cellular signaling 
Mitochondria can be found concentrated at the synapse and in dendrites 
where they play key roles modulating Ca2+ and providind ATP, thereby regulating 
100 
 
neuronal plasticity, cognition, and neuronal survival (Li, Okamoto et al. 2004). 
Calcium is controlled by a variety of cellular mechanisms including: G proteins 
and their receptors, Ca2+ binding proteins, transcription factors, organelle 
reservoirs, and other systems. In AD, the presence of Aβ peptides excitotoxicity 
and resultant dysregulated Ca2+ homeostasis can occur that can lead to impaired 
synaptic transmission and plasticity, cell death, and associated cognitive 
dysfunction (Mattson, Cheng et al. 1992).  
Gelsolin (gsn) is a F-actin severing protein that remodels skeletal structure 
throughout the CNS, but is especially concentrated in growth cones where it is 
essential for Ca2+-dependent actin motility (Tanaka, Kira et al. 1993, Sun, 
Yamamoto et al. 1999). Gsn is reportedly sequestered in an inactivated state by 
phosphatidylinositol 4,5-bisphosphate (PIP2) and activated by Ca2+ (Janmey, Iida 
et al. 1987). Gsn-PIP2 binding has been reported to enhance phosphorylation 
(De Corte, Gettemans et al. 1997); and this phosphorylation hinders association 
with actin filaments (De Corte, Demol et al. 1999). Further, gsn is cleaved by 
caspase-3 during apoptosis and the resultant carboxyl-terminal fragment is 
reportedly increased in AD brain, correlating with disease severity (Ji, Chauhan 
et al. 2009). Additionally, gsn has been shown to bind to Aβ 1-40 and Aβ 1-42, 
and this interaction is reported to be anti-amyloidogenic, sequestering Aβ thereby 
inhibiting Aβ fibrillization and Aβ-induced apoptosis and neurotoxicity (Ray, 
Chauhan et al. 2000, Qiao, Koya et al. 2005). In this study, phosphorylation 
levels of gsn were decreased in the IPL of all three stages of AD progression 
compared to control, suggesting decreased activity of the protein with 
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consequent decreased Aβ sequestering, promoting SP pathology, and, in a 
neuroprotective process, by removal neurotoxic Aβ oligomers. Such a scenario 
implies a cellular response to Aβ elevation. Furthermore, considering the 
absence of apoptosis in PCAD, gsn dephosphorylation may also promote 
neuronal hypertrophy to maintain actin structure in place. 
Regucalcin (human senescence marker protein 30; SMP30; 
gluconolactonase) is a highly conserved, Ca2+ dependent protein that decreases 
with age and plays a key role in Ca2+ homeostasis as an activator of Ca2+ 
membrane pumps (Fujita, Inoue et al. 1998). Since SMP30 is required for 
synthesis of vitamin C, this protein also exhibits antioxidant properties (Kondo, 
Inai et al. 2006). SMP30 deficiency has been reported to dysregulate Ca2+ 
dependent kinases and phosphatases, RNA and DNA synthesis (Yamaguchi and 
Sakurai 1991, Morooka and Yamaguchi 2002, Morooka and Yamaguchi 2002, 
Yamaguchi, Morooka et al. 2002), increase oxidative stress (Son, Zou et al. 
2006), decreased insulin secretion leading to diminished glucose tolerance 
(Hasegawa, Yamasaki et al. 2010), NF-κB activation,  and  increased  
inflammatory response (Jung, Lee et al. 2014). Further, SMP30 has been 
suggested to be a potential biomarker for AD and PD (Yamaguchi 2014) as 
levels were reported to be significantly decreased in animal models (Kim, Lee et 
al. 2012). In the current study, SMP30 phosphorylation levels were significantly 
decreased in the IPL of PCAD, MCI and AD, all compared to age-matched 
control brains. Implications of SMP30 phosphorylation have yet to be elucidated, 
though seven known phosphorylation sites have been identified. However, 
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considering the proposed functions of SMP30 and dysregulation of Ca2+ 
signaling in AD progression, it may be reasonable to speculate that 
dephosphorylation conceivably decreases SMP30 activity.  
 EF-hand domain-containing protein D1 (EFhd1; swiprosin 2) belong to the 
EF-hand superfamily of Ca2+ binding proteins that participate in a myriad of Ca2+ 
dependent processes. EFhd1 exhibits pro-survival activity in neurons and  may 
act as a response to oxidative stress (Dutting, Brachs et al. 2011). Suppression 
of EFhd1 by siRNA has been reported to suppress neurite outgrowth and 
promote apoptosis (Tominaga, Kurihara et al. 2006). Based on these findings 
and the evidence that EFhd1 associates with the inner mitochondrial membrane, 
it is suggested that EFhd1 modulates mitochondrial functions (Tominaga, 
Kurihara et al. 2006). Measured phosphorylation levels of EFhd1 were 
significantly decreased in both MCI and AD brain as compared to control, 
suggesting a decrease in its activity. The literature concerning this protein is 
scarce and effect of phosphorylation is unknown, but considering what is known 
to date with the decrease in phosphorylation in both MCI and AD, it is rational to 
opine that dephosphorylation of EFhd1 decreases its activity. 
 Guanine nucleotide-binding protein G(o) subunit alpha (GNAO1), is a 
component of G protein transmembrane signaling and is involved in a multitude 
of cellular processes. Mutations in GNAO1 can result in epileptic 
encephalopathy, a severe neurological condition characterized by impaired 
behavior, progressive cognitive decline and cerebral atrophy (Nakamura, Kodera 
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et al. 2013). Further, it was believed that these mutations resulted in an impaired 
ability of the protein to localize to the plasma membrane (Nakamura, Kodera et 
al. 2013), suggesting that abnormal GNAO1 signaling can lead to cognitive 
decline. Earlier studies in G protein subunits showed that there was no difference 
in GNOA1 levels in AD brain as compared to control (O'Neill, Wiehager et al. 
1994). Previously, work from our laboratory showed that phosphorylation levels 
of GNAO1 were significantly increased in the hippocampus of the AD brain (Di 
Domenico, Sultana et al. 2011). In this current study, GNAO1 phosphorylation 
was found to be significantly increased in the IPL of AD brains as compared to 
both control and PCAD brains, suggesting that GNAO1 phosphorylation may 
conceivably interfere with GTP binding, downstream coupling to beta and gamma 
G proteins or result in aberrant cellular localization. Further studies deciphering 
the particular residues phosphorylated, the kinases involved, and the impact on 
GNAO1 structure and function are needed to determine the role that 
phosphorylated GNAO1 may play in cognitive decline and dementia in the 
progression of AD. 
Dihydropyrimidinase-related protein 2 (DRP2; collapsin response mediator 
protein 2, CRMP2) is a pleiotropic protein involved in: synaptic assembly, neurite 
outgrowth, guidance and collapse of the growth cone, axonal growth, 
neurotransmitter release, endocytosis, Ca2+  homeostasis, and organization of the 
dendritic field (Goshima, Nakamura et al. 1995, Byk, Dobransky et al. 1996, 
Uchida, Ohshima et al. 2005, Brittain, Piekarz et al. 2009, Hensley, Venkova et 
al. 2011, Ju, Li et al. 2013). CRMP2 is phosphorylated by a number of kinases 
104 
 
which result in breakdown of growth cones, neurite retraction, and hindrance of 
axonal expansion and is reviewed in (Khanna, Wilson et al. 2012). Interestingly, 
phosphorylated CRMP2 is a component found in NFTs (Uchida, Ohshima et al. 
2005) and phosphorylation of CRMP2 has been suggested to be an early 
occurrence in AD progression based on studies of rodent models (Cole, Noble et 
al. 2007). In previous studies, we have shown that CRMP2 is oxidatively modified 
in AD (Castegna, Aksenov et al. 2002) and that phosphorylation levels of CRMP2 
are increased in the hippocampus of AD brain (Di Domenico, Sultana et al. 
2011). In this current study, the phosphorylation levels of CRMP2 were 
significantly increased in the IPL of AD brain as compared to control IPL. This 
result suggests that the decrease in synapses in AD may be directly related to 
the increased phosphorylation of CRMP2.   
  Septins are highly conserved cytoskeletal GTPases are involved in 
various cellular processes and signaling pathways, including: DNA response to 
cytoskeletal damage, protein scaffolding, membrane compartmentalization, cell 
division, vesicle trafficking, exocytosis and apoptosis (Barral, Mermall et al. 2000, 
Kremer, Adang et al. 2007, Spiliotis, Hunt et al. 2008, Hagiwara, Tanaka et al. 
2011). It has also been suggested that 9 of the 14 known septins play a role in 
maturation of the dendritic field, as they may be involved in spine dynamics, 
synaptic transmission and connectivity (Tada, Simonetta et al. 2007, Xie, Vessey 
et al. 2007). Previous studies have shown that Septins contain multiple 
phosphorylation sights that are crucial in regulating functions of septin (Xue, 
Wang et al. 2000, She, Huang et al. 2004, Meseroll, Occhipinti et al. 2013). 
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Abnormal septin function has been noted in multiple neurological disorders such 
as AD, Down syndrome, Parkinson disease and Schizophrenia (Kinoshita, 
Kinoshita et al. 1998, Cheon, Fountoulakis et al. 2001, Barr, Young et al. 2004, 
Ihara, Yamasaki et al. 2007). Septin 2, in particular, is associated with synaptic 
vesicles and neurotransmitter release (Kinoshita, Kimura et al. 2004, Tokhtaeva, 
Capri et al. 2015). Further, it has been reported that septin 2 may regulate 
glutamate uptake by the excitatory amino acid transporter (EAAT1) in astrocytes, 
a mechanism that aids in the prevention of excitotoxicity and resultant neuronal 
death (Kinoshita, Kimura et al. 2004). In AD, septin 2 is associated with both 
NFTs and SPs (Kinoshita, Kinoshita et al. 1998, Pissuti Damalio, Garcia et al. 
2012). Phosphorylation levels of septin 2 were significantly upregulated in PCAD 
as compared to all other groups, suggesting that increased phosphorylation of 
septin 2 may promote increased plasticity and neurotransmission. Further, 
maintaining normal synaptic activity, as in PCAD, has been suggested to protect 
the synapse against Aβ toxicity (Tampellini, Rahman et al. 2009). 
Stathmin is an essential protein that regulates microtubule dynamics, 
playing key roles in neurite outgrowth, synaptic plasticity, learning, and memory 
by preventing microtubule assembly, promoting disassembly, and sequestering 
tubulin dimers (Belmont and Mitchison 1996, Jourdain, Curmi et al. 1997, Mori 
and Morii 2002, Grenningloh, Soehrman et al. 2004, Felkl and Leube 2008). 
Expression of stathmin is reportedly decreased in AD brain (Saetre, Jazin et al. 
2011). Phosphorylation of stathmin decreases its binding affinity towards tubulin, 
thereby promoting microtubule assembly (Amayed, Pantaloni et al. 2002). We 
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found phosphorylation levels of stathmin significantly decreased in AD brain as 
compared to age-matched controls, demonstrating a mechanism for decreasing 
axon and synapse structure and decreasing LTP. 
Syntaxin-binding protein 1 (stxbp1; Munc18) binds to syntaxin, thus 
controlling formation of the SNARE complex and neurotransmitter release 
(Misura, Scheller et al. 2000, Yang, Steegmaier et al. 2000). Additionally, stxbp1 
has also been shown to regulate the filopodia of the growth cone to modulate 
presynaptic plasticity (Broeke, Roelandse et al. 2010). Protein kinase C 
phosphorylation on Ser-306 and Ser-313 has been reported to modulate 
neurotransmission by increasing rapid vesicle cycling and vesicle release 
(Barclay, Craig et al. 2003, Craig, Evans et al. 2003). In the current study, stxbp1 
phosphorylation levels were significantly decreased in AD brain as compared to 
control, which correlates to decreased synaptic efficiency and implicates 
decreased stxbp1 phosphorylation in synapse loss in AD brain. 
Protein levels of 2',3'-cyclic nucleotide-3'-phosphodiesterase (CNP) are 
mainly localized to oligodendrocytes and are considered to be a marker of 
myelination, as it is suggested that CNPI plays a role in maintain the myelin 
sheath (Thompson 1992, Lappe-Siefke, Goebbels et al. 2003). In AD, the activity 
of CNP is reportedly decreased in the hippocampus and putamen and increased 
in the parietal cortex, temporal cortex and parahippocampalis (Vlkolinsky, Cairns 
et al. 2001). In this study of the IPL, phosphorylation levels of CNP isoform CNPI 
were decreased in PCAD (with a near significant decrease in AD). Taken 
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together, this suggests that dephosphorylation of CNPI may conceivably increase 
the activity of the protein in an attempt to prevent synaptic and cognition loss. 
 In conclusion, this current study has identified significant changes in global 
phosphorylation levels of proteins in the IPL of PCAD, amnestic MCI and AD 
subjects, suggesting related alterations in protein activity to the underlying 
mechanisms that may contribute to aberrant changes in: Ca2+ signaling, energy 
metabolism, neuronal plasticity, signal transduction, and oxidative stress 
response. Further, we show how changes in phosphorylation may contribute to 
the progressive cognitive decline in MCI that escalates to the dementia of AD. 
Moreover, examination of the phosphoproteome of PCAD brain suggests 
potential mechanisms that may play key roles in preserving cognitive functions 
despite abundant AD pathology. The results are suggestive of changed activity of 
differentially phosphorylated proteins in all the states of AD. Further activity 
measurements are needed to confirm or refute these suggestions. Moreover, 
targeting the kinases and phosphatases involved in the regulation of these 
proteins may conceivably lead to promising treatment strategies to halt the 
cognitive decline in AD progression. 
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CHAPTER 6: THE NAKED MOLE-RAT 
CHAPTER 6.1 
METABOLIC CLUES TO SALUBRIOUS LONGEVITY IN THE BRAIN OF THE 
LONGEST-LIVED RODENT: THE NAKED MOLE-RAT 
6.1.1 Overview 
Naked mole-rats (NMRs) are exceptionally long-lived rodents that have 
sustained healthspans, exhibiting negligible senescence and a pronounced 
resistance to age-related disease. Uncovering insights underlying these 
extraordinary traits involved in successful aging may conceivably provide crucial 
clues to extend the human lifespan and healthspan. A prominent hallmark in age-
related diseases, such as neurodegeneration and cancer, is the impairment and 
dysregulation of metabolic pathways. Using a 2-D PAGE proteomics approach, 
alterations in levels and phosphorylation of metabolic proteins in the brains of 
NMRs were evaluated in an age-dependent manner. We identified 14 proteins 
with altered levels and/or phosphorylation states that play key roles involved in 
metabolic functions. New insights into potential pathways involved in metabolic 
aspects of successful aging have emerged. 
6.1.2 Introduction 
Most aging research focuses on investigating a few well-characterized 
short-lived species including: Caenorhabditis elegans, Drosophila melanogaster, 
Rattus norvegicus, and Mus musculus (Finch and Austad 2001). While models 
with such short lifespans that provide the ability to perform experiments rapidly, 
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restraining biomedical research to very few models of aging or longevity may limit 
novel discoveries and scientific progression. Not surprisingly, there is a growing 
call for new models that may better mimic human aging and provide better 
translational predictability (Buffenstein, Nelson et al. 2014). Since humans are a 
long-lived species on the basis of their body size (Hulbert, Pamplona et al. 2007), 
it is hypothesized that species with naturally longer lives may yield better insights 
into diseases that afflict humans later in life than do short-lived models that 
commonly die before age-related diseases manifest. Such species likely also 
have evolved mechanisms which allow for extended healthy life spans, in 
contrast to those that do not, and as such provide more precise models for 
human aging (Lewis, Mele et al. 2012). Unlike most other rodents that live 
relatively short lives in absolute terms (as little as 2-3 months in the wild; 2-5 
years in captivity), naked mole-rats (NMRs) live to exceedingly advanced ages 
(4-17 years in the wild and up to 30+ years in captivity), unrivaled by any other 
rodent species (Bobeck 1969, David and Jarvis 1985, Buffenstein 2008, Edrey, 
Hanes et al. 2011). Perhaps even more extraordinary, NMRs exhibit a prolonged 
healthspan, seemingly resistant to age-related deterioration well into old age 
(Buffenstein 2008, Edrey, Hanes et al. 2011, Grimes, Reddy et al. 2014). Insights 
into mechanisms facilitating sustained physiology and metabolism in NMRs may 
have therapeutic implications for human aging and age-associated diseases. 
NMRs are naturally found in the arid and semi-arid regions of the horn of 
Africa (Kenya, Ethiopia and Somalia). Here, they lead an exclusive subterranean 
existence, living in sealed burrows in large eusocial colonies of up to 300 
110 
 
individuals with a strict division of labor culminating in the presence of only one 
breeding female and 2-4 breeding males (Jarvis 1981). This extreme 
environment coupled with their eusocial life-style has led to the evolution of 
several adaptive traits including tolerance of variable oxygen and nutrient 
availability and concomitant metabolic effects (Buffenstein and Yahav 1991, 
Buffenstein and Yahav 1991, Larson and Park 2009). 
NMRs present a number of unique phenotypes that may contribute to their 
unusually long lives. NMRs maintain a low basal metabolic rate throughout their 
lives (O'Connor, Lee et al. 2002). This is accompanied by low heart rates, 
decreased cardiac output, and low fasting blood glucose levels (Ables, Brown-
Borg et al. 2014, Grimes, Reddy et al. 2014). Nevertheless, glucose tolerance 
tests reveal that a large dose of glucose will cause a prolonged blood glucose 
elevation, indicative of insulin insensitivity (Kramer and Buffenstein 2004). This 
insensitivity is characteristic of induced-diabetic animal models, yet healthy 
NMRs show no other signs of diabetic pathology (Dumm, Console et al. 1995, 
Tokuyama, Sturis et al. 1995, Kramer and Buffenstein 2004). Rather, animals 
appear to be extremely sensitive to insulin administration. Unlike mice treated in 
an identical manner, glucose levels in blood not only precipitously drop following 
treatment with human insulin but remain at these low levels for an extended 
period (Dumm, Console et al. 1995, Tokuyama, Sturis et al. 1995, Kramer and 
Buffenstein 2004). These findings suggest that in their normal daily lives they are 
extremely sensitive to insulin signaling. Novel and tightly regulated glucose 
management may play a critical role in lifespan extension as it has been shown 
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that genetic control of insulin signaling through the insulin/insulin-like growth 
factor signaling pathway may significantly expand the lifespan of an organism 
(Guarente and Kenyon 2000).  
In this study, we explored not only the age-dependence of levels of brain 
proteins involved in energy metabolism, but also their global phosphorylation 
status as a means of gathering insights into the active proteome of NMRs during 
their life and development. The brain, in particular, is an essential organ on which 
to study, as cerebral insulin signaling is crucial in maintaining energy and glucose 
homeostasis, arguably key regulators of longevity and aging. Dysregulation of 
these pathways is associated with neurodegenerative diseases and metabolic 
syndromes leading to shortened lifespans and diminished quality of life 
(Butterfield, Di Domenico et al. 2014).  
By evaluating the NMR proteome and phosphoproteome, the results 
obtained have yielded a number of insights on the salubrious aging process of 
NMR with regards to glucose utilization, proteostasis networks, signaling 
pathways, neuronal plasticity, and neuronal structure. A large number of brain 
proteins altered in aging have been identified, too many to be efficiently 
presented and discussed in a single manuscript. Accordingly, to facilitate the 
discussion of the implications of altered protein expression and phosphorylation 
and how they relate to the unusually long and healthy life spans of NMRs, we 
approached this effort by use of functional class of identified proteins. Here, we 
present the results related to metabolism.  
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6.1.3 Materials and Methods 
6.1.3.1 Materials 
The chemicals used in these studies were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) unless otherwise noted. Criterion precast polyacrylamide 
gels, ReadyStrip IPG strips (pH 3-10),  TGS and MOPS electrophoresis running 
buffers, 0.2 nm nitrocellulose membrane, Precision Plus Protein All Blue 
Standards, Sypro Ruby Protein Stain, urea, biolytes, mineral oil, dithiothreitol, 
and iodoacetamide were obtained from Bio-Rad (Hercules, CA, USA). Modified 
trypsin solution was purchased from Promega (Madison, WI, USA). C18 ZipTips, 
and Re-Blot Plus Strong stripping solution were purchased from Millipore 
(Billerica, MA, USA). Pro-Q Diamond phosphoprotein stain, and anti-
phosphoserine, anti-phosphotyrosine, and anti-phosphothreonine antibodies 
raised in rabbits were procured from Invitrogen (Grand Island, NY, USA). 
Amersham ECL rabbit IgG horseradish peroxidase-linked secondary antibody, 
ECL-Plus Western blotting detection reagents and protein A/G beads were 
obtained from GE Healthcare (Pittsburgh, PA, USA). Anti-malate dehydrogenase 
(cytosolic) and anti-lactate dehydrogenase antibodies were purchased from 
Santa Cruz Biotechnology (Dallas, TX, USA).  Anti-glucose-6-phosphate 
dehydrogenase antibody was obtained from Cell Signaling Technology (Danvers, 
MA, USA). 
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6.1.3.2 Animals 
The brains from naked mole-rats used in this study, aged 2-24 years, were 
obtained from the colonies maintained by Dr. Rochelle Buffenstein at the 
University of Texas Health Science Center, San Antonio. These well-
characterized colonies (Buffenstein 2005) were housed in fabricated burrow 
systems with climate conditions that mimicked their natural habitat (30˚C and 30-
50% relative humidity). Their diet consisted of fresh fruits and vegetables, 
provided ad libitum, and supplemented with a high protein and vitamin enriched 
feed (Pronutro, South Africa). NMRs were anesthetized with isofluorane and then 
euthanized via cardiac exsanguination. Brains were immediately harvested and 
flash frozen in liquid nitrogen. All animal procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Texas Health 
Science Center at San Antonio, TX. The experimental groups of animals 
consisted of both male and female breeding and non-breeding adults. For the 
four age groups, n=5-9 individual brains. 
6.1.3.3 Sample preparation 
NMR brains were thawed and individual homogenates were prepared 
using a Wheaton glass homogenizer (~40 passes) with  ice-cold isolation buffer 
[0.32M sucrose, 2mM EDTA, 2mM EGTA, 20mM HEPES, 0.2µg/mL PMSF, 
4µg/mL leupeptin, 4 µg/mL pepstatin, 5 µg/mL aprotinin and 10 µg/mL 
phosphatase inhibitor cocktail 2]. Homogenates were vortexed on ice and 
sonicated for 10 s at 20% power with a Fisher 550 Sonic Dismembrator 
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(Pittsburgh, PA, USA). Protein concentrations of the homogenates were 
determined by the Pierce BCA method (Smith, Krohn et al. 1985). 
6.1.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
Isoelectric focusing (IEF). 2-D PAGE experiments were conducted as 
described previously (Sultana, Boyd-Kimball et al. 2007). Briefly, 200 µg of each 
homogenate was shaken for 2 h at 22˚C in 200 µL of  rehydration buffer [8 M 
urea, 2.0% (w/v) CHAPS, 2 M thiourea, 50 mM DTT, 0.2% Biolytes, 0.01% 
Bromophenol Blue]. Samples were then sonicated for and dispensed into wells 
for application to 11 cm pH 3-10 ReadyStrip IPG strips for isoelectric separation 
of the proteins. Strips were actively rehydrated at 20 °C for 18 h at 50 V using a 
Bio-Rad Protean IEF Cell (Hercules, CA, USA). Isoelectrical focusing continued 
at a constant temperature of 20 °C beginning at 300 V for 2 h, 500 V for 2 h, 
1000 V for 2 h, 8000 V for 8 h, and finishing at 8000 V for 10 h. IPG strips were 
then immediately stored at -80 °C. 
SDS PAGE. IEF strips were thawed and then equilibrated for 10 min in the 
dark with 4 mL of equilibration buffer A [50 mM Tris–HCl, pH 6.8, 6 M urea, 1% 
(w/v) SDS, 30% v/v glycerol, 0.5% DTT]. Strips were then re-equilibrated for 10 
min in the dark with 4 mL of equilibration buffer B [50 mM Tris–HCl, pH 6.8, 6 M 
urea, 1% (w/v) SDS, 30% v/v glycerol, 4.5% IA]. The IEF strips were rinsed in a 
1X dilution of TGS running buffer and placed into Criterion precast 
polyacrylamide gels (8–16% Tris–HCl, linear gradient), 1 IPG + 1 Well Comb, 
11cm. Precision Plus Protein All Blue molecular weight marker was added and 
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the wells were overlaid with agarose gel. The gels were run at a constant voltage 
of 200 V for approximately 65 min at 22˚C in 1X Tris/Glycine/SDS running buffer 
using a Criterion Cell vertical electrophoresis buffer tank. 
6.1.3.5 SYPRO Ruby and Pro-Q Diamond staining 
Gel staining to detect proteins and phosphoproteins was carried out 
according to manufacturer’s directions and as previously described (Triplett, 
Zhang et al. 2015). In brief, gels were fixed, stained with Pro-Q Diamond, 
scanned at 580 nm using a Bio-Rad ChemiDoc XRS+ imaging system (Bio-Rad, 
Hercules, CA, USA), stained with Sypro Ruby, and then scanned again at 450 
nm. Gels were stored in deionized water at 4 °C until extraction of the protein 
spots. 
6.1.3.6 Image Analysis 
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2D-
gel images of NMR samples were quantified by densitometry according to the 
total spot density using PDQuest 2-D Analysis Software (Bio-Rd, Hercules, CA, 
USA). Intensities of individual spots were normalized to the total density of the 
gel. Spot densities of the three older age groups (4-6 year-olds, 7-12 year-olds, 
and 15-24 year-olds) were independently compared to the spot densities from 
the earliest age group (2-3 year-olds) using a Student’s two-tailed t-test and a 
Mann-Whitney U statistical test, both at 95% confidence (i.e. p<0.05). Only spots 
with a significant difference in both tests were considered for in-gel trypsin 
digestion and subsequent identification. 
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Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel 
images of the NMR samples were quantified and matched together in the same 
manner as the SYPRO Ruby-stained gels. Next, the master gel from the Sypro 
Ruby matching and Pro-Q Diamond matching were used for a high match 
analysis. The PDQuest software provided numerical data based on the intensity 
of each protein spot. The phosphoprotein spot densities were then normalized to 
the Sypro Ruby spot densities and the resultant normalized phosphoprotein spot 
densities in the 3 older age groups were independently compared to the earliest 
age group using a Student’s two-tailed t-test and a Mann-Whitney U statistical 
test. Only spots that were significant (p<0.05) in both tests were considered for 
in-gel trypsin digestion and subsequent identification. 
6.1.3.7 In-gel trypsin digestion/peptide extraction 
Significant spots were excised from 2D-gels and transferred to individual 
Eppendorf microcentrifuge tubes for trypsin digestion as described previously 
(Thongboonkerd, McLeish et al. 2002). Briefly, gels were washed with 0.1 M 
ammonium bicarbonate (NH4HCO3) for 15 min, followed by incubation with 
acetonitrile (ACN) for 15 min. The solution was removed and gel plugs were 
allowed to dry under a flow hood. Next, the gel plugs were incubated in 20 mM 
DTT in 0.1 M NH4HCO3 for 45 min at 56°C. The DTT/NH4HCO3 solution was 
removed and 0.05 M IA in 0.1 M NH4HCO3 was added and allowed to incubate at 
22˚C for 15 min. The IA solution was removed and 150 µL of 0.05 M NH4HCO3 
was added and incubated for 15 min at 22˚C. Next, 200 µL of ACN was added 
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and allowed to incubate for 15 min at 22˚C. The solution was then removed and 
the gel plugs were allowed to dry under a flow hood. Then, 10 µL of modified 
trypsin solution in 0.05 M NH4HCO3 was added and incubated with shaking 
overnight at 37 °C. Salts and contaminants were removed from the tryptic 
peptide solutions using C18 ZipTips. Samples were stored at -80˚C until MS/MS 
analysis. 
6.1.3.8 NanoLC-MS with Data Dependent Scan 
Tryptic peptide solutions were reconstituted in 10 µL 5% ACN/0.1% formic 
acid (FA). MS/MS analysis was performed by a nanoAcquity (Waters, Milford, 
MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) system using a data 
dependent scan mode. A capillary column packed in-house (0.1 x 130 mm 
column packed with 3.6 µm, 200Å XB-C18). For separation, a gradient with 0.1% 
FA and ACN/0.1% FA at 200 nL/min was used. The MS spectra were obtained 
by the orbitrap at 30,000 resolution. The MS/MS spectra of the six most intense 
ions in MS scan were acquired by the orbitrap at 7,500 resolution. Using the 
Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, Thermo 
Scientific), data files of each sample were interrogated. For protein identification, 
at least two high-confidence peptide matches were used (false discovery rate 
<1%). Proteins that were matched with the same peptides were reported as one 
protein group. Data from the MS/MS analysis was initially verified by comparing 
the expected molecular weight and isoelectric point of the identified protein to 
that of the extracted plug from the 2-D gel. 
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6.1.3.9 Immunoprecipitation and Western blotting validations 
Immunoprecipitation (IP). Whole brain homogenates (250 µg) were 
suspended in 500 µL IP buffer [0.05% NP-40, leupeptin 4 µg/mL, pepstatin 4 
µg/mL, aproprotin 5 µg/mL, phosphatase inhibitor cocktail 10 µg/mL] in a 
phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na2HPO4, 0.24 M 
KH2PO4]. The samples were then precleared by incubation with Protein A/G - 
agarose beads for 1.5 h at 4˚C and then incubated overnight with anti-malate 
dehydrogenase antibody (1:50 dilution) at 4˚C. Samples were once again 
incubated with Protein A/G – agarose beads for 1.5 h at 4˚C and then washed 5 
times with IP buffer.  The beads were preserved for a 1D-PAGE experiment. 
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Whole 
brain homogenized protein extracts (50 µg) or beads from immunoprecipitation 
experiments were suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8, 
40% glycerol, 8% SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue] 
diluted to 1X with distilled water. Samples were then heated at 95 °C for 5 min, 
cooled on ice, and loaded into a Criterion precast (4-12% Bis-Tris) 
polyacrylamide 18 well gel. Gels were placed in a Criterion Cell vertical 
electrophoresis buffer tank filled with XT MOPS running buffer and run at 80 V for 
15 min and then at 120 V for approximately 100 min.  
1D-Western blotting. 1D-gels were transferred to nitrocellulose 
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad, 
Hercules, CA, USA). After the transfer, membranes were blocked with 3% bovine 
119 
 
serum albumin (BSA) in Wash Blot [150 mM NaCl, 3 mM NaH2PO4, 17 mM 
NaHPO4 and 0.04% (v/v) Tween 20] at 22˚C for 1.5 h. The membrane was 
incubated with a primary antibody (1:3000 dilution) in blocking solution with 
gentle rocking for 2 h at 22˚C. After washing the blots three times for 5 min each, 
the blots were incubated with a horseradish peroxidase (1:5000) secondary 
antibody in Wash Blot at 22˚C with gentle rocking. The membranes were washed 
three times in Wash Blot (10 min each) and developed chemiluminescently using 
Clarity Western ECL substrate. After developing in the dark for 5 min at 22˚C, 
membranes were scanned using Bio-Rad ChemiDoc XRS+ imaging system and 
quantified using Image Lab software (Bio-Rad, Hercules, CA, USA). Blots were 
then stripped with Re-Blot Plus Strong solution and washed three times with 
Wash Blot (5 min each). The membranes were then blocked in 3% BSA for 1.5 h 
and incubated with an anti-tubulin antibody (1:5000) or with anti-phosphoserine, 
anti-phosphothreonine and anti-phosphotyrosine antibodies (1:6000) for 2 h. The 
membranes were washed, incubated with a secondary antibody, and developed 
as described above.  
6.1.3.10 Statistical analysis 
Initial statistical analyses of PDQuest data were performed conservatively 
by using both a two-tailed Student’s t-test and the Mann-Whitney U statistical 
test, comparing each age group independently to the earliest age group. A 
protein spot was considered statistically significant if p<0.05 for both tests. A one-
way ANOVA with post hoc Bonferroni t-test was used in determining significance 
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(p<0.05) between age groups for PDQuest data and Western blot analysis. Fold-
change values of protein spots were calculated by dividing the average, 
normalized spot intensities of the gels of the older age group by the average, 
normalized spot intensities of the gels of the younger age group in the 
comparison. Spot extraction and MS/MS analysis was conducted only for spots 
with a 40% fold change or greater in normalized spot density. Identifications of 
proteins acquired with the SEQUEST search algorithm were considered to be 
statistically significant if p<0.01. All data are presented as mean+SEM. 
6.1.4 Results 
To evaluate age-related protein changes in the brain, the NMR were 
divided into four age groups: 2-3 year-olds (age group 1; young), 4-6 year-olds 
(age group 2; intermediate), 7-12 year-olds (age group 3; old) and 15-24 year-
olds (age group 4; oldest). The average protein spot intensities from each age 
cohort were compared to determine significant differentially expressed and 
phosphorylated proteins.  
Figure 6.1.1 shows representative examples obtained from SYPRO-Ruby-
stained 2-D gel images of the isolated proteins from these four age groups with 
significant differentially expressed proteins labeled and Figure 6.1.2 shows 
characteristic 2-D gels of the isolated protein spots stained with Pro-Q Diamond 
showing significantly altered phosphorylation states identified in each age group. 
PDQuest and MS/MS analyses of all the significant proteins found 14 metabolic 
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proteins whose expression and/or phosphorylation states were significantly 
altered in NMR brains with age. These results are summarized in Table 6.1.1.  
 
 
Figure 6.1.1 Sypro Ruby-stained 2-D gels of NMR metabolism-associated 
proteins with altered expression in brain with age. Representative Sypro 
Ruby-stained 2-D gel images of isolated proteins from the brains of NMRs, aged 
2-3 years (A), 4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins whose 
expression was statistically significantly altered in the particular age group are 
labeled in the images (p<0.05). 
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Figure 6.1.2 Pro-Q Diamond-stained 2-D gels of NMR metabolism-associated 
proteins with altered expression in brain with age. Representative Pro-Q Diamond-
stained 2-D gel images of isolated proteins from the brains of NMRs, aged 2-3 years (A), 
4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins with statistically significantly 
altered phosphorylation states in the particular age group are labeled in the images 
(p<0.05). 
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Table 6.1.1 Metabolic proteins with significantly altered levels and/or 
phosphorylation states with age in the NMR brain. PDQuest and MS/MS 
results of NMR metabolic brain proteins with significant altered expression and/or 
phosphorylation states as a function of age. 
  
 
 
Additional information provided in the table includes: the PDQuest spot 
number, the SwissProt accession number, percentage of the protein sequence 
covered by matching peptides, the number of peptide sequences identified by the 
MS/MS analyses, the confidence score of the protein, the expected molecular 
weight and isoelectric point of the identified protein, the age groups compared 
with the corresponding p-values, and fold-change levels of expression and 
phosphorylation obtained from the PDQuest analyses. Two or more peptide 
sequences were used in the identification of all proteins; and the identified 
protein spots were visually compared against the expected molecular weights 
and isoelectric points to further ensure correct protein identification. The 14 
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metabolic proteins found to have differential expression and/or phosphorylation 
states in one or more age groups were: pyruvate kinase, pyruvate kinase PKM; 
glucose-6-phosphate 1 dehydrogenase; glucose-6-phosphate isomerase; malate 
dehydrogenase (both cytosolic and mitochondrial); L-lactate dehydrogenase b 
chain; cytosolic acyl CoA thioester hydrolase (2 different isoforms); fructose-
bisphosphate aldolase; alpha enolase; cytosolic isocitrate dehydrogenase; 
aspartate aminotransferase; and ATP synthase subunit alpha (isoform 2). 
To validate the identification of these proteins, immunoprecipitation and 
Western blot validation experiments were undertaken. Figure 6.1.3 shows the 
Western blot images using tubulin as a loading control verifying the age-related 
changes in expression of lactate dehydrogenase (LDH) and glucose-6-phosphate 
dehydrogenase (G6PD) with corresponding bar graph representations of the 
data. The results of the Western blot analyses of the expression of LDH 
confirmed a significant increase in the oldest age group as compared to the 
intermediate age group (p=0.0003) and to the old age group (p=0.0003). 
Additionally, the Western blot analysis also showed a statistically significant 
increase (p=0.024) in the oldest age group as compared to the youngest age 
group. Western blot analysis of G6PD confirmed a significant increase in the 
level of G6PD in the brains of the oldest age group as compared to the 
intermediate (p=0.0103) and old age group (p=0.014). 
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Figure 6.1.3 LDH and G-6-P dehydrogenase expression in brain of NMR 
with age. Western blot and corresponding bar graph representations from the 
validation experiments of the changes in the expression of lactate 
dehydrogenase (A & C) and glucose-6-phosphate dehydrogenase (B & D) in the 
brains of NMRs (n=4 for each age group, *p<0.05, ***p<0.001). Immunoreactivity 
with specific antibodies was detected by chemiluminescence. 
 
Figure 6.1.4 shows the images from the immunoprecipitation experiments 
after probing with anti-phosphoserine, anti-phosphothreonine and anti-
phosphotyrosine antibodies in which the immunoprecipitated protein, cytosolic 
malate dehydrogenase (MDH1), was used as the loading control.  
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Figure 6.1.4 Reduced MDH1 phosphorylation in NMR brain with age. 
Western blot and corresponding bar graph representation from immunochemistry 
experiments of the validation of the significant decrease in the phosphorylation of 
cytosolic malate dehydrogenase in the brains of NMRs (n=4 for each age group, 
*p<0.05). Immunoreactivity of anti-MDH1 antibody was detected by 
chemiluminescence. 
The findings from this analysis confirmed a significant decrease in the 
phosphorylation of MDH1 in the NMR brain for the old age group (p=0.044) and 
in the oldest age group (p=0.03), both as compared to the youngest age group.  
6.1.5 Discussion 
Numerous alterations of metabolism are evident in a number of age-
related diseases such as Alzheimer, Huntington and Parkinson diseases, cancer, 
atherosclerosis, and type 2 diabetes mellitus, to name but a few (Berg, Combs et 
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al. 2002, Kahn 2003, Hsu and Sabatini 2008, Cai, Cong et al. 2012, Butterfield, 
Di Domenico et al. 2014). Many of these metabolic diseases directly impact upon 
brain function for the brain is an organ with a high rate of metabolism. The brain 
consumes up to 20% of total glucose and 30% of inspired oxygen to maintain 
neuronal resting potentials, propagate action potentials,  release 
neurotransmitters, and other energy-requiring processes (Madsen, Cruz et al. 
1999). With age, energy metabolism in the brain undergoes a gradual decline 
and the efficacy of these essential brain functions correspondingly diminishes, 
thereby contributing to age related cognitive deficits (Petit-Taboué, Landeau et 
al. 1998, Poon, Shepherd et al. 2006, Navarro and Boveris 2007, Swerdlow 
2007). Not only do changes in metabolism impact upon brain function and 
healthspan, but conversely, aging as well as many age-associated diseased 
states dramatically impact upon metabolism (Finkel, Serrano et al. 2007). For 
example, in cancer, activation of oncogenes and loss of tumor suppressor activity 
alters metabolism by inducing the Warburg effect, promoting glycolysis to support 
cancerous cell growth and survival (Dang 2012). Therefore, examining the age-
related changes in metabolic proteins in the brains of the NMR and 
understanding the mechanisms that contribute to the resistance of senescence-
related diseases in NMRs conceivably may provide crucial clues to metabolic 
mechanisms that promote successful aging and increased healthspan.  
This current proteomics study revealed fourteen metabolic proteins with 
significantly altered expression and/or phosphorylation levels in the brains of 
NMRs as they aged. The NMRs were divided into four age cohorts: young, 
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intermediate, old, and oldest. The brain proteins identified suggest mechanisms 
by which the NMR brain responds to and adapts to the aging process and 
conceivably are clues to better understand how the NMR brain adapted to resist 
age-related degeneration. These 14 proteins that are significantly altered during 
aging are involved in glycolysis, the pentose-phosphate shunt, the malate-
aspartate shuttle, the TCA cycle, and the electron transport chain. 
Levels of pyruvate kinase (PK) were increased in the old NMR age group 
as compared to the youngest age group. PK is a key enzyme that generates ATP 
and modulates glycolytic activity. The expression of a specific isoform of PK, 
pyruvate kinase M (PKM), was lower in the intermediate age group relative to the 
youngest NMR group studied, and the phosphorylation state was decreased in 
both the intermediate and oldest age group in relation to the youngest. PKM is an 
essential glycolytic enzyme that exists as both a dimer and tetramer, and the 
ratio between these two forms determines whether glycolytic flux is directed 
towards catabolic or anabolic pathways (Iqbal, Gupta et al. 2014). Moreover, 
dephosphorylation of PKM has been shown to increase activity of PKM 
(Anastasiou, Yu et al. 2012). Increased PKM activity reportedly promotes anti-
tumor activity by inhibiting tumor cell growth (Stetak, Veress et al. 2007, 
Anastasiou, Yu et al. 2012). Therefore, it is conceivable that the decreased 
phosphorylation state of PKM likely increases PKM activity in older NMRs and 
may contribute to their cancer resistance. In addition, PKM is a known co-
activator of hypoxia-inducible factor 1α (HIF-1α), which modulates HIF-1α 
transcriptional activity, thereby regulating glucose transport and glycolytic 
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enzymes, among other pathways (Luo, Hu et al. 2011) . Old NMRs have been 
previously shown to exhibit high levels of HIF-1α, compared to attenuated 
expression of HIF-1α in aged mice (unpublished data R.B.). Further, it is 
hypothesized that increased expression of HIF-1α is an adaptive response to 
modulate neurodegeneration by providing energy to sustain the cell through 
glycolysis in hypoxic conditions (Ogunshola and Antoniou 2009). Thus, the 
increased expression of PK in the old age cohort as well as the decreased 
phosphorylation of PKM in the oldest group, are mechanisms that conceivably 
contribute to sustaining the required energy demand during old age to maintain 
efficient cellular functioning. 
Cytosolic acyl CoA thioester hydrolase, also known as brain acyl-CoA 
hydrolase (BACH), catalyzes the cleavage of acyl-CoA producing a fatty acid and 
coenzyme A (CoA-SH), thereby modulating many cellular processes. Activity of 
BACH is higher in the brain than in any other organ, and acyl-CoA, fatty acids 
and CoA-SH are involved in: cellular signaling, β-oxidation, inflammation, ion 
fluxes, protein and vesicle trafficking, allosteric regulation of enzymes, gene 
expression, lipid synthesis, and energy metabolism and regulation (Hunt and 
Alexson 2002, Yamada, Kuramochi et al. 2002, Yamada 2005). BACH’s role in 
regulating lipid metabolism may be a crucial factor affecting the aging rate by 
providing cell and membrane stability (Hulbert, Pamplona et al. 2007). The brain 
is rich in lipid content, and BACH is reportedly essential in the prevention of 
neurotoxicity by the dysregulation of neuronal fatty acid metabolism (Ellis, Wong 
et al. 2013). Additionally, BACH can scavenge free fatty acids in the cytosol by 
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linking CoA-SH to form fatty acyl-CoA. This fatty acyl-CoA can then be imported 
into the mitochondria, via the mitochondrial carnitine system, to participate in the 
TCA cycle (Kerner and Hoppel 2000). Analysis of BACH levels showed a 
significant increase from young to old NMR, which then significantly decreased in 
brains of the oldest age group. Expression of BACH isoform 2 was increased in 
the two oldest age groups relative to the youngest NMR, with a decrease in the 
phosphorylation state in the oldest age group. It is not yet clear what effect 
phosphorylation has on the activity of BACH; however, this is an important area 
to explore as BACH activity regulates the proper ratios of activated fatty acyl-
CoA, free fatty acids and CoA-SH (Brocker, Carpenter et al. 2010). Such studies 
are underway in our laboratories. 
Glucose-6-phosphate isomerase (GPI; a.k.a. neuroleukin; autocrine 
motility factor) is a pleiotropic protein performing different functions inside the cell 
and in the extracellular space. In the cytoplasm, GPI catalyzes the second step in 
glycolysis, converting glucose-6-phosphate to fructose-6-phosphate, regulates 
gp78-dependent mitochondrial fission and mitophagy (Fu, St-Pierre et al. 2013, 
Shankar, Kojic et al. 2013), and is reported to protect against ER stress and 
apoptosis by regulation of ER calcium release (Fu, Li et al. 2011). Outside the 
cell, GPI acts as a neurotropic factor for spinal and sensory neurons, contributing 
to maintenance of neuronal integrity (Haga, Niinaka et al. 2000). A decrease in 
phosphorylation of GPI has been reported to lead to an increase in activity 
(Yanagawa, Funasaka et al. 2005). Hence, the increased levels of GPI relative to 
the earliest age group and the decreased phosphorylation levels in the oldest 
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age cohort as compared to the intermediate, demonstrate a potential 
neuroprotective mechanism that may contribute to the NMR’s sustained lifespan 
and healthspan. 
Two additional glycolytic enzymes were identified as being significantly 
altered in the NMR brain: fructose-bisphosphate aldolase (ALDO) and alpha 
enolase (ENO1). ALDO is a pleiotropic protein that not only catalyzes a key 
reaction in glycolysis but is also involved in: endocytosis, assembly and 
regulation of vacuolar H+-ATPase proton pump, mRNA stability, and assembly of 
the actin cytoskeleton (Kao, Noda et al. 1999, Lundmark and Carlsson 2004, 
Canete-Soler, Reddy et al. 2005, Lu, Ammar et al. 2007). Additionally, ALDO has 
been reported to act as a scaffolding protein, mediating the association of F-actin 
with GLUT4, an insulin-responsive transporter of glucose (Kao, Noda et al. 
1999). Furthermore, the presence of ALDO’s substrates reportedly regulates 
glucose transport via GLUT4 by disrupting the aldolase-actin interaction (Kao, 
Noda et al. 1999). In this current study, the phosphorylation state of ALDO was 
decreased in the oldest age group as compared to the youngest. Considering the 
aforementioned roles of ALDO, it is tempting to speculate that an increase in 
ALDO activity via a decreased phosphorylation state may contribute to salubrious 
longevity in the NMR; yet, the functional effects of ALDO phosphorylation have 
yet to be elucidated. However, as ALDOC was previously reported to have an 
increase in phosphorylation of 4.1-fold in the hippocampus of Alzheimer disease 
(AD) brain (Di Domenico, Sultana et al. 2011) and NMR brains have very high 
levels of both beta amyloid (Edrey, Medina et al. 2013) and phosphorylated tau 
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(Orr, Salinas et al. 2014) (pathological hallmarks of AD), elevated ALDO 
phosphorylation in AD may be pathological and the decrease with age in this 
protein in NMR brains may reflect a potential mechanism used by NMRs in an 
attempt to better cope with these potentially toxic proteins. 
ENO1 is primarily known in glycolysis and gluconeogenesis as the 
enzyme that catalyzes the conversion between 2-phosphoglycerate and 
phosphoenolpyruvate. However, enolase has been reported to have multiple 
regulatory functions, acting as: a neurotrophic factor, a hypoxic stress protein, a 
transcription factor in tumor formation and metastasis, a plasminogen binding 
protein in human diseases, an activator of plasminogen, and others (Butterfield 
and Lange 2009, Sedoris, Thomas et al. 2010, Yamada, Marutsuka et al. 2014). 
Previously, we have shown ENO1 to be oxidatively modified and differentially 
expressed in several age-related neurodegenerative disorders (Castegna, 
Aksenov et al. 2002, Perluigi, Fai Poon et al. 2005, Perluigi, Poon et al. 2005, 
Poon, Frasier et al. 2005). Further, ENO1 was shown to have an increased 
phosphorylation by 2.5-fold in the AD brain (Di Domenico, Sultana et al. 2011). 
Conversely, in the present study, the phosphorylation of ENO1 was shown to be 
decreased by 68% in the oldest NMR age group relative to the youngest age 
group. Therefore, we speculate that decreased phosphorylation of ENO1 may be 
a contributing factor to increased lifespan and healthspan in the NMR. 
Lactate dehydrogenase (LDH) catalyzes the interconversion between 
pyruvate and lactate in an anaerobic environment. There are five different 
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isoforms of LDH, and LDHB activity preferentially favors the oxidation of lactate 
to pyruvate, generating energy (Newington, Harris et al. 2013). Moreover, levels 
of LDH are reportedly increased in senescent human fibroblasts (Zwerschke, 
Mazurek et al. 2003), and high amounts of lactate in brain, as a consequence of 
decreased LDHB, have been suggested to be an aging hallmark (Ross, Oberg et 
al. 2010). Therefore, given that NMRs live in a hypoxic environment in the wild, 
the increase in LDHB levels in the oldest NMR cohort as compared to both the 
intermediate and old cohorts conceivably may be a neuroprotective mechanism 
to increase energy output.  
Malate dehydrogenase (MDH2) is a mitochondrial TCA enzyme that 
catalyzes the conversion of oxaloacetate to malate producing NADH. When 
compared to the youngest NMR, MDH2 levels were significantly increased in the 
oldest age group with a decrease in phosphorylation state. Phosphorylation of 
MDH has been reported to decrease its activity (Minard and McAlister-Henn 
1994), suggesting that aged NMR brains may be effectively regulating the high 
levels of MDH2 through inhibitory phosphorylation and thereby maintain a 
physiologic level of activity. Malate dehydrogenase in the cytosol (MDH1) is a 
metabolic protein of the malate-aspartate shuttle that is necessary in the 
transference of reducing equivalents of NADH into the mitochondria for the use 
by complex I of the electron transport chain (ETC).  MDH1 levels were greater in 
the old age group with a decrease in phosphorylation in the two oldest age 
groups, all as compared to the youngest cohort. An increased level of this key 
enzyme would result in increased mitochondrial ATP synthesis. Consequently, 
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the elevated levels of MDH1 and MDH2, along with their decreased 
phosphorylation states in brains from the oldest group of NMR are consistent 
with an increase in energy metabolism that may contribute to NMR health and 
longevity. Congruous with our results, MDH1 is reportedly decreased in aged 
human fibroblasts (Lee, Dho et al. 2012); and, in MDH1 knockdown cells, sirtuin 
1 deacetylase, a regulator of cellular senescence, is decreased, suggesting 
MDH1 plays a role in the regulation of senescence (Lee, Dho et al. 2012) and 
could contribute to increased lifespan of these rodents.   
Aspartate aminotransferase (AAT) is another enzyme involved in the 
malate-aspartate shuttle involved in the transfer of NADH reducing equivalents 
produced in glycolysis to the ETC in mitochondria (Panteghini 1990) . AAT also 
plays a key role in amino acid metabolism by catalyzing an essential step in the 
biosynthesis of purines, pyrimidines, amino acids, and their derivatives (Wrenger, 
Muller et al. 2012), as well as the reversible transamination of α-ketoglutarate (α-
KG) to glutamate. These steps are essential for the production of DNA and RNA, 
increased synthesis of ATP, and the formation of the major excitatory 
neurotransmitter, glutamate. The precise role of the altered phosphorylation state 
is unclear, but it was increased in the brain of the oldest NMR group relative to 
the youngest age group; and this increase may be consistent with the need for 
elevation of glutamate in extended aging and increased neuroplasticity (Segovia, 
Porras et al. 2001, Mattson 2008). 
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Isocitrate dehydrogenase [NADP+] cytoplasmic (IDH1) catalyzes the 
oxidative decarboxylation of isocitrate that produces α-KG. Further, this reaction 
regenerates NADPH, which contributes to cellular defense against reactive 
oxygen species (Bleeker, Atai et al. 2010). In the brain of NMR, the 
phosphorylation state of IDH1 was significantly decreased in the oldest age 
group, relative to the youngest age group, and a decreased phosphorylation 
state has been shown to increase the activity of the enzyme (LaPorte 1993). This 
is consistent with the notion that decreased phosphorylation of IDH1 contributes 
to the increased lifespan of NMRs. In contrast to the increased IDH1 activity in 
the senescent and disease-resistant NMR brain, the activities of IDHs are 
reported to be markedly decreased in aged cells (Samokhvalov, Ignatov et al. 
2004), resulting in impaired insulin secretion (Reitman and Yan 2010).  
Glucose-6-phosphate 1 dehydrogenase (G6PD) shunts glucose-6-
phosphate from the glycolytic pathway to the pentose phosphate pathway, also 
producing NADPH as well as pentose phosphates for fatty acid and nucleic acid 
synthesis. G6PD levels were higher in the oldest age group as compared to both 
the intermediate and old age groups. Therefore, the upregulation of G6PD may 
promote a reduced cellular state to encourage a neuroprotective environment.  
ATP synthase subunit alpha (ATP5A1) is among the catalytic subunits of 
complex V of the ETC. In the oldest NMR cohort, ATP5A1 (isoform 2) was found 
to have decreased inhibitory phosphorylation relative to both the young and 
intermediate age groups. Phosphorylation of ATP5A1 has been reported to 
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decrease activity as a consequence of decreased binding affinity to ATP 
(Alzamora, Thali et al. 2010). Therefore, our results are consistent with the notion 
that as NMRs age, ATP production is increased, perhaps as a compensatory 
mechanism. 
Because this study involved both male and female and both breeding and 
non-breeding animals, a potential caveat for these results may be the 
contribution of breeding status, which could possibly introduce sample variation 
due to hormonal differences (Margulis, Saltzman et al. 1995). Future studies, 
with many more animals, will be necessary to estimate the contribution of 
breeding status to the results obtained. Further, it is tempting to speculate that 
the significant differences found between the youngest cohort and the other ages 
may represent an immature brain in its final steps of development. Studies 
dedicated to understanding and characterizing NMR brain development are 
needed to clarify this potential caveat common among this and many prior NMR 
studies. 
In summary, this current study has identified significant alterations in 
protein levels and phosphorylation states of key metabolic proteins. The 
metabolic pathways in which these proteins are involved are illustrated in Figure 
6.1.5. 
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Figure 6.1.5 Metabolism-associated pathways with differential protein 
levels and/or phosphorylation levels with age in NMR brain. Summary 
schematic diagram of expression proteomics and phosphoproteomics profiles of 
metabolic protein changes in the brain of the NMR as a function of age. Proteins 
with altered levels and/or phosphorylation states are highlighted in red. 
 
Many of these proteins are pleiotropic, having many other interesting 
functions that may contribute to the exceptional longevity and disease resistance 
of the NMR. The results obtained using proteomics and phosphoproteomics have 
revealed important potential mechanisms for increased lifespan and increased 
healthspan of NMRs. Improved understanding of potential mechanisms that 
138 
 
facilitate an extended lifespan and an extended healthspan in the NMR 
conceivably may lead in humans to insights into the prevention of age-related 
diseases and may lead to therapies that aid in the delay of the onset and 
progression of the aging process. 
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CHAPTER 6.2 
AGE-RELATED CHANGES IN THE PROTEOSTASIS NETWORK IN THE 
BRAIN OF THE NAKED MOLE-RAT: IMPLICATIONS PROMOTING HEALTHY 
LONGEVITY 
6.2.1 Overview 
The naked mole-rat (NMR) is a remarkably long-lived rodent that 
possesses several exceptional traits: marked cancer resistance, negligible 
senescence, prolonged genomic integrity, pronounced proteostasis, and 
sustained healthspans. The underlying molecular mechanisms that contribute to 
these extraordinary attributes are currently under investigation to gain insights 
that conceivably may promote and extended human lifespan and healthspan. 
The ubiquitin-proteasome and autophagy-lysosomal systems play a vital role in 
eliminating cellular detritus to maintain proteostasis and have been previously 
shown to be more robust in NMRs when compared to shorter-lived rodents. 
Using a 2-D PAGE proteomics approach, differential expression and 
phosphorylation levels of proteins involved in proteostasis networks were 
evaluated in the brains of NMRs in an age-dependent manner. We identified 9 
proteins with significantly altered levels and/or phosphorylation states that have 
key roles involved in proteostasis networks. To further investigate the possible 
role that autophagy may play in maintaining cellular proteostasis, we examined 
aspects of the PI3K/Akt/mammalian target of rapamycin (mTOR) axis as well as 
levels of Beclin-1, LC3-I, and LC3-II in the brain of the NMR as a function of age. 
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Together, these results show that NMRs maintain high levels of autophagy 
throughout the majority of their lifespan. 
6.2.2 Introduction 
The bathyergid rodent, Heterocephalus glaber, more commonly known as 
the naked mole-rat (NMR) or sand puppy, is a strictly subterranean rodent 
indigenous to North East Africa. These rodents are arguably best known because 
of their unusually long, healthy life spans (15-30 years) when compared to that of 
the traditional rodent models such as mice and rats (1-3 years) (Buffenstein 
2005, Buffenstein 2008, Edrey, Hanes et al. 2011, Ables, Brown-Borg et al. 
2014). This prolonged healthspan has led to research involving many cellular 
systems thought to contribute to the aging process including: oxidative stress or 
damage of biomolecules such as proteins and nucleotides, mitochondrial 
dysfunction, and the autophagy/proteostasis network (Andziak, O'Connor et al. 
2006, Lambert, Boysen et al. 2007, Lewis, Andziak et al. 2013, Edrey, Oddo et 
al. 2014, Zhao, Lin et al. 2014). The ability of the NMR to withstand the chronic 
insult of protein unfolding stressors has been attributed to the efficiency with 
which the rodent maintains the integrity of its proteome by way of a high 
functioning ubiquitin-proteasome system (UPS) and cellular autophagy (Perez, 
Buffenstein et al. 2009, Rodriguez, Wywial et al. 2011, Grimes, Chiao et al. 2012, 
Rodriguez, Edrey et al. 2012, Pride, Yu et al. 2015). 
The UPS functions to maintain cellular proteostasis by degrading 
unwanted, misfolded or damaged proteins that could otherwise aggregate into 
potentially cytotoxic moieties, and UPS dysfunction has been implicated in 
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multiple neurodegenerative disorders (Leroy, Boyer et al. 1998, Fernandez-
Funez, Nino-Rosales et al. 2000, Castegna, Thongboonkerd et al. 2004, Bennett, 
Shaler et al. 2007, Triplett, Zhang et al. 2015). The proteasome cleaves 
damaged proteins into smaller peptide fragments by the proteolytic center that 
contains trypsin-like (T-L), post-glutamyl peptide-hydrolyzing (PGPH), and 
chymotrypsin-like (ChT-L) specificities (Hanna and Finley 2007, Rodriguez, 
Osmulski et al. 2014). Liver and brain samples from NMRs when compared to 
mouse controls, have shown increased ChT-L and T-L activities, suggesting a 
more efficient UPS that may contribute to their inherent resistance to aging and 
age-related diseases (Rodriguez, Edrey et al. 2012, Edrey, Oddo et al. 2014). 
Moreover, human, mouse, and yeast proteasomes were demonstrated to have 
an increased activity when exposed to proteasome depleted cytosolic fractions 
containing a novel HSP-containing complex from NMR samples (Rodriguez, 
Osmulski et al. 2014). 
The autophagy-lysosomal pathway (ALP) is an evolutionarily conserved 
catabolic process by which the cell removes and recycles complexes, protein 
aggregates and damaged organelles (Mizushima 2007). Often seen as a 
mechanism to address starvation to reduce energy output, autophagy provides 
the cell many important functions such as cellular differentiation, growth control, 
defense from xenobiotics, and general housekeeping and maintenance (Cecconi 
and Levine 2008).  Thus, autophagy is generally thought of as a survival 
mechanism. ALP involves a number of proteins such as Beclin-1 and LC3 that 
are crucial in the initiation and recruitment of the autophagosome, which once 
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formed, engulfs the target prior to fusing with the lysosome for recycling (Klionsky 
2005). Further, the PI3K/Akt/mTOR axis plays a central role in cellular 
proteostasis as mTOR activation inhibits autophagy, and mTOR is a direct target 
of the kinase Akt, which is regulated by PI3K. Dysregulation of these pathways 
has been linked to neurodegenerative diseases (Aguado, Sarkar et al. 2010, 
Glick, Barth et al. 2010, Martinez-Vicente, Talloczy et al. 2010, Winslow, Chen et 
al. 2010, Nixon and Yang 2011, Nixon 2013, Tramutola, Triplett et al. 2015).  
A failing proteostasis network in the brain in particular increases 
vulnerability to dysfunctions in UPS and ALP due to the unique shape of neurons 
and their non-mitotic nature (Grimm, Hoehn et al. 2011). Further, these protein 
degradation mechanisms are essential in neuron function including 
neurotransmission and synaptic remodeling (Willeumier, Pulst et al. 2006, Yi and 
Ehlers 2007). Dysregulation of these proteostasis maintenance systems can lead 
to neurodegeneration, diminished quality of life and reduced lifespans (Tanaka 
and Matsuda 2014). 
In the current age-related study of the NMR proteome and 
phosphoproteome, a large number of significantly altered brain proteins were 
identified, whose functions were related to metabolism, proteostasis networks, 
cellular signaling, structure, and neuronal plasticity. Too many proteins were 
identified to be efficiently discussed and expounded upon in a single manuscript; 
consequently, we facilitated discussion of the results by means of protein 
functionality. Here, we report on significant changes in proteins related to 
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proteostasis and autophagy systems in the NMR brain and their impact upon the 
unusually long and salubrious lifespan of the NMR. 
6.2.3 Materials and Methods 
6.2.3.1 Materials 
Criterion precast polyacrylamide gels, TGS and MOPS electrophoresis 
running buffers, ReadyStrip IPG strips, mineral oil, Precision Plus Protein All Blue 
Standards, Sypro Ruby protein stain, biolytes, urea, dithiothreitol (DTT), 
iodoacetamide (IA), and nitrocellulose membranes were purchased from Bio-Rad 
(Hercules, CA, USA). Pro-Q Diamond phosphoprotein stain, and anti-
phosphotyrosine, anti-phosphoserine, and anti-phosphothreonine antibodies 
were procured from Invitrogen (Grand Island, NY, USA). Protein A/G beads 
Amersham ECL IgG horseradish peroxidase-linked secondary antibodies, and 
ECL Plus Western blotting detection reagents were purchased from GE 
Healthcare (Pittsburgh, PA, USA). C18 ZipTips and Re-Blot Plus Strong stripping 
solution were obtained from Millipore (Billerica, MA, USA). Modified trypsin 
solution was purchased from Promega (Madison, WI, USA). Pierce BCA protein 
assay reagents A and B were purchased from Thermo Scientific (Waltham, MA, 
USA).  Anti-p-PI3K (Tyr508) and anti-BAP1 (Ub carboxyl-terminal hydrolase) 
antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).  
Anti-Beclin-1, anti-p-mTOR (Ser2448), anti-mTOR, anti-AKT, and anti-p-AKT 
(Ser473) antibodies were obtained from Cell Signaling Technology (Danvers, MA, 
USA). Anti-LC3-I and anti-LC3-II antibodies were purchased from Novus 
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(Littleton, CO, USA). Anti-VDAC2 antibody was purchased from Abcam 
(Cambridge, MA, USA). All other chemicals used in this study were purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 
6.2.3.2 Animals 
Brains from NMRs were obtained from well-characterized colonies 
(Buffenstein 2005) maintained by Dr. Rochelle Buffenstein at the University of 
Texas Health Science Center, San Antonio. The NMRs were housed in 
fabricated burrow systems under climate conditions that mimicked their natural 
habitat (30˚C and 30-50% relative humidity). The NMRs were fed ad libitum a 
diet that consisted of fresh fruits and vegetables, which was supplemented with a 
high protein and vitamin enriched feed (Pronutro, South Africa). NMRs were 
anesthetized with isofluorane, euthanized by cardiac exsanguination and the 
brains were immediately harvested and flash frozen in liquid nitrogen. All animal 
procedures were approved by the Institutional Animal Care and Use Committee 
at the University of Texas Health Science Center at San Antonio, TX. 
Experimental animal groups consisted of 5-9 individual brains from both male 
and female individuals and of both subordinate and breeding status. NMRs were 
divided into four age groups for analysis: 2-3 year-olds (age group 1; young), 4-6 
year-olds (age group 2; intermediate), 7-12 year-olds (age group 3; old) and 15-
24 year-olds (age group 4; oldest). 
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6.2.3.3 Sample preparation 
Naked mole-rat brain homogenates were prepared using a Wheaton glass 
homogenizer (~40 passes) and diluted with  ice-cold isolation buffer [0.32 M 
sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5 µg/mL 
aprotinin, 4 µg/mL leupeptin, 4 µg/mL pepstatin, and 10 µg/mL phosphatase 
inhibitor cocktail 2]. Homogenate protein concentrations were ascertained by the 
Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al. 1985). 
6.2.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
Isoelectric focusing (IEF). 2-D PAGE experiments were performed as 
previously described (Sultana, Boyd-Kimball et al. 2007). In brief, 200 µg of each 
homogenate, suspended in 200 µL of  rehydration buffer [8 M urea, 2 M thiourea, 
50 mM DTT, 2.0% (w/v) CHAPS,  0.2% Biolytes, 0.01% bromophenol Blue], were 
sonicated and applied to 11 cm pH 3-10 ReadyStrip IPG strips. The strips were 
actively rehydrated and isoelectricly focused. At the end of the run, IPG strips 
were immediately stored at -80 °C. 
SDS PAGE. IEF strips were thawed and equilibrated in DTT and IA-
containing buffers.  IEF strips were rinsed in TGS running buffer before 
placement into 11 cm Criterion precast linear gradient polyacrylamide gels (8–
16% Tris–HCl). Precision Plus Protein All Blue molecular standards and samples 
were run at a constant voltage of 200 V for approximately 65 min at 22˚C in 
Tris/Glycine/SDS running buffer. 
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6.2.3.5 Sypro Ruby and Pro-Q Diamond staining 
After 2D-PAGE, gel staining was carried out according to manufacturer’s 
directions and as described previously (Di Domenico, Sultana et al. 2011). 
Briefly, gels were incubated in 50 mL of fixing solution [10% (v/v) acetic acid, 
50% (v/v) methanol], washed in deionized (DI) water, and stained with 60 mL of 
Pro-Q Diamond for 90 min. Gels were then destained four times in 100 mL of 
solution [20% acetonitrile (ACN), 50 mM sodium acetate, pH 4] for 30 min each. 
The gels were washed three times in DI water (30 min each) and then scanned 
at 580 nm using a Bio-Rad ChemiDoc XRS+ imaging system (Bio-Rad, Hercules, 
CA, USA). Next, 50 mL of Sypro Ruby protein gel stain was added and allowed 
to incubate overnight (15 h). Gels were then rinsed in DI water, scanned at 450 
nm with the ChemiDoc imager, and stored in DI water at 4 °C until protein spot 
extraction. 
6.2.3.6 Image Analysis 
Expression Proteomics. Spot intensities from SYPRO Ruby-stained 2D-
gel images of NMR brain samples were quantified according to the total spot 
density using PDQuest 2-D Analysis Software (Bio-Rd, Hercules, CA, USA). 
Intensities of individual spots were normalized to the total gel densities. 
Normalized spot densities of the four age groups (2-3 year-olds, 4-6 year-olds, 7-
12 year-olds, and 15-24 year-olds) were compared. Only spots with statistically 
significant differences (p<0.05) were considered for in-gel trypsin digestion and 
protein identification by MS/MS. 
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Phosphoproteomics. Protein spots from Pro-Q Diamond-stained 2D-gel 
images of the NMR brain samples were quantified and matched as described 
previously (Di Domenico, Sultana et al. 2011). Next, a high match analysis 
between the master gels from the Sypro Ruby matching and Pro-Q Diamond 
matching was conducted. The phosphoprotein spot densities were normalized to 
the Sypro Ruby spot densities and the resultant normalized spot densities in four 
age groups were compared and spots that were statistically significant (p<0.05) 
were considered for in-gel trypsin digestion and protein identification by MS/MS. 
6.2.3.7 In-gel trypsin digestion/peptide extraction 
Protein spots identifies as significantly altered from the earliest age group 
were excised from 2D-gels and transferred to individual Eppendorf 
microcentrifuge tubes for trypsin digestion as described previously 
(Thongboonkerd, McLeish et al. 2002). In brief, DTT and IA was used to break 
and cap disulfide bonds and the gel plug was incubated overnight at 37°C with 
shaking in modified trypsin solution. Salts and contaminants were removed from 
the tryptic peptide solutions using C18 ZipTips. Tryptic peptide solutions were 
reconstituted in 10 µL of a 5% ACN/0.1% formic acid (FA) solution and stored at -
80˚C until MS/MS analysis. 
6.2.3.8 NanoLC-MS with Data Dependent Scan 
Tryptic peptide solutions were analyzed by a nanoAcquity (Waters, 
Milford, MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) platform with a 
data dependent scan mode. An in-house packed capillary column (0.1 x 130 mm 
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column packed with 3.6 µm, 200Å XB-C18) was used for separation with a 
gradient using 0.1% FA and ACN/0.1% FA at 200 nL/min. The spectra obtained 
by MS were measured by the orbitrap at 30,000 resolution; and the MS/MS 
spectra of the six most intense parent ions in the MS scan were acquired by the 
orbitrap at 7,500 resolution. The latest version of the Swiss-Prot database by 
SEQUEST (Proteome Discoverer v1.4, Thermo Scientific) was used to 
interrogate the data files of each sample. At least two high-confidence peptide 
matches were used for protein identification where the false discovery rate <1%. 
Proteins that were matched with the same peptides were reported as one protein 
group. Protein data reported from these analyses includes: the SwissProt 
accession number, the percentage of the protein sequence identified by 
matching peptides, the number of peptide sequences detected by the MS/MS 
analysis, the confidence score of the protein, the expected molecular weight and 
predicted isoelectric point (pI). 
6.2.3.9 Immunoprecipitation and Western blotting 
Immunoprecipitation (IP). Individual NMR brain homogenates (250 µg) 
were suspended in 500 µL of IP buffer [0.05% NP-40, aproprotin 5 µg/mL, 
leupeptin 4 µg/mL, pepstatin 4 µg/mL, and phosphatase inhibitor cocktail 10 
µg/mL] in a phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M 
Na2HPO4, and 0.24 M KH2PO4]. Samples were precleared by incubation with 
Protein A/G agarose beads for 1.5 h at 4˚C. Next, each sample was incubated 
overnight with anti-VDAC 2 antibody (1:50 dilution) at 4˚C. Samples were then 
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incubated with Protein A/G agarose beads for 1.5 h at 4˚C and washed 5 times 
with IP buffer, preserving the beads for a 1D-PAGE experiment. 
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Sample 
homogenates (50 µg) or beads from VDAC2 immunoprecipitation experiment 
were suspended in 4X sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 
8% SDS, 20% β-mercaptoethanol, 0.01% Bromophenol Blue] (diluted to 1X with 
DI water) and then heated at 95°C for 5 min. Samples were cooled on ice and 
then loaded into Criterion precast 18 well polyacrylamide gels (4-12% Bis-Tris) or 
Criterion 12% TGX stain-free polyacrylamide 18 well gels. Using XT MOPS or 
TGS running buffer, gels were run at 80 V for 15 min and then at 120 V for 
approximately 100 min. Stain-free gels were scanned using a Bio-Rad ChemiDoc 
XRS+ imaging system to measure the total protein load before protein transfer to 
Western blots. 
1D-Western blotting. In-gel proteins were transferred to a nitrocellulose 
membrane (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad, 
Hercules, CA, USA) at 25 V for 30 min. After the transfer, membranes were 
incubated in blocking solution (3% bovine serum albumin (BSA) in TBS-T [8 M 
NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h. The membrane was then 
incubated with primary antibodies: VDAC2 and UCH (1:3000 dilution), tubulin 
(1:5000), and phosphoserine, phosphothreonine and phosphotyrosine antibodies 
(1:6000) and mTOR, p-mTOR (Ser2448), Akt, p-AKT (Ser473), p-PI3K (Tyr508) 
(1:1000 dilution), which were added to the blocking solution with gentle rocking 
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for 2 h. The blots were washed three times with TBS-T (5 min each) and 
incubated with a horseradish peroxidase secondary antibody in TBS-T (1:5000) 
with gentle rocking. The membranes were then washed three more times in TBS-
T (10 min each). Using Clarity Western ECL substrate, membranes were 
chemiluminescently developed in the dark for 5 min, scanned using the 
ChemiDoc XRS+ imaging system, and quantified using Image Lab software (Bio-
Rad, Hercules, CA, USA). Blots were stripped up to two times with Re-Blot Plus 
Strong solution (15 min each) followed by three rinses with TBS-T (5 min each). 
Proteins were normalized either to total protein load, tubulin, or the protein itself 
in cases of phosphorylation measurements. 
6.2.3.10 Statistical analysis 
A conservative analysis was carried out on PDQuest data using both a 
two-tailed Student’s t-test and a Mann-Whitney U statistical test, independently 
comparing each age group to the youngest age cohort. Protein spots were 
considered statistically significant if p<0.05 in both tests. To further determine 
significant differences (p<0.05) between all of the various age groups, a one-way 
ANOVA with post hoc Bonferroni t-test was used. Protein spot fold-change 
values were calculated by dividing the average, normalized spot intensities of the 
gels of older age group by the average, normalized spot intensities of the gels of 
the younger age group in the comparison. For Western blot data, a one-way 
ANOVA with either a post hoc Bonferroni or Dunnett’s multiple comparisons test 
was used. All data are presented as mean+SEM. To ensure a rigorously 
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conservative approach, spots were extracted for MS/MS analysis only if the fold 
change was 40% or greater or smaller in normalized spot density. Identifications 
of proteins acquired with the SEQUEST search algorithm were considered to be 
statistically significant if p<0.01. At least two peptide sequences were used to 
identify each protein. To ensure correct identification of the proteins, a visual 
comparison was made between the expected molecular weight and isoelectric 
point of the identified protein to the spot of the extracted 2-D gel plug.  
6.2.4 Results 
6.2.4.1 Age-related changes in proteins of the proteostasis network   
Figure 6.2.1 Proteins associated with the proteostasis network with altered 
expression with age in the NMR brain. Representative Sypro Ruby-stained 2-
D gel images of isolated proteins from the brains of NMRs, aged 2-3 years (A), 4-
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6 years (B), 7-12 years (C), and 15-24 years (D). Proteins whose expression 
and/or phosphorylation state was significantly altered (p<0.05) in the particular 
age group are labeled in the images. 
 
 
Figure 6.2.2 Proteins associated with the proteostasis network with altered 
phosphorylation levels with age in the NMR brain. Representative Pro-Q 
Diamond-stained 2-D gel images of isolated proteins from the brains of NMRs, 
aged 2-3 years (A), 4-6 years (B), 7-12 years (C), and 15-24 years (D). Proteins 
with significantly altered phosphorylation levels (p<0.05) in the particular age 
group are labeled in the images. 
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Proteostasis network-related proteins with statistically significant changes 
with age in protein levels and phosphorylation states are labeled in the 2-D gel 
images of Figures 6.2.1 & 6.2.2, respectively. PDQuest analyses of all 2-D gels 
found 9 proteostasis network-related proteins with significant changes in the 
NMR brain as a function of age (Table 6.2.1).  
Table 6.2.1 Proteins associated with the proteostasis network with 
significantly altered levels and/or phosphorylation states with age in the 
NMR brain. PDQuest and MS/MS results of NMR brain proteins involved in 
proteostasis networks with significant altered expression and/or phosphorylation 
states as a function of age. 
  
 
Many of these proteins are associated with the UPS. Significant elevation 
of heat shock protein (HSP) response with age was noted by the increased levels 
of HSP70 protein 4 (Figure 6.2.3A) and the decreased phosphorylation levels of 
HSP60 (Figure 6.2.3B).  
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Figure 6.2.3 HSP70, HSP60 and VDACs with age in the NMR brain. Trends in 
median protein levels and/or phosphorylation levels in NMR brain with age for (A) 
HSP70 protein 4, (B) HSP60, and (C) VDACs 1-3 (n=5-9 individual brains per 
age group comparison).  
While the primary function of HSP is to maintain a protein’s native 3-D 
conformation, if a protein is terminally misfolded, some HSPs also function to 
chaperone the protein for UPS degradation.  
The UPS, illustrated in Figure 6.2.4, depicts proteins that have significantly 
altered expression and/or phosphorylation levels with increasing age in the brain 
of the NMR. Two of these proteins are involved in protein ubiquitinylation: ub-like 
modifier-activating enzyme 1 (UBE1) and ub-conjugating enzyme E2 variant 2 
(UBE2v2). Both exhibit altered phosphorylation levels in the older age cohorts. 
Further supporting the notion of increased UPS activity in the NMR with age is 
the increased expression of ub-carboxy-terminal hydrolase (UCH), the protein 
responsible for the removal of poly Ub chain, one Ub at a time from the C-
terminal end, before entry into the proteasome. 
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Figure 6.2.4 Proteins associated with the Ubiquitin-Proteasome System 
with altered protein levels and/or phosphorylation levels in brain of NMR 
with age. Summary schematic diagram of expression proteomics and 
phosphoproteomics profiles of changes in proteins related to the ubiquitin-
proteasomal system in the brain of the NMR as a function of age. Proteins with 
significantly altered protein and/or phosphorylation levels are indicated.  
 
Interestingly, a component of the central proteasome itself, proteasome 
subunit beta type 1 (PSβ1), showed decreased phosphorylation levels in the 
intermediate and oldest age cohorts (Table 6.2.1). 
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Autophagy-related proteins with altered levels and/or phosphorylation 
states in one or more age cohorts includes all thee isoforms of the voltage-
dependent anion channel (VDAC): VDAC1, VDAC2, and VDAC3. VDACs are the 
major outer mitochondrial membrane porins and regulators of energy metabolism 
and mitophagy. Levels of both VDAC2 and VDAC3 were significantly increased 
in the old age group as compared to control (Table 6.2.1), while phosphorylation 
levels decreased with age for all VDACs (Figure 6.2.3C). 
6.2.4.2 Immunoprecipitation and Western blotting validations 
Immunoprecipitation and Western blot experiments were conducted on 
selected proteins to confirm MS/MS results. Western blot analysis of UCH 
(Figure 6.2.5A) confirmed a significant increase in the level of UCH in the brains 
of the oldest age group (p=0.049). Interestingly, the Western blot also showed a 
significant increase in UCH levels for the intermediate (p=0.011) and old age 
groups (p=0.013) when compared to the youngest age group.  
The results of the Western blot analyses of the expression of VDAC2 
(Figure 6.2.5B) verified a significant increase in the old age group (p=0.005), 
while also showing increased levels of VDAC2 in the oldest age group (p=0.025) 
both as compared to the youngest age group.  Analyses of the 
immunoprecipitation of VDAC2 with anti-phosphoserine, anti-phosphothreonine 
and anti-phosphotyrosine antibodies confirmed a significant decrease in the 
phosphorylation of VDAC2 in the brain of the NMR for the intermediate age 
157 
 
group (p=0.04), the old age group (p=0.01), and in the oldest age group 
(p=0.048) as compared to the youngest age group (Figure 6.2.5C). 
 
 
Figure 6.2.5 UCH and VDAC2 in brain of NMR with age. Western blot and 
corresponding bar graph representations from the validation experiments of the 
changes in the protein levels of (A) Ub carboxy-terminal hydrolase (UCH), (B) 
voltage-dependent anion channel 2 (VDAC2), and (C) the immunochemistry 
experiment validation of the significant decrease (*p<0.05) in the phosphorylation 
of VDAC2 in the brains of NMRs (n=4-6 for each age group). Immunoreactivity 
with specific antibodies was detected by chemiluminescence. 
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6.2.4.3 PI3K/Akt/mTOR axis in NMR brain with age 
Figure 6.2.6 The PI3K/Akt/mTor axis and autophagy. Diagram summarizing 
the PI3K/Akt/mTOR axis signaling pathway leading to the nucleation and 
formation of the phagophore to initiate the autophagy-lysosomal pathway. 
To further investigate the role that autophagy (illustrated in Figure 6.2.6) 
may play in the brain of the NMR with age, the PI3K/Akt/mTOR axis was 
examined. Western blots were probed for p-PI3K (Tyr508), Akt, p-Akt (Ser473), 
mTOR, and p-mTOR (Ser2448) (Figure 6.2.7). Analyses revealed that the p-PI3K 
protein level was found to be significantly increased from the early to 
intermediate age group (p=0.0001) and then significantly decreased from the 
intermediate to the old age group (p=0.0007). Additionally, there was a significant 
decrease from the intermediate to the oldest age group (p<0.0001).  
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Figure 6.2.7 PI3K/Akt/mTOR axis in NMR brain with age. Western blots and 
corresponding bar graph representations from the evaluation of the 
PI3K/Akt/mTOR axis in the brain of the NMR (n=5-8 for each age group, *p<0.05, 
**p<0.001, ***p<0.0001). Proteins were normalized to the total load of the gel. 
Immunoreactivity with specific antibodies was detected by chemiluminescence. 
 
The p-Akt/Akt ratio was decreased from the intermediate age group to the 
old age group (p=0.031). Similar to the other proteins in the PI3K/Akt/mTOR axis, 
the p-Akt/Akt ratio increases from the youngest to the intermediate age group 
(data trended toward significance). There were no significant changes in the 
protein levels of mTOR; however the p-mTOR/mTOR ratio follows a 
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corresponding trend to that of p-PI3K, in which there is a significant increase 
from the early to intermediate age group (p=0.013) and a significant decrease 
from the intermediate age grouop to the old and oldest age groups (p=0.0009) 
and (p=0.0013), respectively. 
 
Figure 6.2.8 Beclin-1 and LC3 in NMR brain with age. Western blots and 
corresponding bar graph representations of Beclin1 and the LC3-II/LC3-I ratio in 
the brain of the NMR (n=6-8 for each age group, ***p<0.0001). Proteins were 
normalized to the total load of the gel. Immunoreactivity with specific antibodies 
was detected by chemiluminescence. 
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We further analyzed the quantitative index of autophagy, the LC3-II/LC3-I 
ratio in all age groups. The LC3 ratio showed no significant changes with age 
(Figure 6.2.8). Additionally, we analyzed levels of the autophagy initiator protein, 
Beclin-1, which showed a significant decrease in the oldest age group (p<0.0001) 
(Figure 6.2.8). 
6.2.5 Discussion 
 Not only are NMRs the longest-lived rodent, but they also maintain an 
extended healthspan. This extraordinary salubrious lifespan has been attributed 
to, in part, by mechanisms that contribute to maintaining proteostasis (Zhao, Lin 
et al. 2014). Processes that promote sustained cellular homeostasis, such as 
unfolded protein response and proteasome and autophagy pathways, remove 
damaged or unwanted proteins, macromolecules and organelles which can be 
cytotoxic and lead to neuronal death (Di Domenico, Head et al. 2014). 
Additionally, these proteostasis systems play a critical role in maintaining health 
by modulating protein levels in response to fluctuating physiological 
environments (Di Domenico, Head et al. 2014). Previous studies have shown 
that NMRs exhibit a more robust proteostasis as compared to shorter-lived 
rodents (Perez, Buffenstein et al. 2009, Rodriguez, Wywial et al. 2011, Grimes, 
Chiao et al. 2012, Rodriguez, Edrey et al. 2012, Zhao, Lin et al. 2014, Pride, Yu 
et al. 2015). In this current study, we evaluated age-related changes in the NMR 
proteome and phosphoproteome involved in proteostasis networks. These 
findings suggest that the NMR is able to maintain this health-sustaining, robust 
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proteostasis throughout the majority of their lifespan. Here, we discuss the 
implications of proteins with significant differential levels and phosphorylation 
states from the respective proteomics analyses (Table 6.2.1) as well as selected 
autophagy-related proteins evaluated via Western blot analyses. 
Typically, susceptibility to age-related diseases correlates to a declining 
capacity to generate a stress response (Gutsmann-Conrad, Heydari et al. 1998, 
Njemini, Abeele et al. 2002). Consistent with this notion, in the brain of the NMR, 
levels of HSP70 (protein 4) were increased and phosphorylation of HSP60 
decreased with age. HSP70 is a highly conserved pleiotropic protein that 
executes many cellular functions including: folding of newly synthesized proteins, 
prevention of protein aggregation, aiding in endocytosis, signal transduction, 
protein targeting, and relaying proteins to the ubiquitin-proteasome system and 
autophagy-lysosomal pathways (reviewed in (Meimaridou, Gooljar et al. 2009)). 
Moreover, HSP70 mediates proteasome assembly during stress (Grune, Catalgol 
et al. 2011), and together with its co-chaperone, HSP40, HSP70 is involved in 
mitigation of proteotoxic insults to the proteasome (Rodriguez, Osmulski et al. 
2014). Further, overexpression of HSP70 has been shown to impede apoptotic 
mechanisms (Mayer and Bukau 2005, Arya, Mallik et al. 2007) and to curtail 
neurodegeneration and senescence (Bonini 2002, Klucken, Shin et al. 2004). 
Previously, HSP70 levels in NMRs have been shown to be higher in liver lysates 
compared to those in mice (Rodriguez, Osmulski et al. 2014), consistent with the 
idea that the increased levels of this important chaperone with age in the brain 
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observed in the current study may suggest a more robust and global proteostasis 
in these long-lived animals. 
HSP60 primarily functions in the mitochondria to properly fold proteins. In 
addition, HSP60 has been reported to have anti-apoptotic properties as it can 
bind and inhibit pro-apoptotic proteins, Bax and Bak, to prevent 
neurodegeneration (Arya, Mallik et al. 2007, Chandra, Choy et al. 2007). 
Dephosphorylation of HSP60 has been reported to enhance chaperone functions 
(Khan, Wallin et al. 1998). Therefore, the data from our current study suggest 
that HSP60 may contribute to proper mitochondrial function in older NMR brains 
by preventing protein aggregation and by suppressing apoptotic mechanisms to 
impede neuronal loss. 
Ubiquitinylation directs proteins to specific cellular targets, such as 
proteasomes or DNA, as well as regulating protein interactions and activity 
(David, Ziv et al. 2010). Protein ubiquitylation requires the activation and transfer 
of Ub to a protein in a three-step process. Two proteins involved in this 
ubiquitinylation process, UBE1 and UBE2v2, were found to have altered levels 
and/or phosphorylation states in the brains of NMR in different age groups. In the 
old age group, protein phosphorylation levels of UBE1 were found to be 
increased compared to the youngest age group. UBE1 not only catalyzes the first 
step in the Ub-proteasomal pathway, but it is also essential for the protein 
ubiquitinylation that modulates DNA double-strand break repair, suggesting an 
important role in policing genomic integrity and preventing disease pathogenesis 
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(Moudry, Lukas et al. 2012). Posttranslational modifications to UBE1 isoforms 
are still poorly understood (Schulman and Harper 2009). Known putative roles of 
UBE1 phosphorylation include targeting this protein to different subcellular 
locations and modulation of nucleotide excision repair (Stephen, Trausch-Azar et 
al. 1996, Nouspikel and Hanawalt 2006). However, with multiple UBE1 isoforms 
containing multiple phosphorylation sights in various domains of the protein, the 
implications of increased phosphorylation of UBE1 in this current study are as of 
yet, uncertain. However, as this critical enzyme is reported to be the apex of 
downstream signaling (Schulman and Harper 2009), we opine that UBE1 may be 
involved in maintaining a healthy genome and conceivably may be related to the 
dearth of cancer in this long-lived rodent. 
 Ubiquitinylation is a dynamic process and protein eventual protein 
destination depends on the lysine to which it is attached and whether it is 
monoubiquitinylated, homo-polyubiquitinylated, or hetero-polyubiquitinylated 
(Johnson, Ma et al. 1995, Shang, Deng et al. 2005). The UBE2v2 preferentially 
ubiquitinylates Lys63, which is reported to participate in chaperoning proteins for 
DNA repair, lysosomal degradation of epidermal growth factor receptors, and NF-
κB activation by degradation of class I major histocompatibility complex 
molecules (Hofmann and Pickart 1999, Duncan, Piper et al. 2006, Huang, 
Kirkpatrick et al. 2006, Wu, Conze et al. 2006). Here, protein levels of UBE2v2 
were increased in the intermediate age group, while phosphorylation levels were 
decreased in the intermediate and oldest age groups. The intricacies of UBE2 
structure and function are complex; and as such, the implications of altered 
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phosphorylation states have yet to be elucidated, though we speculate that this 
protein may be involved in promoting the ability for NMR to maintain a healthy 
genome. 
UCHs are a family of proteins responsible for the removal of the poly-Ub 
tags. Dysregulation of UCH may result in the accumulation of poly-Ub proteins; 
and this accumulation is reported in many chronic neurodegenerative diseases, 
as they are present in the senile plaques and neurofibrillary tangles in Alzheimer 
disease (AD) and in the Lewy bodies of Parkinson disease (Schwartz and 
Ciechanover 1999). Further, in AD, it is hypothesized that the UPS-mediated 
degradation of amyloid-beta (Aβ) is impaired, which leads to ubiquitinylated Aβ  
aggregating into neurotoxic plaques (Hong, Huang et al. 2014). Previously, we 
have shown that a particular UCH variant, UCHL1, is oxidized in AD brain, which 
could conceivably inhibit Aβ degradation (Castegna, Aksenov et al. 2002, 
Sultana, Boyd-Kimball et al. 2006). However, it has been reported that even 
though NMRs exhibit Aβ levels similar to that of  3xTg-AD mice, there is no 
accumulation of senile plaques in the NMR brain (Edrey, Medina et al. 2013, 
Edrey, Oddo et al. 2014). Moreover, in mice ubiquitinylated proteins accumulate 
with age; however, in NMRs levels of ubiquitinylated proteins of 2 year-old and 
26 year-old rodents were similar (Perez, Buffenstein et al. 2009). Therefore, the 
increase of UCH levels in the brain of the oldest age group may function to 
maintain prolonged cellular proteostasis via availability to mediate disposal of 
increasing levels of neurotoxic proteins, such as Aβ. 
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When attached to the 26S proteasome and after the removal of Ub by 
UCH, the protein is degraded by threonine proteases in the core of the 26S 
proteasome (Voges, Zwickl et al. 1999). In this current study, PSB1, which is 
responsible for PGPH activity, was found to have decreased levels of 
phosphorylation in the intermediate and oldest age groups as compared to the 
youngest age group. Decreases in proteasomal function and/or expression have 
been reported in multiple neurodegenerative diseases including: AD, PD, 
Huntington disease, amyotrophic lateral sclerosis, and prion diseases (Keller, 
Hanni et al. 2000, Ciechanover and Brundin 2003, Bukhatwa, Zeng et al. 2010, 
Ebrahimi-Fakhari, Wahlster et al. 2012, Martins-Branco, Esteves et al. 2012). 
Moreover, PSB1, the variant identified in this current study, has been reported to 
promote anti-apoptotic activity of plasminogen activator inhibitor 2 (PAI2) (Fan, 
Zhang et al. 2004). While the consequences of the phosphorylation of this 
subunit are unclear, it has been shown that phosphorylation of β-subunits in the 
prokaryote M. tuberculosis can inhibit proteasomal assembly (Anandan, Han et 
al. 2014). While there are multiple β-subunits in eukaryotes, unlike prokaryotes 
that have only one type, the reduced phosphorylated states in the oldest NMR 
brains could suggest that there is an increased affinity towards proteome 
assembly and therefore, an increased degradation of unwanted or damaged 
proteins, clearing the cell of detritus to promote healthy cellular function. This 
observation would be consistent with the observed high levels of proteasome 
activity reported for brain lysates of the NMR (Edrey, Oddo et al. 2014). 
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Voltage dependent anion channels (VDACs) are outer mitochondrial 
membrane porins that are involved in mitochondrial metabolic processes by 
opening at low membrane potentials to regulate metabolic flux of small 
hydrophilic molecules and ions (Blachly-Dyson and Forte 2001, Shoshan-
Barmatz and Gincel 2003). VDACs also participate in mitochondrial autophagy 
by recruiting Parkin to docking sites for the removal of defective mitochondria, 
targeting the organelle for degradation by lysosomes (Geisler, Holmstrom et al. 
2010, Sheldon, Maldonado et al. 2011, Sun, Vashisht et al. 2012). Decreased 
levels of VDACs could lead to an increased presence of malfunctioning 
mitochondria, leading to increased protein oxidation and cellular detritus and 
ensuing neuronal dysregulation. However, in this study, the increased levels of 
VDACs suggest that the metabolic flux and the policing of mitochondrial function 
are improved in the aging brain of the NMR. VDACs are known to be 
phosphorylated by multiple kinases including: PKA, GSK3β, PKC, p38 MAP 
kinase, Nek1, and endostatin reduced hexokinase 2 (Chen, Gaczynska et al. 
2010, Sheldon, Maldonado et al. 2011). Phosphorylation of VDAC1 by Nek1 has 
been reported to open the channel (Chen, Gaczynska et al. 2010). VDAC 
phosphorylation by GSK3β or PKA increases the interaction between VDAC and 
tubulin, blocking the channel (Sheldon, Maldonado et al. 2011). The 
consequences of the decreased phosphorylation levels of VDAC2 and VDAC3 in 
the aged NMR brain are unclear. Further investigations are needed to elucidate 
the implications of this reported global decrease in phosphorylation in brains of 
NMR rodents with age.  
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 To further assess the role that autophagy may contribute to the sustained 
healthspan of the NMR by regulating cellular proteostasis, the PI3K/Akt/mTOR 
axis, Beclin-1 and LC3 were examined in the NMR brain as a function of age. 
Previous data suggested that the NMR, under basal conditions, maintains higher 
levels of autophagy, thereby removing potentially toxic proteins before they can 
negatively impact organ functionality (Rodriguez, Wywial et al. 2011) and that 
macroautophagy was shown to be substantially higher in NMRs than in shorter-
lived mice (Rodriguez, Wywial et al. 2011, Pride, Yu et al. 2015). Further, when 
the autophagy markers LC3-I, LC3-II and Beclin-1 were measured in one-day-old 
NMRs and one-day-old mice, the NMRs were shown to have a higher LC3-
II/LC3-I ratio, even though their Beclin-1 levels were lower, suggesting that 
NMRs have a significantly higher basal levels of autophagy than mice (Zhao, Lin 
et al. 2014). Although Beclin-1 plays a critical role in the regulation of 
autophagosome formation, it is also a shorter-lived protein involved in the 
formation of pre-autophagosomal structures. Consequently, it is generally 
accepted that the LC3-II/LC3-I levels usually correlate more reliably with the 
number of autophagosomes and can be used to monitor autophagosome 
formation (Klionsky, Abeliovich et al. 2008). Here, we measured the levels of 
Beclin-1 in the brain of the NMR as a function of age. Beclin-1 was significantly 
decreased in the oldest age group relative to the youngest age group. When the 
LC3-II/LC3-I ratio was measured, the levels of this quantitative index of 
autophagy did not significantly change, suggesting that NMRs do maintain a high 
level of autophagy throughout a vast majority of their lives.  
169 
 
The serine/threonine kinase, mTOR, is a major modulator of autophagy 
that receives inputs from many different signaling pathways (Cuyas, Corominas-
Faja et al. 2014). One of the most important upstream positive regulators of 
mTOR is Akt. The hyperphosphorylation of Akt induces a complete inhibition of 
TSC2 and activation of mTOR through direct phosphorylation. In turn, the 
mechanism of activation of Akt is induced by another kinase, PI3K. All together, 
these proteins are recognized as the PI3K/Akt/mTOR axis, which plays a central 
role in controlling one of the processes of proteostasis, autophagy. Our results 
showed increased phosphorylation of Akt and PI3K (p85 subunit) at Ser473 and 
Tyr508, respectively, in the intermediate NMR age group. Surprisingly, the 
hyperphosphorylation of these two proteins do not appear to affect NMR aging 
negatively. Indeed, the increase of PI3K/Akt activity in intermediate-aged NMRs 
in this study could reflect the diversity of one of the several main downstream 
targets, mTOR. Consistent with this notion, our data showed a 
hyperphosphorylation of mTOR at Ser2448 in the brain of the intermediate age 
group.  
Taken together, these results demonstrate a plausible mechanism by 
which NMRs resist development of  age-related diseases, even though they 
show high levels of oxidative damage to visceral tissues, even at young ages 
(Andziak and Buffenstein 2006, Andziak, O'Connor et al. 2006). Given that NMRs 
endogenously produce high levels of Aβ at a young age, yet live more than two 
decades with these high levels, it appears that this species is exceedingly 
tolerant of high Aβ levels and has evolved mechanisms to counter its 
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neurotoxicity (Edrey, Medina et al. 2013, Edrey, Oddo et al. 2014). One possible 
explanation could be the sustained activity of the autophagy pathway in the older 
age groups. Moreover, the slight elevation of mTOR activity in the intermediate 
age group could be a response to these increased levels of Aβ. In fact, a recent 
paper published from our lab, supporting earlier findings by LaFerla, Oddo and 
others, showed increased activity of the autophagy pathway in AD and down 
syndrome subjects, suggesting that Aβ could be one of the major causes causing 
hyperactivation of the pathway (Perluigi, Pupo et al. 2014). 
Our results of this age-related study in the brain of the NMR expose 
significant alterations in protein levels and phosphorylation states of proteins 
involved in the functioning of the proteostasis network. Mechanisms that remove 
cellular detritus promote an efficient, functional environment. Additionally, by 
using long-lived species to identify specific proteins involved in these processes, 
targets for potential therapies are identified that may aid in the delay of the onset 
and progression of the aging process in humans.  
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CHAPTER 6.3 
The Extraordinary, Long-lived Naked Mole-Rat: Quantitative Proteomic and 
Phosphoproteomic Insights into Mechanisms Promoting Healthspan 
Involve Neurite Outgrowth and Neurotransmission 
6.3.1 Overview 
Aging is the greatest risk factor for developing neurodegenerative 
diseases, which are associated with diminished neurotransmission and neuronal 
brain structure and function. However, in the brain of the remarkable naked mole-
rat (NMR), several salubrious traits have evolved to avert or delay age-related 
deterioration. Not only does the NMR hold the world record as the longest-lived 
rodent, but the NMR also possesses a extended healthspan, lasting 75-80% of 
its life span. Further, aged NMRs exhibit negligible senescence, pronounced 
genomic integrity, robust proteostasis, and a marked resistance to cancer. Using 
a proteomic approach, statistically significant changes with age in expression and 
phosphorylation levels of proteins associated with neurite outgrowth and 
neurotransmission were identified in the brain of the NMR. We hypothesize that 
such changes contribute to the extended lifespan and healthspan of the NMR 
6.3.2 Introduction 
The naked mole-rat (NMR; sand puppy) is a subterranean rodent 
indigenous to the sub-Saharan region of North East Africa. Living in large, 
eusocial colonies in an underground and thermally stable ecological niche, NMRs 
have evolved several remarkable traits that have made this rodent an intriguing 
animal research model to investigate, some of which include: extremely long 
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lifespan, sustained heathspan, negligible senescence, resistance to cancer, 
protein stability, high tolerance to hypoxia and oxidative stress, tightly regulated 
metabolism, and efficient removal of cellular detritus, among others (Hulbert, 
Pamplona et al. 2007, Buffenstein 2008, Perez, Buffenstein et al. 2009, 
Rodriguez, Wywial et al. 2011, Lewis, Mele et al. 2012). The current study 
focuses on brain proteins and underlying mechanisms that promote neurite 
outgrowth and neurotransmission in the NMR with age. 
Mitochondrial dysfunction and resultant decreased ATP production is 
implicated in various neuronal degenerative diseases and leads to decreased 
neuroplasticity and neurite outgrowth (Cheng, Hou et al. 2010). Moreover, in AD 
up to 50% of synapses are lost throughout the brain (Masliah, Terry et al. 1989). 
Uncovering proteins and related mechanism that prevent such catastrophic 
neuronal loss may conceivably identify potential therapeutic targets to halt or 
even ameliorate neurodegenerative damage. 
Making new synaptic connections in the brain is dependent upon neurite 
outgrowth and neuronal pathfinding, processes in which the axon is extended to 
target cells by the growth cone. The growth cone is a highly motile, actin-based 
structure located at the tip of neuronal processes that contain lamellipodia and 
filopodia projections that respond to surrounding environmental cues to direct 
growth cone movement (Dent and Gertler 2003, Lowery and Van Vactor 2009).  
Once the growth cone has finalized an axon terminal formation at the 
synapse, neurotransmitters can be repeatedly released, triggering enlargement 
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of the axonal spines. In order to maintain rapid neurotransmitter activity, efficient 
priming, releasing and recycling of synaptic vesicles is essential. 
In this study, significant changes in the NMR brain proteome and 
phosphoproteome with age were identified. A large number of altered brain 
proteins were determined by proteomics and/or phosphoproteomics. To facilitate 
discussion of the various proteins that may be involved in promoting healthy 
longevity in the NMR, proteins were grouped according to their functionality. In 
this report, we report on significant changes with age in neuroplastic-related brain 
proteins and phosphoproteins in the NMR and their contribution to underlying 
mechanisms that may contribute to the unusually long and salubrious lifespan of 
this rodent. 
6.3.3 Materials and Methods 
6.3.3.1 Materials 
All chemicals used in this study were purchased from Sigma-Aldrich (St. 
Louis, MO, USA) unless otherwise noted. Criterion precast polyacrylamide gels, 
ReadyStrip IPG strips, TGS and MOPS electrophoresis running buffers, mineral 
oil, Precision Plus Protein All Blue Standards, Sypro Ruby protein stain, biolytes, 
urea, dithiothreitol (DTT), iodoacetamide (IA), and nitrocellulose membranes 
were purchased from Bio-Rad (Hercules, CA, USA). Pro-Q Diamond 
phosphoprotein gel stain, and anti-phosphoserine, anti-phosphothreonine, and 
anti-phosphotyrosine antibodies were purchased from Invitrogen (Grand Island, 
NY, USA). Protein A/G beads, Amersham ECL IgG horseradish peroxidase-
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linked secondary antibodies, and ECL Plus Western blotting detection reagents 
were procured from GE Healthcare (Pittsburgh, PA, USA). C18 ZipTips and Re-
Blot Plus Strong stripping solution were obtained from Millipore (Billerica, MA, 
USA). Modified trypsin solution was purchased from Promega (Madison, WI, 
USA). Pierce BCA protein assay reagents A & B were purchased from Thermo 
Scientific (Waltham, MA, USA).  Anti-septin7, anti-CRMP2 and anti-cofilin1 
antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).   
6.3.3.2 Animals 
Brains from NMRs, aged 2-24 years, were acquired from the well-
characterized colonies (Buffenstein 2005) of Dr. Rochelle Buffenstein at the 
University of Texas Health Science Center, San Antonio. The fabricated burrow 
systems, which housed the NMRs, mimicked conditions of their natural habitat 
and were maintained at 30˚C with 30-50% relative humidity. The NMR diet 
consisted of fresh fruits and vegetables (fed ad libitum), supplemented with a 
high protein and vitamin enriched feed (Pronutro, South Africa). NMRs of 
different ages were anesthetized with isofluorane and euthanized by cardiac 
exsanguination. Brains were immediately harvested and flash frozen in liquid 
nitrogen. All animal procedures were approved by the Institutional Animal Care 
and Use Committee at the University of Texas Health Science Center at San 
Antonio, TX. Experimental animal groups consisted of 5-9 individual brains from 
both male and female individuals, of both subordinate and breeding status. 
NMRs were divided into the following four age groups for analysis: 2-3 year-olds 
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(age group 1; young), 4-6 year-olds (age group 2; intermediate), 7-12 year-olds 
(age group 3; old) and 15-24 year-olds (age group 4; oldest). 
6.3.3.3 Sample preparation 
NMR brains were homogenized using a Wheaton glass homogenizer (~40 
passes) with  ice-cold isolation buffer [0.32 M sucrose, 2 mM EDTA, 2 mM 
EGTA, 20 mM HEPES, 0.2 µg/mL PMSF, 5 µg/mL aprotinin, 4 µg/mL leupeptin, 
4 µg/mL pepstatin, and 10 µg/mL phosphatase inhibitor cocktail 2] and then 
sonicated for 10 s on ice. Protein concentrations of homogenates were 
determined by the Pierce BCA method (Rockford, IL, USA) (Smith, Krohn et al. 
1985). 
6.3.3.4 Two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
Isoelectric focusing (IEF). 2-D PAGE experiments were performed as 
previously described (Sultana, Boyd-Kimball et al. 2007). Briefly, 200 µg of each 
sample was suspended in 200 µL of rehydration buffer [8 M urea, 2 M thiourea, 
50 mM DTT, 2.0% (w/v) CHAPS, 0.2% Biolytes, 0.01% bromophenol Blue], 
applied to IPG strips (pH 3-10), actively rehydrated and isoelectricly focused. 
After completion of the run, IPG strips were immediately stored at -80 °C. 
SDS PAGE. IPG strips were thawed and equilibrated in DTT and IA-
containing buffers.  Strips were rinsed in TGS running buffer and placed into 
Criterion precast polyacrylamide gels (8–16% Tris–HCl). Precision Plus Protein 
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All Blue molecular standards and samples were run at a constant voltage of 200 
V for approximately 65 min at 22˚C in Tris/Glycine/SDS running buffer. 
6.3.3.5 Sypro Ruby and Pro-Q Diamond staining 
After completion of 2D-PAGE, gels were stained according to 
manufacturer’s directions and as described previously (Di Domenico, Sultana et 
al. 2011). In brief, gels were fixed  [10% (v/v) acetic acid, 50% (v/v) methanol] 
and stained with 60 mL of Pro-Q Diamond for exactly 90 min. Gels were 
incubated four times in destaining solution [20% acetonitrile (ACN), 50 mM 
sodium acetate, pH 4] (100 mL, 30 min each). The gels were scanned at 580 nm 
using ChemiDoc XRS+ imaging system (Bio-Rad). Next, gels were incubated 
overnight (15 h) in 50 mL of Sypro Ruby protein gel stain. Gels were imaged at 
450 nm and stored in DI water in covered containers at 4 °C until protein spot 
extraction. 
6.3.3.6 Image Analysis 
Expression Proteomics. Spot intensities from SYPRO Ruby-stained gel 
images were quantified according to total spot density and normalized to total gel 
density using PDQuest analysis software (Bio-Rad). Normalized spot densities of 
the four age groups were compared and only spots with statistically significant 
differences in protein spot densities between age groups (p<0.05) were 
considered for in-gel trypsin digestion and protein identification by MS/MS. 
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Phosphoproteomics. Spot intensities from Pro-Q Diamond-stained gel 
images were quantified and matched as described previously (Di Domenico, 
Sultana et al. 2011). A high match analysis between the Sypro Ruby and Pro-Q 
Diamond-stained gels was conducted. Phosphoprotein spot densities were 
normalized to Sypro Ruby spot densities in order to differentiate between a lightly 
phosphorylated protein that is highly abundant and a protein of low abundance 
that is highly phosphorylated. The normalized spot densities were compared 
between the four age groups, and spots that were statistically significant (p<0.05) 
were considered for in-gel trypsin digestion and protein identification by MS/MS. 
6.3.3.7 In-gel trypsin digestion/peptide extraction 
Significantly differential protein spots were excised from 2D-gels and 
transferred to individual Eppendorf microcentrifuge tubes for trypsin digestion as 
previously described (Thongboonkerd, McLeish et al. 2002). In brief, DTT and IA 
were used to break and cap disulfide bonds and the excised gel plugs were 
incubated overnight (17 h) in modified trypsin solution with shaking at 37°C. Salts 
and contaminants were removed from the tryptic peptide solutions using C18 
ZipTips. Tryptic peptide solutions were reconstituted in 10 µL of a 5% ACN/0.1% 
formic acid (FA) solution and stored at -80˚C until MS/MS analysis. 
6.3.3.8 NanoLC-MS with Data Dependent Scan 
Reconstituted tryptic peptide solutions were analyzed by a nanoAcquity 
(Waters, Milford, MA)-LTQ Orbitrap XL (Thermo Scientific, San Jose, CA) 
platform using a data dependent scan mode and separated by a capillary column 
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(0.1 x 130 mm column packed in-house with 3.6 µm, 200Å XB-C18) with a 
gradient using 0.1% FA and ACN/0.1% FA at 200 nL/min. Spectra obtained by 
MS were measured by the orbitrap at 30,000 resolution; and the MS/MS spectra 
of the six most intense parent ions were acquired by the orbitrap at 7,500 
resolution. Swiss-Prot database by SEQUEST (Proteome Discoverer v1.4, 
Thermo Scientific) was used to interrogate the data files for sample identification. 
Proteins were identified by at least two high-confidence peptide-matched 
sequences with a false discovery rate <1%. Proteins matched with the same 
peptides were reported as one protein group. Tabular data reported from these 
analyses includes: the SwissProt accession number, the percentage of the 
protein sequence identified by matching peptides, the number of peptide  
sequences sequnced in the MS/MS analysis, the confidence score of the protein, 
the protein’s expected molecular weight (MW) and isoelectric point (pI). 
6.3.3.9 Immunoprecipitation and Western blotting 
Immunoprecipitation (IP). Brain homogenates (250 µg) were suspended 
individually in 500 µL of IP buffer [0.05% NP-40, aproprotin 5 µg/mL, leupeptin 4 
µg/mL, pepstatin 4 µg/mL, and phosphatase inhibitor cocktail 10 µg/mL] in a 
phosphate buffer solution, pH 8 [8 M NaCl, 0.2 M KCl, 1.44 M Na2HPO4, and 
0.24 M KH2PO4]. Samples were incubated with Protein A/G agarose beads in 
500 mL of IP buffer for 1.5 h at 4˚C. Each sample was incubated overnight with 
anti-cofilin1 antibody (1:50 dilution) at 4˚C. The next day, samples were 
incubated with Protein A/G agarose beads for 1.5 h at 4˚C and washed with IP 
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buffer (500 mL, 5 times), preserving the protein-linked beads for a 1D-PAGE 
experiment. 
One-dimensional polyacrylamide gel electrophoresis (1D-PAGE). Sample 
homogenates (50 µg) or beads from immunoprecipitation were suspended in 4X 
sample loading buffer [0.5 M Tris, pH 6.8, 40% glycerol, 8% SDS, 20% β-
mercaptoethanol, 0.01% Bromophenol Blue] (diluted to 1X with DI water). 
Samples were heated at 95°C for 5 min, cooled on ice and loaded into Criterion 
precast 18 well polyacrylamide gels (4-12% Bis-Tris). Using MOPS running 
buffer, gels were run at 80 V for 15 min and then at 120 V for approximately 100 
min.  
1D-Western blotting. In-gel proteins were transferred to nitrocellulose 
membranes (0.2 nm) using a Trans-Blot Turbo Blotting System (Bio-Rad) at 25 V 
for 30 min. Membranes were blocked in solution (3% bovine serum albumin 
(BSA) in TBS-T [8 M NaCl, 2.4 M Tris, and 0.1% (v/v) Tween 20]) for 1.5 h. 
Membranes were then separately incubated with primary antibodies: CRMP2 and 
septin7 (1:3000 dilution), tubulin (1:5000), and phosphoserine, phosphothreonine 
and phosphotyrosine antibodies (1:6000) for 2 h. The blots were washed with 
TBS-T (3 times, 5 min each), incubated (1 h) with a horseradish peroxidase 
secondary antibody in TBS-T (1:5000), and washed again in TBS-T (3 times, 10 
min each). Western blots were chemiluminescently developed (in dark, 5 min) 
with Clarity Western ECL substrate, scanned with the ChemiDoc and quantified 
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using Image Lab software (Bio-Rad). Blots were stripped up to two times with 
Re-Blot Plus Strong solution (15 min each) for further probing. 
6.3.3.10 Statistical analysis 
An initial, conservative analysis was carried out on PDQuest data using 
both a two-tailed Student’s t-test and a Mann-Whitney U statistical test, 
independently comparing each age group to the youngest age group. Protein 
spots were considered significant if p<0.05 in both tests. Significant differences 
(p<0.05) between the age groups for PDQuest data were determined using one-
way ANOVA with post hoc Bonferroni t-test. Fold-change values of proteins were 
calculated by dividing the average, normalized spot intensity of older age group 
by the average, normalized spot intensity of the younger age group in the 
comparison. For Western blot data, a one-way ANOVA with a post hoc Tukey 
multiple comparisons test was used. All data are presented as mean+SEM. 
Proteins identified by the SEQUEST search algorithm were considered 
statistically significant if p<0.01. At least two peptide sequences were used to 
identify each protein and a visual comparison was made between the expected 
MW and pI of the identified protein to the spot of the extracted 2-D gel plug. 
6.3.4 Results 
Age-related changes in neuroplasticity-related proteins 
Neuroplasticity-related proteins with statistically significant alterations in protein 
and phosphorylation levels in the four cohorts are labeled Figures 6.3.1 & 6.3.2. 
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Figure 6.3.1 Proteins associated with neurite outgrowth and 
neurotransmission with altered expression and/or phosphorylation levels 
with age in the NMR brain. Representative Sypro Ruby-stained 2-D gel images 
of isolated proteins from the brains of NMRs, aged 2-3 years (A), 4-6 years (B), 
7-12 years (C), and 15-24 years (D). Proteins whose expression and/or 
phosphorylation state was significantly altered (p<0.05) in the particular age 
group are labeled in the images. 
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Figure 6.3.2 Proteins associated with neurite outgrowth and 
neurotransmission with altered phosphorylation levels with age in the NMR 
brain. Representative Pro-Q Diamond-stained 2-D gel images of isolated 
proteins from the brains of NMRs, aged 2-3 years (A), 4-6 years (B), 7-12 years 
(C), and 15-24 years (D). Proteins with significantly altered phosphorylation 
levels (p<0.05) in the particular age group are labeled in the images. 
 
PDQuest analyses of gels from all age groups identified 9 proteins related 
to neurite outgrowth and neurotransmission with significant changes in the NMR 
brain as a function of age (Table 6.3.1).  
183 
 
Table 6.3.1 Proteins associated with neurite outgrowth and 
neurotransmission with significantly altered levels and/or phosphorylation 
states with age in the NMR brain. PDQuest and MS/MS results of NMR brain 
proteins related to plasticity, structure and neurotransmission with significant 
altered expression and/or phosphorylation states as a function of age.  
 
These altered proteins were: cofilin-1; isoform 2 of dihydropyrimidinase-
related protein 2, aka collapsin response mediator protein 2; destrin, aka actin 
depolymerizing factor; isoform 3 of spectrin alpha chain; septin-7; Syntaxin-
binding protein 1; synapsin-2 isoform IIB; and both isoform 3 and 4 of dynamin1. 
Immunoprecipitation and Western blotting validations 
Immunoprecipitation and Western blot experiments were carried out on 
selected proteins to confirm MS/MS results and provide confidence of all 
proteomic or phosphoproteomic identifications. Western blot analysis of CRMP2 
(Figure 6.3.3A) confirmed a significant increase in CRMP2 levels in the brain of 
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the oldest age group compared to the two younger age groups (p=0.008) and 
(p=0.011), respectively. The Western blot analyses of the levels of septin-7 
(Figure 6.3.3B) verified a significant increase in the old age group (p=0.038) 
compared to the youngest, while also showing increased levels of septin-7 in the 
intermediate age group (p=0.034) also compared to the youngest age group.  
Analyses of the immunoprecipitation of cofilin-1 with anti-phosphoserine, anti-
phosphothreonine and anti-phosphotyrosine antibodies confirmed a significant 
decrease in the phosphorylation of cofilin-1 in the brain of the NMR for the 
intermediate age group (p=0.039), the old age group (p=0.037), and in the oldest 
age group (p=0.037) all relative to the youngest age group (Figure 6.3.3C). 
 
Figure 6.3.3 CRMP2, septin-7, and cofilin-1 in NMR brain with age. 
Immunoprecipitation and Western blot analyses of (A) significant elevation of 
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CRMP2 protein levels in oldest age group (B) increased septin-7 protein levels in 
the middle age groups, and (C) levels of phosphorylated Ser/Tyr/Thr residues 
normalized to total cofilin-1 protein levels after immunoprecipitation showing 
significant decrease (*p<0.05) in the phosphorylation of cofilin-1 in the brains of 
NMRs (n=4-6 for each age group). Immunoreactivity with specific antibodies was 
detected by chemiluminescence. 
6.3.5 Discussion 
Evaluation of the proteins and phosphoproteins that significantly change 
with age in the brain of the NMR, which are related to mechanisms associated 
with neuroplasticity, fall into two different yet connected processes: neurite 
outgrowth and neurotransmission. 
Neurite outgrowth 
Rapid assembly and disassembly of the actin cytoskeleton at the leading 
edge of the cone is required for motility of the growth cone (Lin and Forscher 
1995, Minamide, Striegl et al. 2000). Actin depolymerizing factor (ADF; destrin) 
and cofilin-1, members of the ADF/cofilin family, modulate actin dynamics in the 
growth cone by binding and depolimerizing F-actin at the negative end of the 
filaments (Lappalainen and Drubin 1997, Gungabissoon and Bamburg 2003), 
and ADF/cofilin regulate the rate at which these monomers separate from the 
actin filament (Maciver and Hussey 2002). Further, overexpression of cofilin has 
been reported to increase neurite outgrowth (Meberg and Bamburg 2000). In 
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fact, cofilin activity reportedly is essential for neurite extension by the growth 
cone (Endo, Ohashi et al. 2003). Interestingly, cofilins also are involved in cellular 
stress responses to heat shock and chemical stress, in which actin becomes 
saturated with cofilin inducing actin rod bundling (known as cofilin/actin rods), 
thereby halting actin polymerization and depolymerization (Munsie and Truant 
2012). Upon dissipation of environmental stressors, the cofilin/actin rods 
dissipate. However, if the stressed environment persists, as in 
neurodegenerative diseases, the cofilin/actin rods block neuronal trafficking and 
lead to disruption of synapses and eventual apoptosis (Minamide, Striegl et al. 
2000, Cichon, Sun et al. 2012). In the current study, NMRs exhibited increased 
ADF/cofilin-1 levels with significant elevation of ADF levels in the two oldest age 
cohorts compared to the youngest age group and increased cofilin-1 levels in the 
old age group. Additionally, ADF phosphorylation was decreased in the oldest 
age group, while cofilin-1 phosphorylation was decreased in all age groups as 
compared to the youngest.  Phosphorylation at Ser-3 reportedly inactivates 
ADF/cofilin, while dephosphorylation activates actin depolymerization (Toshima, 
Toshima et al. 2001, Endo, Ohashi et al. 2003). Taken together, the increased 
levels and activity of ADF/cofilin suggest a possible mechanism by which the 
NMR brain maintains a high numbers of synapses, consistent with salubrious 
aging. 
Dihydropyrimidinase-related protein 2 (DRP2; collapsin response mediator 
protein 2, CRMP2) is a pleiotropic protein that participates in a wide array of 
activity in and out of the growth cone, including: organization of the dendritic field, 
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guidance and collapse of the growth cone, neurite outgrowth, synaptic assembly, 
neurotransmitter release, endocytosis, and Ca2+  homeostasis (Goshima, 
Nakamura et al. 1995, Byk, Dobransky et al. 1996, Uchida, Ohshima et al. 2005, 
Brittain, Piekarz et al. 2009, Hensley, Venkova et al. 2011, Ju, Li et al. 2013). In 
previous studies, we have shown that CRMP2 is oxidatively modified in brain of 
subjects with Alzheimer disease (AD) (Castegna, Aksenov et al. 2002) and that 
phosphorylation levels of CRMP2 are increased in the hippocampus of AD brain 
(Di Domenico, Sultana et al. 2011). In this current study, levels of CRMP2 were 
significantly increased in the oldest NMRs compared to both the intermediate and 
old age groups.  This increase in CRPM2 suggests that older NMR brains have 
increased neuronal plasticity and provides another mechanism by which the 
NMR is able to ward away cognitive decline with age.       
Members of the septin family are highly conserved cytoskeletal GTPases 
involved in various cellular functions, including: dendritic field maturation, spine 
dynamics, synaptic transmission, vesicle trafficking, DNA response to 
cytoskeletal damage, protein scaffolding, membrane compartmentalization, cell 
division, and apoptosis (Barral, Mermall et al. 2000, Kremer, Adang et al. 2007, 
Tada, Simonetta et al. 2007, Xie, Vessey et al. 2007, Spiliotis, Hunt et al. 2008, 
Hagiwara, Tanaka et al. 2011).  Septin7, in particular, is reportedly essential in 
the regulation of dendritic branching and spine morphology (Xie, Vessey et al. 
2007). Additionally, septins can function cooperatively, forming hetero-filaments 
of 3 or more septins, the most notable of which being septin2/septin6/septin7 
(Barral and Kinoshita 2008). Furthermore, septins have abnormal function in 
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several neurological disorders including AD and Parkinson disease (Kinoshita, 
Kinoshita et al. 1998, Cheon, Fountoulakis et al. 2001, Barr, Young et al. 2004, 
Ihara, Yamasaki et al. 2007). In this study of the NMR brain, expression of 
septin7 was significantly increased in the old age group with respect to the 
youngest age group, suggesting increased brain plasticity is a survival 
mechanism with aging of NMRs. 
Neurotransmission 
 Rapid release and recycling of synaptic vesicles is one facet required for 
efficient neurotransmission. In the brain of the NMR, four proteins involved in this 
process were altered with age. 
Syntaxin-binding protein 1 (stxbp1) apparently plays a role in both neurite 
extension and neurotransmission. Not only is stxbp1 reported to regulate the 
filopodia of the growth cone to modulate plasticity (Broeke, Roelandse et al. 
2010), but stxbp1 also can bind to syntaxin and  modulate the formation of the 
SNARE complex and subsequent neurotransmitter release (Misura, Scheller et 
al. 2000, Yang, Steegmaier et al. 2000). In the current study, the expression of 
stxbp1 was increased in the oldest age group compared to the youngest, and 
phosphorylation levels of stxbp1 were decreased in the two oldest groups relative 
to the youngest. Protein kinase C phosphorylation on Ser-306 and Ser-313 of 
stxbp1 reportedly modulates neurotransmission by increasing rapid vesicle 
cycling and vesicle release (Barclay, Craig et al. 2003, Craig, Evans et al. 2003). 
However, since PhosphoSite lists over 30 residues of stxbp1 that can be 
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phosphorylated, it is conceivable that the global phosphorylation events 
measured here may be responsible for modulation of other cellular activities, 
such as changing affinity to binding partners or cellular localization or other 
activities. Furthermore, based on the NMR’s long healthspan well into old age in 
addition to the implications of other proteins identified in this study, it may not be 
likely that the decreased phosphorylation of stxbp1 seen here would decrease 
synaptic activity. Further investigations into decreases of phosphorylation at 
particular phosphorylation sites are warranted.  
Dynamin-1 (dnm1) is a brain-specific GTP-dependent motor protein that is 
abundant in the post-synaptic synapse (Raimondi, Ferguson et al. 2011). 
Interestingly, dnms are the only known molecular motor proteins to utilize a 
twisting motion, and dnm1 does so by pinching off synaptic vesicles from the 
plasma membrane during endocytosis (Soulet, Yarar et al. 2005, Roux, Uyhazi et 
al. 2006, Raimondi, Ferguson et al. 2011). Dnm1 phosphorylation plays a key 
role in regulating synaptic vesicle endocytosis (reviewed in (Smillie and Cousin 
2005)). Dnm1 is activated by the dephosphorylation that occurs upon 
depolarization of the axon terminal, and then is deactivated by phosphorylation 
upon repolarization. We speculate that upregulation of dnm1 activity observed in 
the current study among the two oldest NMR age-groups compared to the 
youngest age group, may be the result of the brain’s defensive mechanism to 
ameliorate reduced neurotransmission by increasing the uptake of excitatory 
neurotransmitters into the post-synaptic synapse. 
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Spectrin is an α-β heterodimer that  makes up to 2-3% of all proteins in the 
brain and is responsible for cross-linking actin filaments to form a resilient 3-D 
cellular matrix to increase stability of the cytoskeleton as well as to stabilize 
transmembrane proteins (Yan, Winograd et al. 1993, Zhang, Zhang et al. 2013). 
In addition to actin, spectrin also can cross-link membrane lipids and proteins 
(Baines 2009). Spectrin is found at greater concentrations at the presynaptic 
membrane and are thought play a role in synaptic transmission and organization, 
since spectrin mutations in Drosophila disrupted neurotransmission and resulted 
in aberrant synaptic protein localization (Featherstone, Davis et al. 2001). In the 
current study, expression of spectrin alpha chain, isoform 3 is increased in the 
brain of old-aged NMRs relative to the youngest, and in addition, the 
phosphorylation level of this protein is decreased in the brains of the two oldest 
NMR groups. Spectrin is known to be phosphorylated at numerous residues; 
however, the consequences of spectrin phosphorylation are not yet clear (Baines 
2009). However, based upon the reputation of the NMR in terms of successful 
aging, we speculate decreased phosphorylation may contribute to the long 
healthspan and lifespan of the NMR. 
 In summary, the NMR, with its many unique traits associated with 
salubrious aging, is an exceptional model organism in the study of proteins to 
target for therapeutic interventions in the aging process. The findings of the 
current age-related study of brain from NMRs identifies changes in protein 
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expression and/or phosphorylation levels of key proteins involved in mechanisms 
that may be responsible for the increase in neuronal plasticity and the lack of 
senescence noted in the NMR. 
 
Figure 6.3.4 Proteins associated with neurite outgrowths that are increased 
in levels and/or activity in brain in older NMR age groups. NMR brain 
proteins associated with neurite outgrowths that have significantly altered 
phosphorylation levels and/or protein levels with age. 
 
These identified brain proteins are illustrated in figures 6.3.4 and 6.3.5. Further 
investigations into these proteomics-identified proteins may be warranted to 
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identify targets for potential therapies that conceivably may aid in the delay of 
aging onset and progression in humans.  
 
Figure 6.3.5 Proteins associated with neurotransmission that are increased 
in levels and/or activity in brain in older NMR age groups. Proteins that play 
a role in neurotransmission that were significantly altered in phosphorylation 
and/or levels in the brain of the naked mole-rat with age. 
 
Copyright © Judy Carol Triplet 2015 
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CHAPTER 7 
CONCLUSIONS AND FUTURE STUDIES 
7.1 Conclusions 
 The studies in this dissertation examined the proteome and 
phosphoproteome in brain from the PINK1 KO model of familial PD, the IPL of 
PCAD, amnestic MCI and AD subjects, and changes with age in brain of the 
long-lived naked mole-rat. The majority of the significantly altered proteins 
identified in this dissertation work are involved in vital processes such as: energy 
production, disposal and recycling of cellular detritus, stress response, and 
neuroplasticity. Furthermore, the proteins identified with altered expression or 
phosphorylation in the neurodegenerative brain reflect increased oxidative stress, 
altered energy metabolism, diminished proteostasis networks, and decreases in 
neurotransmission and neurite outgrowth. Conversely, in the NMR brain, many 
alterations in protein levels and protein activities seemingly support underlying 
biochemical mechanisms that promote a healthy and efficient cellular state.   
 Depletion of ATP is a major factor in the cascade leading to apoptosis. In 
brain of AD subjects and PINK1 KO mice, declines in levels and/or activity of 
energy-related proteins associated with the mitochondria, such as MDH1, and 
VDACs were observed. Interestingly, VDACs were consistently identified as 
significantly altered in all of the studies put forth in this dissertation. VDACs are 
critical regulators not only of mitochondrial flux but of mitophagy as well. 
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Therefore dysregulation of VDACs may result in a considerable shift in 
metabolism and homeostasis that promotes a neurodegenerative environment. 
 Accumulation of cellular detritus, including the aggregation of proteins, is 
detrimental to proteostasis. In the IPL of AD brain and in brain of PINK1 KO 
mice, proteins involved in proteostasis networks are diminished in levels and/or 
activity, including heat shock proteins and proteasomal subunits to name a few. 
In contrast, in the brain of the senescent-resistant NMR, proteins associated with 
autophagy and proteasomal pathways are increased in expression and activity. 
In the NMR, these processes are thought to be a primary contributing factor in 
promoting a healthy lifespan. 
Brain plasticity is critical to healthy brain functioning. In addition to PINK1’s 
role in policing mitochondrial integrity, it also contributes to neurite outgrowth. 
Consistent with this notion, the ablation of PINK1 leads to decreased levels of 
proteins associated with mechanisms of neuroplasticity, such as EF2 which 
mediates protein production in the growth cone, and CRMP2 which is a 
pleiotropic protein that plays roles in growth cone guidance and in 
neurotransmitter release and recycling, among other functions. Dysregulation of 
CRMP2 was also evident in the AD brain and associated with the decreased 
synapses present in AD brain, where in the NMR brain, increased CRMP2 
activities were associated with negligible senescence.  
Taken together, the work in this dissertation study has identified global 
mechanisms and specific key proteins involved not only in promoting 
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neurodegenerative environments, but also in encouraging sustained good health 
and a long lifespan. Further investigations into these key proteins may 
conceivably provide targets for potential global combatting of neurodegenerative 
diseases as well as providing insights into the prevention of age-related disease 
for an extended, healthy human lifespan. 
7.2 Future Studies 
 Based on the results of the studies in this dissertation, future 
investigations may be warranted in the following areas: 
1. For a great number of proteins identified with significantly altered 
phosphorylation levels, the implications of the global trends in 
phosphorylation were unclear. Further investigations are warranted 
to establish not only the identity of the exact amino acid residues 
with altered phosphorylation but also to determine how the 
phosphorylation or dephosphorylation of that residue impacts the 
function of the protein in order to determine if targeting upstream 
kinases and phosphatase could be a potential therapeutic strategy. 
2. Mitochondrial dysfunction is present in numerous degenerative 
diseases, and as such, the PINK1 KO mouse model is a good 
general model organism to evaluate consequences of mitochondrial 
impairment. Therefore, it would be interesting to evaluate pathways 
associated with PINK1 in the NMR brain to examine if PINK1 is 
involved in promoting the healthy lifespan of the naked mole-rat. 
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3. Compare the changing levels of proteins and protein 
phosphorylation states that were seen in the brain of the NMR to 
the levels of proteins and protein phosphorylation in wild-type mice 
or in neurodegenerative animal models. Evaluating alterations in 
proteomes and phosphoproteomes with age within a species, such 
as rodents, may be key in discovering underlying mechanisms for 
the substantial difference in average lifespans within a species, 
such as between a mouse and a naked mole-rat. 
4. NMRs reportedly have uncommonly high levels of oxidative 
stress, even at an early age compared to mice and these levels do 
not seem to be significantly altered over their lifespan. However it 
would be interesting to investigate whether individual proteins in the 
NMR brain have significant levels of oxidative modification.   
 
197 
 
APPENDIX A 
DATA TO SUPPLEMENT TABLES AND FIGURES 
Figure 4.2 
Sample p-CaM 
Spot 
Density 
p-14-3-3ε 
Spot 
Density 
p-NFM 
Spot 
Density 
p-V-
ATPase 
Spot 
Density 
p-
MAPKK1 
Spot 
Density 
p-
MAPK1 
Spot 
Density 
WT1 0.394 0.566 63.2 0.560 0.061 0.132 
WT2 0.584 0.484 25.9 0.436 0.092 0.052 
WT3 1.23 0.835 56.2 0.205 0.051 0.102 
WT4 0.728 0.296 17.7 0.574 0.072 0.032 
WT5 0.602 0.500 35.0 0.451 0.053 0.030 
WT6 
 
WT 
average 
0.699 
 
0.706 
0.415 
 
0.516 
13.8 
 
35.3 
0.414 
 
0.440 
0.045 
 
0.0623 
0.085 
 
0.0722 
KO1 0.195 0.264 5.36 0.034 0.100 0.133 
KO2 0.207 0.096 10.6 0.301 0.187 0.183 
KO3 0.686 0.401 25.3 0.167 0.137 0.337 
KO4 0.364 0.232 4.57 0.120 0.115 0.155 
KO5 0.065 0.052 2.78 0.044 0.096 0.116 
KO6 
 
KO 
average 
 
0.220 
 
0.290 
 
0.180 
 
0.204 
 
9.02 
 
9.61 
 
0.0902 
 
0.126 
 
0.171 
 
0.134 
 
0.230 
 
0.192 
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T-TEST 0.0166 0.00605 0.0168 0.0009 0.0017 0.0091 
 
 
Figure 4.3 
Sample p-(S/T/Y) 
Density 
MAPK1 
Density 
p-(S/T/Y) / 
MAPK1 
p-(S/T/Y) / 
MAPK1 
Normalized on 
% WT 
WT1 3729000 2967300 1.257 118.1 
WT2 4969692 4795650 1.036 97.37 
WT3 5788620 5283150 1.096 103.0 
WT4 3378744 3935550 0.8585 80.67 
WT5 
 
WT average 
3020668 2812250 1.074 
 
1.064 
100.9 
 
100 
KO1 3977952 3233375 1.230 115.6 
KO2 3130452 1717800 1.822 171.2 
KO3 3640788 2867175 1.270 119.3 
KO4 4689648 4029825 1.164 109.3 
KO5 
 
KO average 
 
TTEST 
3379536 2363025 1.430 
1.383 
134.4 
 
130.0 
 
0.0449 
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Sample p-(S/T/Y) 
Density 
CaM Density p-(S/T/Y) / CaM p-(S/T/Y) / CaM 
Normalized on 
% WT 
WT1 1631068 5223816 0.3122 86.20 
WT2 2014540 5848704 0.3444 95.09 
WT3 2100898 6224832 0.3375 93.17 
WT4 2683157 6288840 0.4267 117.8 
WT5 
 
WT average 
2262004 5794380 0.3904 
 
0.3622 
107.8 
 
100 
KO1 1972918 5408352 0.3648 100.7 
KO2 1603478 6557364 0.2445 67.50 
KO3 1862208 6236028 0.2986 82.44 
KO4 1189974 5058216 0.2353 64..94 
KO5 
 
KO average 
 
TTEST 
674774 4547808 0.1484 
 
0.2583 
40.96 
 
71.31 
 
0.036 
 
Figure 4.4 
Sample HSP70 
Density 
Tubulin 
Density 
HSP70/Tubulin HSP70/Tubulin 
Normalized on 
%WT 
WT1 4331460 13845625 0.3128 82.94 
200 
 
WT2 5220075 13979229 0.3734 99.00 
WT3 5435885 12296284 0.4421 117.2 
WT4 5511100 13455716 0.4096 108.6 
WT5 4297230 12739381 0.3373 89.43 
WT6 
 
WT average 
5625340 14502261 0.3879 
 
0.3772 
102.8 
 
100 
KO1 3974880 13134667 0.3026 80.23 
KO2 3696735 12922805 0.2861 75.84 
KO3 3885945 11930787 0.3257 86.35 
KO4 4754120 11849117 0.4012 106.4 
KO5 3917585 12462229 0.3144 83.34 
KO6 
 
KO average 
 
TTEST 
3495625 14320665 0.2441 
 
0.3123 
64.72 
 
82.81 
 
0.0471 
 
Sample Aldolase A 
Density 
Tubulin 
Density 
Aldolase A 
/Tubulin 
Aldolase A 
/Tubulin 
Normalized on 
%WT 
WT1 7932552 9644440 0.8225 97.67 
WT2 6712612 7791772 0.8615 102.3 
WT3 7857792 9057960 0.8675 103.0 
201 
 
WT4 6945800 8517158 0.8155 96.84 
WT5 6410650 8283870 0.7739 91.89 
WT6 
 
WT average 
7879655 8642781 0.9117 
 
0.8422 
108.26 
 
100 
KO1 8625669 9088261 0.9491 112.7 
KO2 8321452 9132410 0.9112 108.2 
KO3 7769898 8642781 0.8963 106.4 
KO4 7539447 8142134 0.9260 110.0 
KO5 7651680 8357796 0.9155 108.7 
KO6 
 
KO average 
 
TTEST 
8742375 8757812 0.9982 
 
0.9340 
118.5 
 
110.9 
 
0.0494 
 
Figure 5.2 
Cohort p-(S/T/Y) 
Density 
Gelsolin 
Density 
Normalized 
p-(S/T/Y) 
/Gelsolin 
Control 26410804 8251880 110.2899 
Control 24994831 13064464 65.92735 
Control 32453708 9918776 112.7491 
Control 23991991 7445928 111.0336 
PCAD 14226915 10569496 46.38349 
202 
 
PCAD 11531447 8133272 48.85686 
PCAD 10169737 4684968 74.80146 
PCAD 12601929 5517232 78.70871 
MCI 8940038 11951072 25.77742 
MCI 14615885 8878040 56.73029 
MCI 16071040 6927112 79.94638 
MCI 17095694 7990736 73.72367 
AD 19843361 10038000 68.12006 
AD 20318612 14476896 48.36438 
AD 14975317 11145400 46.30068 
AD 15379564 12617024 42.00433 
    
 PCAD MCI AD 
Gelsolin vs. vs. vs. 
 Control Control Control 
 
 
  
Unpaired t test 
 
  
P value 0.0371 0.0489 0.0087 
P value summary * * ** 
Significantly different? (P < 0.05) Yes Yes Yes 
One- or two-tailed P value? Two-tailed Two-tailed Two-tailed 
t, df t=2.668 df=6 t=2.464 df=6 t=3.824 df=6 
    
 
Cohort p-(S/T/Y) 
Density 
CRMP2 
Density 
Normalized 
p-(S/T/Y) 
203 
 
/CRMP2 
Control 27004654 27662404 90.70648 
Control 25457969 22789766 103.7943 
Control 23084812 18160264 118.1119 
Control 22249549 23657156 87.38729 
PCAD 30123807 21950450 127.5135 
PCAD 26448443 24246206 101.3552 
PCAD 18553140 18325724 94.06886 
PCAD 28924632 17363982 154.7776 
MCI 26446933 14864066 165.3205 
MCI 31846194 17028974 173.7635 
MCI 23164730 18149600 118.5905 
MCI 36045047 17054842 196.3756 
AD 45606800 15209434 278.6161 
AD 49687126 20690252 223.135 
AD 41909647 9043476 430.5942 
AD 43096019 17033656 235.0817 
    
 PCAD MCI AD 
CRMP2 vs. vs. vs. 
 Control Control Control 
    
Unpaired t test    
P value 0.2559 0.0118 0.0073 
P value summary ns * ** 
204 
 
Significantly different? (P < 0.05) No Yes Yes 
One- or two-tailed P value? Two-tailed Two-tailed Two-tailed 
t, df t=1.256 df=6 t=3.572 df=6 t=3.975 df=6 
 
Figure 6.1.3 
Age Group 
(Years) 
Lactate DH 
Density 
Tubulin Density Lactate DH 
/Tubulin 
2-3 19418475 41507755 0.4678 
2-3 17982189 41588153 0.4324 
2-3 18517989 39603600 0.4676 
2-3 
 
2-3 average 
15790482 42013871 0.3758 
 
0.4359 
4-6 15450078 39753666 0.3886 
4-6 13827288 39695076 0.3483 
4-6 12609426 40267503 0.3131 
4-6 
 
4-6 average 
18027634 45683693 0.3946 
 
0.3612 
7-12 14461128 40503512 0.3570 
7-12 12844722 42107507 0.3050 
7-12 16611282 43582365 0.3811 
7-12 
 
7-12 average 
14959707 37058472 0.4037 
 
0.3617 
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15-24 19291707 37806519 0.5103 
15-24 19375896 38388398 0.5047 
15-24 25254705 43981610 0.5742 
15-24 
 
15-24 average 
22778967 41356035 0.5508 
 
0.5350 
Bonferroni's 
multiple 
comparisons 
test 
Mean Diff. 95% CI of diff. Significant? Summary Adjusted P 
Value 
2-3 vs. 4-6 0.07472 -0.01322 to 0.1627 No ns 0.1205 
2-3 vs. 7-12 0.07418 -0.01376 to 0.1621 No ns 0.1249 
2-3 vs. 15-24 -0.09910 -0.1870 to -0.01115 Yes * 0.0239 
4-6 vs. 7-12 -0.0005405 -0.08848 to 0.08740 No ns > 0.9999 
4-6 vs. 15-24 -0.1738 -0.2618 to -0.08588 Yes *** 0.0003 
7-12 vs. 15-24 -0.1733 -0.2612 to -0.08534 Yes *** 0.0003 
 
Age Group 
(Years) 
G-6-P DH 
Density 
Tubulin 
Density 
G-6-P DH 
/Tubulin 
2-3 9671480 56057187 0.172539 
2-3 7389144 43835650 0.161210 
2-3 9659608 44315586 0.217973 
2-3 
 
2-3 average 
10078488 45241686 0.222770 
 
0.193621 
4-6 6870248 41413680 0.165893 
4-6 5273688 39767931 0.132612 
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4-6 4816056 42965244 0.112092 
4-6 
 
4-6 average 
6717728 45338078 0.148170 
 
0.139692 
7-12 3718624 41607657 0.089374 
7-12 5686240 40952268 0.138850 
7-12 7212520 40550328 0.177866 
7-12 
 
7-12 average 
7531216 42632037 0.176656 
 
0.145687 
15-24 11837616 49987287 0.236813 
15-24 10214176 45148602 0.212139 
15-24 20048840 53684568 0.373456 
15-24 
 
15-24 average 
14740152 57738450 0.255292 
 
0.269425 
Bonferroni's 
multiple 
comparisons 
test 
Mean 
Diff. 
95% CI of diff. Significant? Summary Adjusted P Value 
2-3 vs. 4-6 0.05393 -0.04800 to 0.1559 No ns 0.7271 
2-3 vs. 7-12 0.04793 -0.05400 to 0.1499 No ns 0.9838 
2-3 vs. 15-24 -0.07580 -0.1777 to 0.02613 No ns 0.2225 
4-6 vs. 7-12 -0.005995 -0.1079 to 0.09594 No ns > 0.9999 
4-6 vs. 15-24 -0.1297 -0.2317 to -
0.02780 
Yes * 0.0103 
7-12 vs. 15- -0.1237 -0.2257 to - Yes * 0.0144 
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24 0.02181 
 
Figure 6.1.4 
Age Group 
(Years) 
p-(S/T/Y) 
Density 
MDH1 Density p-(S/T/Y) 
/MDH1 
2-3 22530330 14210046 1.5855 
2-3 12102257 10201410 1.1863 
2-3 20850128 14519304 1.4360 
2-3 
 
2-3 average 
25334718 12245742 2.0689 
 
1.5692 
4-6 26105308 22387808 1.1661 
4-6 20754607 20070612 1.0341 
4-6 17815050 16167846 1.1019 
4-6 
 
4-6 average 
21535826 18628516 1.1561 
 
1.1145 
7-12 15132851 15639156 0.9676 
7-12 19911379 20049768 0.9931 
7-12 18341153 16362270 1.1209 
7-12 
 
7-12 average 
20793016 17441028 1.1922 
 
1.0684 
15-24 20203075 18940986 1.0666 
15-24 23705433 18233750 1.3001 
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15-24 21961747 22980186 0.9557 
15-24 
 
15-24 average 
19798099 24089832 0.8219 
 
1.0361 
Bonferroni's 
multiple 
comparisons 
test 
Mean 
Diff. 
95% CI of diff. Significant? Summary Adjusted P Value 
2-3 vs. 4-6 0.4547 -0.03635 to 0.9457 No ns 0.0771 
2-3 vs. 7-12 0.5007 0.009704 to 0.9917 Yes * 0.0445 
2-3 vs. 15-24 0.5331 0.04211 to 1.024 Yes * 0.0303 
4-6 vs. 7-12 0.04606 -0.4450 to 0.5371 No ns > 0.9999 
4-6 vs. 15-24 0.07846 -0.4126 to 0.5695 No ns > 0.9999 
7-12 vs. 15-
24 
0.03240 -0.4586 to 0.5234 No ns > 0.9999 
 
Figure 6.2.3 
Age Group 
(Years) 
Normalized 
HSP70 
Levels 
Normalized 
HSP60 
Phosphorylati
on 
Norm.  
p-VDAC1 
Norm. 
p-VDAC2 
Norm 
p-VDAC3 
2-3 485.6761 157.3854 220.184 131.1058 122.9305 
2-3 3.13846 149.5847 1.352814 138.5488 129.9094 
2-3 2.170132 1.38977 149.8377 89.21897 83.65559 
2-3 6.216057 127.3967 1.028139 65.15015 92.26586 
2-3 2.799221 64.24349 127.5974 75.97629 71.23867 
 
2-3 100 
 
100 
 
100 
 
100 
 
100 
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average 
4-6 1.568981 0.482541 0.757576 48.91094 45.86103 
4-6 302.8931 0.532131 1.190476 66.31009 62.17523 
4-6 0.930413 74.96239 0.21645 1.095502 282.0846 
4-6 6.007525 0.863043 1.893939 1.224385 4.924471 
4-6 3.18785 1.024208 174.3506 3.544271 97.34139 
4-6 1312.111 0.241271 20.671 0.902178 2.688822 
4-6 5.904756 0.551521 1.244589 0.837737 4.984894 
 
4-6 
average 
 
       233.229 
 
11.2367 
 
28.618 
 
17.546 
 
71.437 
7-12 704.4624 1.198407 1.298701 0.902178 4.199396 
7-12 667.2274 2.201317 0.487013 0.547751 4.018127 
7-12 949.4534 39.71907 4.004329 2.51321 10.36254 
7-12 972.1629 161.9152 1.136364 0.773296 3.897281 
7-12 604.7066 0.348396 0.4329 0.354427 2.44713 
7-12 734.6716 0.004132 0.541126 66.9545 3.111782 
7-12   1.244586 43.14345 4.89426 
 
7-12 
average 
 
772.1141 
 
29.3418 
1.3064 16.456 4.7044 
15-24 311.5622 0.696792 1.839827 58.77046 55.10574 
15-24 821.3906 0.64021 0.919913 24.61657 23.08157 
15-24 404.138 0.302939 0.703463 0.773296 60.84592 
15-24 785.6852 62.6223 0.21645 0.193324 0.574018 
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15-24 821.87 0.418965 104.329 0.902178 58.24773 
15-24 201.0346 0.000636 13.74459 8.184044 7.673716 
15-24 936.1727 119.7548 36.41775 0.128883 20.33233 
15-24 889.5203 42.9233 0.974026 57.77162 54.16918 
   0.919913 75.36409 5.951662 
 
15-24 
average 
 
646.4217 
 
28.42 
17.785 
 
25.189 
 
31.776 
Bonferroni's multiple 
comparisons test for 
HSP70 
Mean 
Diff. 
95% CI of diff. Significant? Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 -133.2 -685.3 to 418.9 No ns > 0.9999 
2-3 vs. 7-12 -672.1 -1243 to -101.2 Yes * 0.0150 
2-3 vs. 15-24 -546.4 -1084 to -8.878 Yes * 0.0448 
4-6 vs. 7-12 -538.9 -1063 to -14.30 Yes * 0.0417 
4-6 vs. 15-24 -413.2 -901.2 to 74.81 No ns 0.1350 
7-12 vs. 15-24 125.7 -383.5 to 634.9 No ns > 0.9999 
Bonferroni's multiple 
comparisons test 
For HSP60 
Mean 
Diff. 
95% CI of diff. Significant
? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 88.76 4.143 to 173.4 Yes * 0.0359 
2-3 vs. 7-12 70.66 -13.96 to 155.3 No ns 0.1461 
2-3 vs. 15-24 71.58 -10.81 to 154.0 No ns 0.1180 
4-6 vs. 7-12 -18.11 -95.35 to 59.14 No ns > 0.9999 
4-6 vs. 15-24 -17.18 -91.98 to 57.61 No ns > 0.9999 
7-12 vs. 15-24 0.9218 -73.87 to 75.72 No ns > 0.9999 
Bonferroni's multiple 
comparisons test for  
Mean 
Diff. 
95% CI of diff. Significant? Summar
y 
Adjusted P 
Value 
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p-VDAC1 
2-3 years vs. 4-6 years 0.1319 -0.03835 to 
0.3022 
No ns 0.2133 
2-3 years vs. 7-12 years 0.1824 0.01212 to 
0.3527 
Yes * 0.0308 
2-3 years vs. 15-24 
years 
0.1519 -0.01026 to 
0.3141 
No ns 0.0762 
4-6 years vs. 7-12 years 0.05047 -0.1050 to 
0.2059 
No ns > 0.9999 
4-6 years vs. 15-24 
years 
0.02002 -0.1265 to 
0.1666 
No ns > 0.9999 
7-12 years vs. 15-24 
years 
-
0.03045 
-0.1770 to 
0.1161 
No ns > 0.9999 
Bonferroni's multiple 
comparisons test of 
p-VDAC2 
Mean 
Diff. 
95% CI of diff. Significant? Summar
y 
Adjusted P 
Value 
2-3 years vs. 4-6 years 0.2559 0.1017 to 0.4101 Yes *** 0.0004 
2-3 years vs. 7-12 years 0.2593 0.1051 to 0.4135 Yes *** 0.0004 
2-3 years vs. 15-24 
years 
0.2322 0.08529 to 
0.3791 
Yes *** 0.0008 
4-6 years vs. 7-12 years 0.00338
6 
-0.1374 to 
0.1442 
No ns > 0.9999 
4-6 years vs. 15-24 
years 
-
0.02372 
-0.1564 to 
0.1090 
No ns > 0.9999 
7-12 years vs. 15-24 
years 
-
0.02711 
-0.1598 to 
0.1056 
No ns > 0.9999 
Bonferroni's multiple 
comparisons test of  
p-VDAC3 
Mean 
Diff. 
95% CI of diff. Significant? Summar
y 
Adjusted P 
Value 
2-3 years vs. 4-6 years 0.09454 -0.1998 to 
0.3889 
No ns > 0.9999 
2-3 years vs. 7-12 years 0.3154 0.02104 to 
0.6098 
Yes * 0.0307 
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2-3 years vs. 15-24 
years 
0.2258 -0.05460 to 
0.5062 
No ns 0.1768 
4-6 years vs. 7-12 years 0.2209 -0.04785 to 
0.4896 
No ns 0.1594 
4-6 years vs. 15-24 
years 
0.1313 -0.1221 to 
0.3846 
No ns 0.8960 
7-12 years vs. 15-24 
years 
-
0.08961 
-0.3430 to 
0.1638 
No ns > 0.9999 
 
Figure 6.2.5 
Age Group 
(Years) 
UCH Density Tubulin 
Density 
Normalized 
UCH / Tubulin 
2-3 2851686 44505952 87.61379 
2-3 2759994 45814200 82.37528 
2-3 3604284 46936732 105.00140 
2-3 4555672 49830838 125.00950 
4-6 5124438 47750646 146.7425 
4-6 4663548 51077178 124.8471 
4-6 4908006 51205880 131.0612 
4-6 5784966 53079396 149.0266 
7-12 5354748 52102270 140.5307 
7-12 6036012 52537734 157.0969 
7-12 4785048 50003598 130.8501 
7-12 4856598 52662550 126.1012 
15-24 5832432 52280214 152.5461 
15-24 4545396 50018736 124.2590 
15-24 4200280 50529060 113.6648 
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15-24 4309260 50477702 116.7326 
Dunnett's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significa
nt? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 -37.92 -66.81 to -
9.030 
Yes * 0.0111 
2-3 vs. 7-12 -38.64 -67.53 to -
9.756 
Yes ** 0.0098 
2-3 vs. 15-24 -30.05 -58.94 to -
1.162 
Yes * 0.0413 
 
Age Group 
(Years) 
VDAC2 Tubulin VDAC2 
/Tubulin 
2-3 11370942 44140320 96.22315 
2-3 12029837 41349105 108.67060 
2-3 11608083 42878619 101.1203 
2-3 11424412 45403533 93.98592 
4-6 11408708 42828849 99.49900 
4-6 12654145 45058419 104.90000 
4-6 12501523 40796532 114.46120 
4-6 13941916 46549251 111.87380 
7-12 13679860 44917299 113.7592 
7-12 14047446 45207603 116.0659 
7-12 15104759 42399819 133.0664 
7-12 15805771 44166276 133.6729 
15-24 16433705 48851208 125.6547 
15-24 16788237 52365474 119.7509 
15-24 20508688 62373906 122.8156 
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15-24 20679550 73103360 105.6629 
Dunnett's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significant
? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 -13.18 -29.75 to 
3.384 
No ns 0.1290 
2-3 vs. 7-12 -24.64 -41.21 to -
8.074 
Yes ** 0.0048 
2-3 vs. 15-24 -18.97 -35.54 to -
2.404 
Yes * 0.0249 
 
Age Group 
(Years) 
p-(S/T/Y) VDAC2 p-(S/T/Y) 
/VDAC2 
2-3 25070355 23862224 87.670840 
2-3 23857290 20204054 98.534470 
2-3 21015465 16304812 107.554600 
2-3 20745590 16294564 106.240100 
4-6 15912785 18574561 71.488010 
4-6 10264595 20668630 81.441520 
4-6 13422590 16548263 67.684540 
4-6 18079380 15836576 95.263790 
7-12 16780335 16762373 83.535430 
7-12 17740360 18093088 81.819220 
7-12 15535520 15947413 81.290750 
7-12 10481460 12070680 72.459550 
15-24 17145040 18298536 78.185780 
15-24 16154435 16884556 79.837650 
15-24 16618855 16661357 83.233150 
215 
 
15-24 20159150 18506790 90.096410 
Dunnett's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significan
t? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 17.78 0.7602 to 
34.80 
Yes * 0.0404 
2-3 vs. 7-12 22.72 5.703 to 
39.74 
Yes ** 0.0099 
2-3 vs. 15-24 17.16 0.1414 to 
34.18 
Yes * 0.0481 
 
Figure 6.2 
 
Normalized  
p-PI3K 
2-3 Years 4-6 Years 7-12 
Years 
15-24 Years 
113. 316. 648. 93. 
105. 344. 241. 58. 
96. 308. 126. 69. 
94. 379. 109. 63. 
86. 103. 98. 100. 
106. 93. 101. 127. 
  77. 87. 
   52. 
Bonferroni's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significan
t? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 -190.0 -291.2 to -
88.85 
Yes *** 0.0001 
2-3 vs. 7-12 -25.33 -121.8 to 
71.11 
No ns > 0.9999 
2-3 vs. 15-24 18.88 -71.34 to 
109.1 
No ns > 0.9999 
4-6 vs. 7-12 164.7 63.52 to 
265.8 
Yes *** 0.0007 
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4-6 vs. 15-24 208.9 113.6 to 
304.1 
Yes **** < 0.0001 
7-12 vs. 15-24 44.21 -46.01 to 
134.4 
No ns > 0.9999 
 
 
Normalized  
p-Akt 
2-3 Years 4-6 Years 7-12 
Years 
15-24 Years 
141. 219. 129. 84. 
148. 239. 115. 128. 
70. 129. 60. 273. 
73. 195. 53. 103. 
67. 109. 25. 70. 
 56.*  87. 
   93. 
    
Bonferroni's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significant? Summ
ary 
Adjusted P 
Value 
4-6 vs. 2-3 78.40 -15.24 to 
172.0 
No ns 0.1210 
4-6 vs. 7-12 101.8 8.165 to 
195.4 
Yes * 0.0306 
4-6 vs. 15-24 58.49 -28.20 to 
145.2 
No ns 0.2756 
 
 
Normalized  
p-PI3K 
2-3 Years 4-6 Years 7-12 
Years 
15-24 Years 
76. 265. 152.* 121. 
136. 202. 57. 58. 
62. 167. 126. 72. 
95. 174. 65. 69. 
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103. 47.* 43. 154.* 
128. 106. 42. 41. 
   97. 
    
Bonferroni's multiple 
comparisons test 
Mean 
Diff. 
95% CI of diff. Significan
t? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 -82.80 -151.4 to -
14.16 
Yes * 0.0130 
2-3 vs. 7-12 33.40 -35.24 to 
102.0 
No ns 0.9994 
2-3 vs. 15-24 23.67 -41.78 to 
89.11 
No ns > 0.9999 
4-6 vs. 7-12 116.2 44.51 to 
187.9 
Yes *** 0.0009 
4-6 vs. 15-24 106.5 37.83 to 
175.1 
Yes ** 0.0013 
7-12 vs. 15-24 -9.733 -78.37 to 
58.91 
No ns > 0.9999 
 
Figure 6.2.8 
 
Normalized 
Beclin-1 
2-3 Years 4-6 Years 7-12 
Years 
15-24 Years 
109. 98. 84. 45. 
100. 100. 86. 38. 
97. 101. 76. 25. 
86. 89. 66. 41. 
106. 88. 83. 100. 
102. 92. 71. 116.* 
 96. 84. 59. 
    
218 
 
Bonferroni's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significant? Summ
ary 
Adjusted P 
Value 
2-3 vs. 4-6 5.143 -17.38 to 
27.67 
No ns > 0.9999 
2-3 vs. 7-12 21.43 -1.095 to 
43.95 
No ns 0.0689 
2-3 vs. 15-24 48.67 25.29 to 
72.04 
Yes **** < 0.0001 
4-6 vs. 7-12 16.29 -5.354 to 
37.93 
No ns 0.2408 
4-6 vs. 15-24 43.52 21.00 to 
66.05 
Yes **** < 0.0001 
7-12 vs. 15-24 27.24 4.714 to 
49.76 
Yes * 0.0120 
 
 
LC3-II/LC3-I 
2-3 Years 4-6 Years 7-12 Years 15-24 Years 
87. 80. 105. 82. 
94. 76. 104. 83. 
102. 106. 84. 80. 
95. 85. 103. 79. 
108. 95. 84. 100. 
113.  111. 103. 
   90. 
   91. 
Bonferroni's multiple 
comparisons test 
Mean 
Diff. 
95% CI of 
diff. 
Significant
? 
Summar
y 
Adjusted P 
Value 
2-3 vs. 4-6 11.43 -7.067 to 
29.93 
No ns 0.5178 
2-3 vs. 7-12 1.333 -16.31 to 
18.97 
No ns > 0.9999 
2-3 vs. 15-24 11.33 -5.167 to 
27.83 
No ns 0.3515 
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4-6 vs. 7-12 -10.10 -28.60 to 
8.400 
No ns 0.7609 
4-6 vs. 15-24 -0.1000 -17.52 to 
17.32 
No ns > 0.9999 
7-12 vs. 15-24 10.00 -6.500 to 
26.50 
No ns 0.5527 
 
Figure 6.3.3 
CRMP2 
Age 
Group 
2-3 4-6 7-12 15-24 
 112.02810 91.20329 85.89200 116.70740 
 103.42720 83.99056 88.99440 101.48190 
 98.89340 74.40849 72.86880 104.06040 
 85.65129 83.06218 89.11713 104.64650 
SS DF MS F (DFn, DFd) P value 
1640 3 546.8 F (3, 12) = 7.977 P = 0.0034 
822.5 12 68.54 
  2463 15 
   Tukey's multiple comparisons 
test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value 
2-3 vs. 4-6 16.83 -0.5464 to 34.21 No ns 0.0587 
2-3 vs. 7-12 15.78 -1.598 to 33.16 No ns 0.0797 
2-3 vs. 15-24 -6.724 -24.10 to 10.66 No ns 0.6682 
4-6 vs. 7-12 -1.052 -18.43 to 16.33 No ns 0.9978 
4-6 vs. 15-24 -23.56 -40.94 to -6.178 Yes ** 0.0079 
7-12 vs. 15-24 -22.51 -39.89 to -5.126 Yes * 0.0108 
 
Septin-7 
Age Group 2-3 4-6 7-12 15-24 
 60.11256 144.154
2 
145.034
9 
161.08360 
 105.6591
0 
165.870
5 
158.037
6 
149.56410 
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 100.2287
0 
155.489
9 
159.520
5 
105.29490 
 133.9996
0 
143.832
2 
149.282
5 
94.47577 
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between 
columns) 
7562 3 2521 F (3, 12) = 
4.686 
P = 
0.0217 
Residual (within columns) 6455 12 537.9   
Total 14017 15    
Tukey's multiple comparisons 
test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value 
2-3 vs. 4-6 -52.34 -101.0 to -3.647 Yes * 0.0340 
2-3 vs. 7-12 -52.97 -101.7 to -4.279 Yes * 0.0318 
2-3 vs. 15-24 -27.60 -76.29 to 21.08 No ns 0.3733 
4-6 vs. 7-12 -0.6322 -49.32 to 48.06 No ns > 0.9999 
4-6 vs. 15-24 24.73 -23.96 to 73.42 No ns 0.4628 
7-12 vs. 15-24 25.36 -23.33 to 74.05 No ns 0.4422 
 
Cofilin-1 
Age Group 2-3 4-6 7-12 15-24 
 96.44344 73.0699
1 
61.9647
4 
66.76112 
 81.95702 40.2358
7 
72.7016
6 
87.00309 
 121.8742
0 
82.9013
2 
64.8332
3 
60.22153 
 99.72531 76.0143
0 
71.2137
8 
56.64687 
ANOVA table SS DF MS F (DFn, DFd) P value 
Treatment (between 
columns) 
3111 3 1037 F (3, 12) = 
4.920 
P = 
0.0187 
Residual (within columns) 2530 12 210.8   
Total 5641 15    
Tukey's multiple comparisons 
test Mean Diff. 95% CI of diff. Significant? Summary Adjusted P Value 
2-3 vs. 4-6 31.94 1.464 to 62.42 Yes * 0.0390 
2-3 vs. 7-12 32.32 1.841 to 62.80 Yes * 0.0366 
2-3 vs. 15-24 32.34 1.862 to 62.82 Yes * 0.0365 
4-6 vs. 7-12 0.3770 -30.10 to 30.86 No ns > 0.9999 
4-6 vs. 15-24 0.3972 -30.08 to 30.88 No ns > 0.9999 
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7-12 vs. 15-24 0.02020 -30.46 to 30.50 No ns > 0.9999 
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